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EDITORIAL
The mapping of human genes has been an
important step in the deve lopment of medicines
and other aspects of hea lth care, emphasized by
the wo rldwide interest in the Human Genome
Proj ect that began in 1990 in the United States at
the Nationa l Institutes of Health . It is with thi s
deep respect for the profound importance of
genetics that we are proud to present our newest
issue of the Uni versity of Western Ontari o
Medical Journal. Case reports, reviews, and indepth di scuss ions cover a vari ety of topi cs on thi s
fasc in ating theme. Maj or impli cations for the
future, present and pas t underli e each of these
arti c les.
The future is a fo cal point of both
specul ati on and hope w hen it comes to the
detection of blood vessel anomalies and
microvascular di sease, as described in an
enli ghtening article w ithin the Clinical Procedures
departmental section here in. Prenatal geneti c
di agnos is helps us predi ct the future of an unborn
child, as hi ghli ghted in a feature arti cle in thi s
issue. M eanwhile, on a broader sca le, th e endl ess
possibiliti es behind the cuttin g edge tec hnology in
personali zed cancer management are also
explored in the Medi cine and Technology
departmenta l secti on. A feature arti cle di scu sse
how
our
seeming ly
innocuous
current
environmental exposures can even affect our
future generati ons!
And yet, despite all its predi cti ve powe r,
geneti c di seases continue to burden oc iety in the
present time. What are the impli cati ons of long
QT syndrome on quali ty of life? Wh at rol e does
geneti cs pl ay for pati ents di agnosed w ith
rheumato id arthriti s? How should we sc reen for
he mochro matos is? Our authors address these
issues. Far more un common conditi ons, such as
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fibrodysplasia oss ificans progressa, can be
detected early with genetic screening today, as
described in the Zebra Files. Our Interdisciplinary
Coll aboration authors weigh in on the necessity of
support when it comes to Huntington ' s Disease.
But the folli es of genetics are al so addressed what does it mea n to label one another as ill or
health y, parti cul arl y when
it comes
to
alcoho li sm? Thi s dil emma is eloquently outlined
in our Hea lth Promotion departmental article.
is a lso essential to look back in time .
Our contributors do not forget to take an in depth
look at the past. As our History of Medicine
departmenta l arti c le
demonstrates,
genetic
research has affected indi genous peoples, and
ethi ca l considerati ons have ari sen from hi torical
cha ll enges, leading to stricter implementation of
inforn1ed consent princ iples today.
[t

Genetics connects all of humanity, from
past to present to future, and underscores the
simil ariti es and di fferences between us all.
Understanding our pas t allows us to plan for the
future. The recent period of volatility for the
Uni vers ity of We tern Ontari o Medical Journal is
hi ghli ghted in thi s i ue, w ith a reflection piece
th at addresses the maj or changes that have
occurred
within
the
journal 's
structure,
operations, and content, ultimate ly producing the
impre ive coll ecti on of quality articles that you
see now.
We hope that you find thi s issue re levant
in looking toward the future, keeping up with the
present, and under tanding the pas t when it comes
to genetics and its wide-ranging impacts. Enjoy!
-Wendy N g and Amber M enezes
Editors-in-chief

HISTORY OF THE UWO MJ
A Bump in the Road for the UWOMJ
In 2005, the University of Western
Ontario Medical Journal had not printed an actual
issue in two years, despite its long, successful
history as Canada's second oldest medical student
journal. At that point, the only printed issue that
had been distributed in recent memory was the
Obstetrics and Gynecology issue. Meanwhile, the
Pediatrics issue had been laid out in full - with
cover art, student articles and advertisements
included - but there were no funds for printing,
nor a printing service set up. However, there were
still bills to be paid for the layout of the
Pediatrics issue. At the same time, some articles
had already been collected for the History of
Medicine issue, but there was no realistic plan in
place for the issue to go forward.
My four years as the managing editor of
the UWOMJ have been exteremely rewarding.
When 1 both started medical school and joined the
UWOMJ in 2005 , the position of " Managing
Editor" was newly created and loosely defined my original job description was merely to
implement a peer or faculty review process for
student articles - but I learned quickly there was
so much more to be done, and l vastly expanded
my role.
The company that had taken care of
UWOMJ's layout, printing and distribution in
previous years reportedly went bankrupt and fled
North America. My phone calls and emails were
not returned. The UWOMJ was caught
unprepared in a confusing state of affairs. Many
students were frequently asking me when their
articles would be printed and questioning when
the next issues would be coming out. Multiple
advisors recommended to me that I should simply
put a stop to printing the journal at all, and that I
resort to online copies only. But this was not an
acceptable answer to me - it was of utmost
importance that the UWOMJ remain in print.
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It was with thi s realization that I began to
seek out alternatives for both advertising and
printing. Individually so liciting advertisements
for the journal was not at all an easy task - I came
to thi s discovery through trial and error. I
contacted CU Advertising, and with the help of
my colleague Renata Villela, we signed our first
contract with them for the Oncology iss ue. At the
same time, I looked for a new printing company. I
visited several, collecting proofs and comparing
prices, before I finally decided to work with
Imprint. I was confident that their staff would
ensure that the journal was printed to our high
standards.

The Oncology issue was the first edition of
the UWOMJ to accept only articles reviewed and
approved by faculty at UWO. Recruiting
contributors was a challenge in itself, and I
designed an original new layout for the issue. I
contacted dozens of faculty in 2005, asking them
to join our faculty review board. Articles that did
not meet rigorous review standards were rejected.
I designed and sent out a peer review form to
reviewers and requested countless revisions from
authors. I acted as a mediator between all authors
and reviewers to maintain absolute anonymity in
the process.
Finally, 1 needed a new process for
distribution of the journal. I put together a long
I ist of mailing addresses, and we had our first
'' mailing label sticker party" in the UWOMJ
office. Amber and I carried the journals down to
the mailroom, and the bulk of our very first new
journals were on their way!
However, a sustainable structure for the
UWOMJ was sorely needed. Renata offered to
take care of the contracts, while I worked on the
journal itself. This was how the two divisions of
the Editorial Board of the journal were born:
Renata took charge of the Contracts and Awards
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Division, while I headed up the Managerial
stream. The backlogged Pediatrics and History of
Medicine issues were published online.

provided
much-appreciated
encouragement for this first
generously funded the awards.

When Amber Menezes helped collect
articles for the subsequent Family Medicine issue,
authors were responsible for ensuring that their
articles were indeed reviewed and approved by
UWO physician faculty members before
submission. This process has proven sustainable
and has maintained the high quality of articles
appearing in the UWOMJ.

We are incredibly lucky to have a
remarkable editorial team taking on the
immensely rewarding and challenging experience
of running the UWOMJ. Laura Hinz organized
our first Awards Ceremony, where plaques were
presented to very deserving winning contributors.
She also initiated the creation of the new
Interdisciplinary Collaboration department of the
journal,
reflecting
the
growing
medical
multidisciplinary nature of health care today.

The first online summer supp lement of the
UWOMJ was put together by Stephen Chihrin in
2005. This has become an annual tradition.
Tiffany Kwok continued to produce the summer
supplement and put together the Cardiovascular
issue, our first alternatively funded issue. She also
ensured that the UWOMJ office was clean and in
a functional state for our editoria l staff - a
massive task, given the mess that it was in before!
Renata instituted some amazing new
changes for the UWOMJ. Recently, she has
spearheaded the process for the UWOMJ to be
catalogued by PubMed. Notab ly, she suggested
that we recognize our writers' and artists' talents
and hard work with departmental and feature
article awards, as well as cover art awards. We
had our first Awards meeting in the early summer
of 2008 . Dr. Fai sal Rehman, who has been our
most active facu lty supporter from our rocky start,
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food
meeting,

and
and

It has been unmistakably clear that the
transition into sustainable operations has
progressed pectacularly. We are fortunate to
have an extraordinary group working on ensuring
that the UWOMJ continues its high-quality
publishing and distribution, whi le consistently
exceeding our readership's expectations. The
graduatin g students of the UWO Medicine C lass
of 2009 have seen our medical journal recover
dramatically over the past few years from its
lowest point in 2005 . I eagerly look forward to
following the journal as a UWO alumnus, with
such a capable new editoria l team at the lead!
WendyNg
Managing Editor-in-chief

Join the hospital that's
building for the future.
H

umber River Regional Hospital is quickly earning a reputation for excellence in the
delivery of acute medical care . We offer a full range of medical services, and are
working actively to make our hospital a better place- for our patients and our physicians.

NEW HOSPITAL APPROVED
Our redevelopment plan , officially approved by the Ontario government, will see us move to a
new showcase acute care facility in 2014. By joining Humber River now, you can be a part of
program and facility planning for Ontario's newest hospital project. Help us build our new
hospital ; one we plan to make the technologically advanced centrepiece of our New Model of
Care. Preliminary site work is underway, and planning has already begun .
We offer placements for clinical clerks, residents and clinical fellows. Humber River Regional
Hospital is affiliated with University of Toronto and a number of HRRH physicians hold
teaching appointments at the University.

EXCITING CAREER OPPORTUNITIES
Fundamental to the success of our hospital are the remarkable individuals who comprise our
medical team. Their expertise, commitment and caring are integral to fulfilling our vision as
the hospital of choice ... committed to patient and family needs.
To meet the growing community demand for our services, we are looking for
physicians who demonstrate excellence in clinical care to join our medical
team . If you are interested contact us by email: mlatter@hrrh.on.ca

CLINICAL PROCEDURES
Nailfold Capillaroscopy and Hereditary Disease: Current Applications
and Future Prospects
Edward Weiss (Meds 2012) a nd Paul Lau (Meds 2011)
Fa culty Reviewer: Dr. janet Pope
Nail fo ld capillaroscopy is a proven non-invasive method of examining the peripheral microvasculature.
Primaril y u ed to a e s rheumato logica l di sease, it is being increasingly recogni zed as a versatile tool that
can detect blood vesse l abnorma liti es in a wide range of conditi ons, including a number of hereditary
di seases. As a compl ement to geneti c testing and other clini ca l examinati ons, capill aroscopy can often yield
important diagnos tic clues, and has the potentia l to aid research in hereditary conditi ons as disparate as
te langiectas ia, glaucoma, and schi zophreni a.

Introduction
At an estimated length of between 50,000
and I 00,000 miles, th e vasc ul ar system of the
human body holds th e distincti on of being longer
than the road networks of many sma ll countri es.
As a conduit fo r metabo lites, hom1ones,
e lectrolytes, and drugs , it excels in its fun cti on
and is exquisitely sensiti ve to constant changes in
suppl y and demand. Its very pervas iveness can,
however, act as a doubl e-edged sword patho logies that affect one area of the vasculature,
such as atherosclerosis or Marfan 's synd rome, are
likely to affect other areas as we ll.
As a di agnostic too l, the ti ght integrati on
of the vascul ature with all oth er body orga ns and
systems can often be used to the c lini c ian and
pati ent ' s advantage , since signs observed at one
po int in th e vessel netwo rk ca n indi cate patho logy
at a di stant site. T he presence of caput medusa
around the umbili cus, fo r exa mpl e, is useful in
di agnos ing portal hypertension and inferi or vena
cava o bstructi on. Often, however, abnorma liti es
in the vascul ar system are more subtl e and require
suita bl e clini ca l skill to ascertain them.
Na il fo ld capill aroscopy (NC) is the in vivo
mi croscopi c examinati on of the capill ari es found
in the skin just prox ima l to the na il. T he
capill ari es in thi s area run para ll e l to th e surface
of the skin , and can be eas il y visuali zed w ith
Page
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appro pri ate li ghting and magnifi cation . U sing
onl y a magni fy ing g lass, the 19th century Italian
phys ician Gi ovanni Ra or1 was able to describe
abnorma l capillarosco pi c findings and re lated
th em to conjuncti val inflammation.' In the
twenti eth century, the practi ce of N C was refin ed
and now it is used most prominently to detect
markers of rheumatologica l di sease, such as
systemi c sclerosis. However, there are indi cations
that NC may a lso be he lpful in the diagnosis and
progno is of vari ou hereditary conditions that
invo lve the mi crova cul ature. In thi s articl e, we
hope to illustrate a genera l approac h to NC as a
too l in assess ing rh eumato logica l patho log ies as
we ll as its potenti a l utility in the context of
geneti c di sease.

Procedure
T raditi onall y, NC has been performed
w ith a li ght mi cro cope. The pati ent is seated a nd
acclimati zed to the ambi ent temperature of the
examining room. lmmer ion oil or c lear gel i
appli ed to the nailfold area to enhance
transparency of th e skin and make the capillaries
more visibl e, and the li ght source is positioned at
a 45 degree ang le to the nailfold . A green L ED or
green-filtered li ght is often used to furth er
enhance visibili ty, as li ght in th e blue-green part
of the spectrum is preferenti a lly absorbed by
hemoglo bin. A w ide view of the termina l
capill ari es can be obta ined with a 1Ox-60x

magnification, and more detailed views can easily
be achieved with higher magnification (250x2
1000x). Photomicrographs can be taken at the
time of examination for further study or archival
purposes.
The capillaries can also be examined with
hand-held
instruments,
such
as
an
ophthalmoscope or a dermatoscope, although
these often make it more difficult to spot areas of
diminished
vascularity. 3
More
recently,
specialized videocapillaroscopic systems have
been developed to facilitate the analysis of
capillary abnormalities, although the expen e of
these systems may be prohibitive for some
clinicians.
The more common findings in patients
with microvascular abnormalities include the
of large
or giant
capillaries,
presence
disorganization of the vascular array, tortuous
vessels, microhemorrhage, loss of capillaries, and
4
ramified, or "bushy," capillaries.

Rheumatological Findings
Classically, nailfold capillaroscopy has
been utilized to differentiate patients presenting
with isolated Raynaud's phenomenon (RP) from
those who may have underlying connective tissue
disorders causing secondary RP. The nailfold
capillaries of healthy patients and isolated RP
patients appear as parallel hairpin loops with
visible afferent, transitional and efferent portions
(Figure 1). In contrast, secondary RP patients may
possess deviatory capillary patterns directing the
clinician to investigate for certain connective
5
tissue or autoimmune rheumatic diseases.
The scleroderma pattern has been
extensively characterized and represents a
multitude of nailfold capillary changes seen in
6
Three
patients with systemic scleroderma.
variations of the scleroderma pattern have led to
the categorization into early, active and late
phases (Figure 2). Specific findings that have
been described include giant capillaries proposed
to be a result of an autoregulatory response to
tissue hypoxia, capillary microhemorrhages due
to early vascular damage, avascular fields due to
UWOMJ, Vol 78, Issue 3

increasing hypoxia and architectural di sruption of
capillaries.
Similar to systemic sclerosis, variations of
the sclerodem1a pattern are also seen in patients
with other connective tissue diseases such as
dermatomyositis , systemic lupus erythramatosus,
antiphospholipid syndrome, Sjogren' syndrome
7
and occasionally rheumatoid arthritis.

Figure I. Normal nailfold capillaries. (Courte y of
Dr. Joerg Piper)

N ailfold
Capillaroscopy
Hemorrhagic Telangiectasia

in

Hereditary

An
autosomal
dominant
disorder
characterized by easily bleeding telangiectases on
the skin and mucosal surfaces, hereditary
hemorrhagic teleangiectasia (HHT; OMIM
187300) can lead to arteriovenous malformations
in many organs and paradoxical septic emboli .8
Therefore, early diagnosis is important for better
prognosis. Currently, three typical teleangiectases
are required to make the diagnosis of HHT, with
genetic testing only positive for a small subset of
families.
If not diagnosed, arteriovenous
malformations and septic emboli may be missed.
One study demonstrated that over 80 percent of
patients with HHT show enlarged afferent
portions of the capillary loop, a finding that was
not evident in matched patients without HHT. 8
More importantly, five of nine patients without
visible macroscopic cutaneous telangiectases but
having a clinical diagnosis of HHT showed
enlarged afferent capillary loops. Although
further studies are needed to validate this , nailfold
capillaroscopy appears promising as a diagnostic
aid when a definitive diagnosis of HHT can ' t be
Page
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0
Fi gure 2. Ca pillaroscopy findin gs in systemi c scleros i . (A) No rma l na il fo ld pattern . (B) Early sclerodetma
pattern , w ith dil ated and giant ca pillari es . (C) Ac ti ve sc lerodem1a pa tt em hows frequent g iant capill ari es and
hemorrhages . (D) La te sclerodc1111a pattem shows severe capill ary architec ture di orga ni za ti on. (Co urte y of Dr.
Soumya C hatterjee)

made based on clini ca l in fo m1ati o n alone (for
exampl e, if it is suspected but not yet proven).

Capillary Blood
Glaucoma

Flow

Measurements

and

As one of th e leading cau es of blindn ess in the
world , g laucoma represents a s ignifi cant threat to
ocul ar hea lth and day- to-day fun cti on. One of th e
most co mmon sub ty pes, primary open-angle
glaucoma (POAG; OMIM 1377 60), is known to
have a signifi cant geneti c compo nent, as the
preva lence of POAG amo ng those with a pos iti ve
fa mil y hi story is 5- to 20-fo ld g reater than th e
9
no m1al po pul ati o n. T he progress ion of POAG is
often in sidio us, and it is estim ated that more than
half of those w ith th e di ease re main unaware of
the ir conditi on until their vis ion begins to
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deteri orate. Thu , screening measures fo r those
w ho have a famil y hi story of POAG and o thers at
increased ri k have an important role in
preventing the progress io n of glaucoma to v isua l
damage and blindne s. Unfortunate ly, the class ic
sig n of deve lo ping g laucoma, a hig h intra-oc ular
pressure, i onl y detectabl e in about half of those
w ith the di sease. 11
A ltho ug h the precise patho phys iology of
POAG is compl ex and still not complete ly
understood, it has been noted that abeiTation s in
systemi c bl ood fl ow are often cone lated w ith th e
12
incidence of glaucoma. One such abnorma lity is
the degree of periphera l capillary vasospasti c ity
after a peri od of coo ling. Usin g capill aroscopy, it
is poss ibl e to mea ure blood flo w in the na ilfo ld
vesse ls and estimate the extent to whi ch flow

stops in response to cold. Patients with POAG
often show an exaggerated vasospastic response
relative to normal controls, which may indicate a
systemic abnormality of blood flow regulation . 12
Thus, capillaroscopic examination in patients with
ri sk factors for POAG may be useful in research
and eventually in screening for thi s di sease,
especially when an elevated intra-ocular pressure
is not detectable.

possibly enab le families with a hi story of
schi zophreni a
to
be
mindful
of early
manifestations of mental illness and seek
appropri ate treatment. Active research in thi s area
is underway, and it is hoped that being ab le to
identify a distinct subc lass of people with
schi zophreni a may assist in future genetic studies
aimed at di scoverin g the underlying etio logy for a
truly debilitating disease.

Capillary Abnormalities and Psychiatry
One of the more intriguing domains of
medicine
that
can
be
examined
with
capillaroscopy relates to hereditary mental illness,
namely schizophrenia. As early as 1939,
researchers discovered that a disproportionate
number of patients with schizophrenia exhibited
abnom1alities of the nailfold capillaries and
increased visibility of the nailfold plexus, the
dense subcutaneous network of capillaries found
prox imally adjacent to the fingernail , which is
13
generally not visible past puberty. Typical
findings upon examination of the nailfold include
a highly visible capillary plexus (Figure 3), and
oddly-patterned
individual
capillaries
with
14
numerous horizontal anastamoses.
Subsequent studies in the 1960's and
onwards aimed to establish an objective scale for
measuring visibility of the plexus and
concurrently
found
evidence
that
the
endophenotype of high plexus visibility was
positi ve ly correlated with familial , rather than
14
sporadic, schizophrenia, as well as more severe
and more negative symptoms. 15 Conversely, it is
estimated that 70% of patients with familiar
schizophrenia
have
an
elevated
plexus
16
visibility. Thi s demonstrates that schi zophrenia
is a more complex disease, with abnormalities
that extend beyond the brain in many patients.

Figure 3. Nailfold venous pl ex us images w ith
associated Maricq plexus visibility score (0 = no
visib le plexus, 4 = high ly visib le plexus) . (A)
Nom1al, 0/4 on Maricq scale. (B) Ab normal, 4/4 on
Maricq sca le. (Courtesy of Dr. John Vuketich)

Conclusion
Taken together, these data suggest that an
elevated plexus visibility has the potential to be a
suitable non-invasive biomarker for those at ri sk
of developing hereditary schizophrenia or
17
schizotypic personality features.
Given the
young age at which many patients with
schizophrenia begin to show symptoms, the
ability to screen for nailfold abnormalities could
UWOMJ, Vol 78, Issue 3

Nailfold capillaroscopy i a tried and true
clinical method that has app lications to many
di sparate
pathologies.
While
the
usual
investigation s th at comprise genetic workups
cannot be rep laced by a simple observation of
nailfold capillaries, a thorough examination of the
microvasculature can often yie ld clues that aid in
Page I l l

diagnosis and prognosi·s, wi.th a mm1mum o f
expense and invasiveness. It is important to be
aware that capillary abnormalities and other
vascular signs can be missed if not sought and
that magnification of the nailbeds in patients with
m~ny di seases can be a useful and relatively easy
skill to acquire.

8.
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DIAGNOSTIC REVIEW
Osteoarthritis: An Old Disease Cast in a New Light through Greater
Understanding of the Human Genome
Rachel Bevan (Meds 2012) and jason Essue (Meds 2011)
Faculty Reviewer: Dr. Andrew Leask
The successful mapping of the human genome offers the potential to greatly advance our understanding of
various disease processes. Osteoarthritis is a disease of particular interest because there is ignificant
morbidity and societal burden associated with this condition . Furthermore, the prevalence of this disease is
expected to rise dramatically with the aging of the baby-boomer generation (individuals born between 1946
and 1964), with a concomitant elevation in health care costs in Canada and abroad. Osteoarthritis was
previously viewed as a commonp lace disease resulting from environmental 'wear and tear' , that was an
inevitable part of aging. However, new advances have demonstrated that osteoarthritis is a surprising ly
comp lex multi-factorial disease that is affected by both environmental and genetic variables. This review
discusses some of the environmenta l and genetic factors that influence the progression of osteoarthritis.
Recent advances in biomarkers that are associated with increased disease risk are also discussed. Finally,
the potential impact of genetics on both early diagnosis of disease, and prediction of how a patient will
respond to a particular pharmacological treatment is presented.

Introduction
Ever since the discovery of the three1
dimensional structure of DNA the field of
genetics has intrigued both sc ientists and the
general public alike for its potential impact on
disease diagnosis. Indeed, the concept of genetics
as a primary player in the role of diseases is
assumed by most of the lay public today. One of
the goals of understanding genetic influences in
the disease process is to aid in treatment of
patients through
the development of a
personalized medical approach. Predictive genetic
testing is one area that has garnered great interest
in the past decade, especia lly since the sequencing
of the human genome. 2 The goal of predictive
genetic testing is to determine if an individual is
likely to develop a disease state based upon the
presence/absence
of particular
genes
or
biomarkers. Although c hallenging, determining
how best to treat a patient based on their genetic
make-up is simplified in the cases where a
particular gene or mutation is the direct cause of
particular disease. For examp le, cystic fibrosis is
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an autosomal recessive disease; for the disease to
occur, each copy of the CFTR gene must have a
mutation that renders the resultant protein non.
I .3'4
fu nct10na
However, in many cases the disease
process is not straightforward; the pre ence of a
particular genetic variant doesn ' t necessarily lead
to the disease. Instead, diseases, espec ially those
of a chronic nature, are multi-fact01ial, resulting
from a complex set of interactions among many
different genetic and environmenta l factors. In
general, there is no single gene that causes the
disease, but genetic factors are likely to contribute
to an increased probability of developing the
condition. Thus, it is imperative to develop
methods to identify individuals at risk.
Osteoarthritis (OA) is one example of a
multi-factorial disease that is influenced by
genetic and environmental variab les. OA was
previously viewed as a commonplace disease
resulting from environmental 'wear and tear ' that
was an inevitable part of aging. 5 However, new
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advances have demonstrated that OA is a
surpri sing ly complex multi-factorial di sease that
is affected by both env ironmenta l and genetic
56
vari ables. • Thi s rev iew di scusses some of the
environmental and geneti c fac tors th at influence
the progress ion of OA. Recent advances in
biomarkers that increase di sease ri sk are also
discussed.
Finally, the potenti a l impact of
geneti cs on both earl y di agnos is of di sease, and
predi ction of how a pati ent will respond to a
parti cular
pharmaco logica l
treatment
are
presented.

susceptibility. 13 Th e intrinsic local-mechanica l
ri sk factors fo r OA include joint. ali gnment,
.
5, 13
muscle
weakness,
and
propnoceptwn .
Extrinsic loca l-mechani ca l ri sk factors include
phys ical acti vity, occupations involving strenuous
. . . .
s 13 A
repetiti ve motions, obes ity, and JOint lllJUry. '
number of systemi c risk factors have been
reported, including age, sex, et~icity , b~ne
density, nutriti ona l fac tors, and genetic factors .

Disease Burden of Osteoarthritis

At present, the best way to characterize
O A invo lves measuring j oint space narrowing on
radi ographs,
evaluating
clinical
symptoms
suggesti ve of O A (i. e. pa in), and direct
arthroscopi c visuali zati on of the articular surfaces
w ithin the joint capsul e (parti cularly in the case of
knee OA) . 10 • 14 However, these methods are often
onl y abl e to detect OA after irreparable joint
damage has occurred. T hus, there is a need to
identi fy more sensiti ve methods to detect OA
prior to irreversible j oint damage, in order to
improve morbidi ty outcomes. In parti cular, there
is great interest in identi fy ing specific biological
markers that w ill refl ect the biological changes
that occur w ithin the j o int during the earl y phases
the A di sease process.
S ince OA primarily
affects bone, cartilage, and synovial ti ssue, it is
logica l to co n ider the structural molecules
deri ved fro m th e e tis ue a potenti a l biolog ica l
14
markers of OA. Notabl e candidate biolog ical
markers inc lude:

OA affects 10- 12% of the adult popul ati on
in North America and is a leading cau e of pain,
phys ica l di sability, and use of hea lth care
7
serv ices. •8
OA is a degenerati ve di sease
characteri zed by the earl y deteri orati on of
arti cular cartil age from w ithin the j o int, and later
by compl ete loss of arti cular cartil age, damage to
the subchondral bone, severe deformiti es, and
10
di sabling pain.5·9• The consequences of disease
11
are detrimental to overall qua li ty of life in many
ways, inc luding fa ti gue, reduced income due to
impa ired
labour
force
engagement,
hospitali zati on, surgery, medi cati on side effects,
fa mil y
instabili ty,
and
decreased
socia l
8
parti c ipati on. A larmingly, th e number of peopl e
affected by OA is ex pected to increase
dramati call y as the baby-boomer generati on ages.
For in stance, in Canada approx imately 3 milli on
people are currentl y li vin g with OA. T hi fi gure
is ex pected to rise to 5 milli on by the yea r 2026. 11
Unl ess better methods are deve loped to di ag nose
and treat OA, the direct and indirect costs
associated w ith caring fo r such indi vidua l will
ri se substanti a ll y w ith broader impli ca ti ons for the
overa ll eco nomi c burde n.

Risk Factors for Osteoarthritis
The ri sk fac tors fo r OA can be class ifi ed
13
as e ither systemi c or loca l-mechani cal.
Th e
loca l-mechanica l ri sk fac tor are then further
cia sift ed a intrin sic or extrin sic to th e j oint in
questi on. In acco rdance w ith thi s model, OA is
w ide ly be li eved to be th e result of loca l ri sk
fac tors acting within the context of systemi c

Page 114

Biomarkers in Osteoarthritis:
Personalized Medicine

Targets for

l. N-termin al cross- linked telopeptide of
ty pe l coll age n (NTX- l) as a marker of
bone degradati on;
2. C- termina l cross- linked telopeptide of
ty pe II coll agen (CTX- II) as a marker of
carti Iage degradati on;
3. G lucosy l-ga lactosy l-pyridinoline
(GicGal-P YD) as a marker of syno vium
degradation. 14 • 15
It should also be noted that the biomarkers
described above represent the net outcome of
di sease and do not indicate how the di sease
? ri ginate? , n ~ r do they represent targets for drug
mtervent1 on m OA . However, these biomarker

are useful to clinicians to stage the disease
process in patient . Furthermore, biological
markers may enable clinicians to differentiate
patients based on risk of experiencing rapid
progression of OA as these individuals will be in
greatest need of targeted early intervention . 16
Biomarkers are also expected to advance the
process of drug development by providing costeffective and sensitive indicators of a drug ' s
15
Unfortunately, a single specific
effectiveness.
biological marker has yet to emerge to fulfill
these lofty objectives, and it seems likely that it
will be nece ary to u e a combination of markers
in order to adequately characterize OA.
Additionally, practical issues such as tissue
specificity, clearance rates, potential circadian
14
and differences due to gender,
variations,
ethnicity, and age need to be resolved prior to
widespread acceptance of candidate biological
markers .
It is also important to highlight that recent
genome-wide linkage studies have identified
several gene variants that appear to predi pose to
OA. 14• 17 In these studies, researchers relied upon
microarrays capable of assessing 300,000 or more
single-nucleotide polymorphisms (SNPs) in a
given DNA sample. These microarrays examined
interpersonal differences in inherited genetic
variability by comparing the prevalence of gene
variants among patients who have a given disea e
1
with controls who do not have the disease.
Several chromosome regions and genes
have been identified that are associated with OA
prevalence (FRZB, BMP2, CD36, PTGS2, and
NCOR2) or OA progression (CILP, TNFRSFllB,
and ESRl ; ADAM12 is associated with both
.
) 14 17
prevalence and progressiOn
. '
Most o f t he
genes identified encode proteins that are involved
14
in signal-transduction pathways.
This work
should help to clarify the relationship between
genetic susceptibility, the genomic expression of
aberrant genes that predispose to OA via
biological markers, and the actual manifestation
and rate of onset of the disease process. More
significantly, further clarification of such
pathways in preclinical and clinical models of OA
will lead not only to the identification of new
clinically relevant biological markers, but help
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achieve the ultimate goal of OA researchers in
both academia and industry, which is to de velop
novel drug targets and therapies to combat thi s
.. .
d. · 14 I S 17
de b 11ttatmg con ttiOn . · ·

Predictive Genetic Testing
OA is a good example of a multi -factorial
disease with a large societal burden for which
predictive genetic testing could play a role in the
future. In general, the goal of predictive genetic
testing is to identify asymptomatic individuals at
ri k for di ea e ba ed on particular biomarkers
and/or genes that have been linked to
predisposition to a particular disease. This differs
from the majority of current medical tests, which
are diagnostic, and thus seek to determine the
etiology of a patient's current disease state . Thus,
there is a fundamental uncertainty as to whether
or not the di ease state will develop and how
severe the disease will manifest if it does in fact
develop . This is especially true in complex multifactorial diseases such as OA where it is difficult
to make accurate predictions due to the influence
of environmental factors ?

Pharmacogenomics
Genetic diagnosis and biomarker testing is
important not only for current and future disease
states, but also in predicting how an individual
might respond to particular medications. The
study of the genetic basis of differential drug
response has been termed 'pharmacogenomics' .
ln general, many genes play a role tn
phannacokinetics and pharmacodynamics of
various drug responses.
Pharmacogenomics
research eeks to elucidate the genetic basis of
how individuals or sub-populations respond to
different drugs in terms of side-effects, toxicity,
and drug efficacy. Such knowledge can lead to
the development of biomarker tests to predict
which individuals will respond well to particular
. h t a lso he Ip .m targetmg
.
d rugs. 19·20 It mtg
drug
development to specific sup-populations that may
be more likely to respond to a patiicular
21
therapy. In general, knowledge of the genetic
factors that relate to drug response will provide a
powerful tool for treatment in the future . 19•20
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However, the deve lopment of detail ed
geneti c test that can be linked to a populationspec ifi c drug response is quite complex.
A
number of teps are invol ved, including:
1. ldentifi cati on of genes that are in vol ved in
the drug response (e.g. pharmaco kineti cs
and pharmacodynami c of the drug);
2. Determining differing variants of these
gene ;
3. Determining whether or not these
di ffe rent geneti c va ri ants corre late w ith a
di ffere nti al drug respon e.
One recent success of the fi eld is the drug
warfa rin , whereby spec ifi c variants of parti cul ar
genes were found to corre late w ith response to
warfa rin at parti cul ar doses. n As of A ugust 2007,
the FDA has updated prescribing informati on fo r
warfa rin to incl ude th e in formati on that th e
geneti c make-up of a patient may influence how
they respond to wa rfarin .23 However, it i not
clear that the benefits out- we igh the costs. In a
recent study on non- va lvular atrial fibrill ation , it
was determined th at there is little benefit to
geneti c testing for warfarin do ing, based on an
estimated cost of $400 (US) per ge neti c te t,
except in pati ents at the hi ghe t ri sk for
24
hemorrage. Thi s is like ly to change as th e cost
of ge neti c testing decrea e w ith th e advancement
25
o f sequencing techno log ies , however it does ca ll
into
questi on
the
cost-effecti ve ness
of
personali zed medi cin e. 26

compl ete human haplotype mapping proj ect (the
HapMap proj ect which provides a compl ete
27 30
li sting of human SNPs) • will he lp . in t~e
acqui sition of know ledge about the genettc basts
for human disease. However, even these advanced
techniques are not sufficient to deal with
probl ems like incompl ete penetrance, whereby
presence of the di sease allele(s) does not
.
necessaril y mean that that d tsease
wt"11 occur. 31
Furthermore, mode ls for the genetic basis of
di sease should account for the effect of epigenetic
24
control of gene express ion.
Epigenetic control
of gene express ion (and problems w ith epi genetic
control) have been hown to play a fundamental
role in both Prader-Willi and Angelman
di seases 33 , and is th ought to be implicated in the
di sea e proces for many di seases, including auto34
immun e di seases and p yc hiatric di sorders .
Rea li zing the full benefits of personalized
medic ine and predi cti ve genetic testing i till far
29
in the future. Nonethe less, it i important to be
awa re of these rapidl y evo lving fields as they hold
the potenti a l to revo luti oni ze medicine.
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ETHICS
Ethical Implications of Germ Line Genetic Engineering
Ha ssan Mir (Meds 2012) and Christina Morgan (Meds 2011)
Fa culty Reviewer: Dr. Lois Champion
Following the recent decision by th e Obama admini stration to li ft strict limi tati ons on embryonic stem cell
research, geneti c engineering has once again come to the forefro nt of scientifi c di scuss ion. An upcoming
FDA-approved tria l using human embryoni c stem cell s in recentl y para lyzed indiv iduals has further
pro mpted an ana lys is of the lega l and ethi ca l issues surrounding the use of germ line geneti c engineering.
Though prohibited g loba ll y due to inadequate safety and effecti veness, it is inev itable that these concerns
w ill one-day be met by continua l techno logica l advancements. Neverthe less, there remains a plethora of
issues such as equal access ibility for all soc ioeconomi c groups, autonomy of descendents, and effect on the
human gene poo l to name a few. In thi s di sc uss ion, it is important to make the di stinction between germ
line geneti c eng ineering used fo r therapeutic purposes (a ltering DNA to correct a geneti c defect before it
manifests itse lf as a di sease) and enhancement purposes (a ltering DNA to improve an indi v idual above
" norma l" fun cti oning) . A lth ough the use of thi s technology could be justifi ed fo r therapeuti c purposes, it is
very di ffi cult, if not imposs ible, to mora lly defend interventions fo r enh ancement purposes.

Introduction
Geneti c engin eering has once again come
to the fo refront of scientifi c di scuss ion foll owing
President Obama 's recent dec ision to lift stri ct
limitati ons on human emb ryo ni c stem cell
research set by the prev ious admini strati on in
Ameri ca. Co inc iding w ith thi s was th e approva l
of a phase I stem ce ll tri al by the Food & Drug
Admini strati on a imed primaril y at testing the
safety of thi s therapy in e ight to ten compl ete ly
para lyzed pati ents with severe pina l injuri es. 1
T he stem cell s, whi ch were obtained from
emb ryos that wo uld have otherw ise been
di scarded, w ill a lso be used to test for any s igns
1
of fun ctiona l recovery in these pati ents.
A lot of controver y has surrounded
a lterati ons made spec ifi ca ll y in the germ line
(s perm or egg), s ince they affect every ce ll in the
child and would be transmitted to all future
2
descendants. It is important to make the
di stincti on between germ line geneti c engineering
used for th erapeuti c purposes (a ltering DNA to
correct a geneti c defect before it manifests itself
as a di sease) and enhancement purpo es (a ltering
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DNA to improve an indi vidual above " normal"
average func ti o ning). ~
C urrentl y, many laws around the world
prohibit th e u e of germ line genetic eng ineering
due to safety concern
and the poss ible
impli cati ons for future generations. In addition ,
th e fo ur prin cipl es of bi oethi cs, 3 - beneficence ,
non-ma lefi cence, autonomy, and justice
influence the debate regarding the future use of
thi s tec hno logy. Thi s arti c le eva luates some
re leva nt lega l and ethi ca l arguments that are
important in determinin g w hether gern1 line
geneti c eng ineering should be utilized in humans
in the future.

Current Legislation
There are well defin ed Can adian and
internati onal laws governing the use of germ line
geneti c engineering. Canada 's Ass isted Human
Reproduction Act (2004) prohibits the alteration
of " the genome of a ce ll of a human being or in
vitro embryo uch that the alteration is capable of
be ing
transmitted
to
descendants. " 4
The
prohibition is large ly due to the question abl e

nature
of
the
safety,
effectiveness,
appropriateness and efficiency of the technology. 5
This view is shared intemationally, 6• 7 and thus
there are currently no legal cases pertaining to this
topic around the world.
While the law dictates what can and
cannot be done, the technology 's controversial
nature makes it necessary to assess the many
ethical issues involved. Laws often reflect
changing societal values, and therefore are
constantly evolving. As a result, ethical analysis
becomes
invaluable
for
future
policy
development.

The Costs and Benefits of Germ Line Genetic
Engineering
The principles of beneficence and nonbackbone
of
maleficence
constitute
the
89
bioethics. • Beneficence asserts that there is an
obligation to treat and improve the condition of
others when it is possible to do so. Hence, altering
the genome for therapeutic purposes on a
permanent and heritable basis to prevent future
genetic diseases becomes an obligation. This
suggests that even within our limited capabilities,
it is our duty to prevent any unnecessary harm
and suffering and to improve the quality of life
for future generations. The promise of
enhancement to increase human functioning to
above normal levels may seem very alluring and
advantageous. Potentially favourable outcomes
include a dramatic increase in life expectancy, a
delay in the natural aging process, and increased
tolerance and functioning of our immune
system. 10 • 11 It is also fair to argue in favour of
enhancements that improve health and mental
acuity in general. Such enhancements will
increase survivorship, quality of life as well as the
c fu
.
12
life expectancy 10r
ture generatiOns.
Nevertheless, the majority of techniques
involved in this technology are in their early
testing stages. This imposes numerous technical
barriers that jeopardize the effectiveness and
safety of such procedures, hence challenging the
principle of non-maleficence; this principle states
that a therapy should have a net benefit, loosely
9
translating to "do no harm". Additionally, germ
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line genetic engineering experiments invol ving
animal model s are hi gh ly inefficient and produce
greatly variabl e offspring. The process requires
breedin g to be repeated through several
generations until it results in a stable and
pem1anent animal line with the desired properties.
Not only would this be highl y dangerous in
humans, but because of the threat this presents to
human dignity, it would also be impossible to
justify morally. 10 Insertion or modification of
certain genes may also have unknown and
potentially harmful interactions with other genes
in the recipient genome. Similarly, the removal of
disease- linked genes may remove the beneficial
effects of those genes. 10 Due to the unpredictable
and largely unknown hazards of such procedures
in humans, taking such risks is difficult to justify
despite the potential benefits .

Respecting the Right to Self-Governance
Autonomy
is
the
right
to
se lfdetermination , which embodies freedom and the
10
ability to determine one ' s own future. In germ
line genetic engineering, one must consider
autonomy of the parent, the child, and his or her
progeny. According to the principle of
reproductive autonomy, parents have the right to
use whatever therapeutic means available to
ensure that they have a normal pregnancy and a
healthy baby. However, this principle excludes
the parents ' attempts to enhance the traits of their
genetically normal offspring. Similar to situations
where parental autonomy can be taken away in
cases of soc ial concern (such as child neglect) , the
American Association for the Advancement of
Science has argued that strict legislation should
regulate and differentiate between germ line
genetic engineering for therapeutic versus
enhancement applications. 10
The autonomy of the child and subsequent
progeny must also be considered. Upon reaching
adulthood, a child is considered a rational agent
and it is therefore safe to assume that he or she
would consent to most genetic augmentations . 13
While this argument may apply for therapeutic
purposes, autonomy for enhancement ordeals is
more complicated. Traits that a parent may
choose
to
Improve
(such
as
improved
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mathematica l versus phys ical abilities) may not
be what the child or their progeny would have
chosen to enhance if given the choice as rational
adults. In such instances, issues of informed
consent and violati on of autonomy ari se, leading
to the poss ibili ty of lega l cases that cha llenge the
reproducti ve autonomy of the parents versus the
autonomy of the c hild .

The Role of Justice
Justi ce is another fu ndamenta l ethical
concept and requires that harms and benefits be
di stributed equall y among the who le popul ati on. 3
If certain procedures become cl ass ifi ed as
therapeuti c, it is reaso nabl e fo r indi vidua ls to ask
that such services be made uni versa ll y ava il abl e.
It can be argued that getm line therapy is
ana logo u to large ly access ibl e publi c hea lth
initi ati ves aimed at preventing heart di sease and
the refore should a lso be access ibl e to the maj ority
of th e po pul ati on. Neverthe less, even if
th erapeutic germ line geneti c engineering
becomes covered under a uni versal health plan,
such as Medi care in Canada, long wa itin g li sts
w ill like ly pose a myri ad of probl ems.
O n the other hand, th e prospect of germ
line geneti c engineering for enhancement
purposes becomin g covered under public hea lth
10
in surance is hi ghl y unlikely. Thus, the wea lth y
wo uld have greater access to thi s techno logy,
furth er expanding the di vide between different
soc ioeconomi c group in soc iety. Thi s skewed
access ra ises a few criti ca l concem s. Those
unabl e to affo rd thi s procedure wo uld likely have
some undes irabl e traits and co uld be viewed as
14
abnonnal. In co ntras t, those abl e to afford it
wo uld have greater contro l over shaping the
human gene poo l by remov ing undes irabl e traits
w hil e enhancing benefi c ia l ones, leading to a
form of e ugeni cs within ociety. Additiona ll y,
a lterati ons in the germ lin e wo uld be carri ed on
throughout the progeny of an indi vidua l,
mainta ining thi s inequa li ty th ro ughout future
generati ons.

Conclusions
As we venture into the twenty-first
century, technological advancements continue to
expand the hori zons of human potential, while
a lso ra isin g important ethical issues; germ line
genetic engineering is one such advancement.
Although these procedures are legally prohibited
due to their lack of safety and effecti veness, it is
important to develop an understanding of the
implicati ons on soc iety to he lp make more
informed decisions about their future uses.
Though by no means exhausti ve, thi s paper aimed
to ana lyze and di scuss the four major principles of
bi oethi cs
benefi cence,
non-maleficence,
autonomy, and justi ce - as related to germ line
geneti c eng ineering. Through thi s analysis, it
seems that thou gh the use of thi s technology
could be j ustifi ed for therapeutic purposes, it is
very difficult, if not imposs ibl e to defend mora lly
fo r enh ancement purpo es.
A mong other concerns, the ava ilability of
thi s therapy to the publi c would require extreme ly
c lose monitoring of its hea lth effects (harms and
benefits in both th e short and long term), as we ll
as ensuring equa l access for everyone in a time ly
manner regardless of their soc ioeconomic status.
Fa ilure to do so could result in de leterious
situati ons from dire hea lth effects for pati ents and
their progeny to di criminati on based on ones
genetic make-up. Though there are e ndless
po sibiliti es in improv ing both the qua lity and
quantity of human life, it is criti ca l to ensure that
geneti c eng ineering i safe, effecti ve, reasonabl e
for future generations, and equall y access ibl e
before it can become a viable component of both
th e sc ienti fic and g loba l community.
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HEALTH PROMOTION
The Blameworthy Gene
j ennifer N. Bondy (Meds 2012) a nd Laura Hin z (Meds 2011}
Faculty Reviewer: Dr. Raj Harricharan
W ith improved techniques of genetic ana lysis, medici ne is becomi ng increas ingly re liant on genes to
di agnose and treat di sease. However, a geneti c diagnos is is a value-laden enti ty w ith s ignificant potentia l to
change the way we categorize peopl e as ill or hea lthy, fl awed or norma l, and responsible for or a hapless
victim of d isease. Nowhere are these va lue j udgements more preva lent than the fie ld of mental hea lth.
T hi s article w ill exami ne the meaning and impli cati ons of genetic di agnoses, and appl y the theories to the
example of alcoho li sm .

"Genetic Diagnosis" Defined and Clarified
''He lp us fin d the gene fo r in ert disease
here."
Slogans such as thi s have become
increas ingly common s ince the human genome
was sequenced. T hese s logans seem to impl y that
once we have fo und the gene, the cure w ill
natura ll y fo ll ow. They also imply that we cannot
be truly certain of a diagnos is until it is proven by
geneti c techn ology.
These attitudes have the
potential to mod ify the way we conceptua li ze
both the di sease and the patient. Is a person w ith a
genetic diagnos is but no symptoms a patient? ls a
patient w ith sympto ms but no gene defect si mply
a ma lingerer? The answe rs to these que ti ons
have the potenti a l to change the way the person
(or pati ent, depend in g on the in te rpretation) ts
categori zed, pa lli ated, and sti gmati zed .
T he term ' geneti c di ag nosis ' i oft u ed in
the li terature, but req uires evera l clarifi ca ti ons.
T he fi rst is the timin g of the di agnos is. One may
have a di sease and later d iscover that it has a
geneti c component. Thi s impac ts th e patient by a
process that has been termed 'genetic izati on ' : the
patients are re li eved of blame fo r the ir conditi ons,
18
they are s impl y victims of fa ul ty genes. Such a
di agnos is, however, does not prevent susceptibl e
indi vidua ls from looking ahead ; there are
impli cati ons fo r fa mil y pl anning as the conditi on
13 14
could potentiall y be passed on to offspring. • In
contrast, one may receive genetic testing befo re
the onset of symptoms.
When the geneti c
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precedes the cli ni ca l di agnosis, the indiv idual
14
may be prematurely thrust into the sick role .
Thi s broadened defi nition of the sick ro le carri es
with it soc ieta l repercussions, a it increases the
14
number of pati ents requiring interventi on .
A
geneti c di agno is can carry permanent tigma and
13 14
may damage one ' s fee ling of personal controi. •
Secondl y, it is important to keep in mind
whi ch di sease is be ing examin ed w ith the 'geneti c
diagnos is' . Certa in di eases have more ignifi cant
geneti c contributions, thus affecting the potenti al
14
fo r remedy. For instance, a geneti c di agnosis of
Huntington ' s di ease corre lates we ll w ith clini cal
progress ion to the di sorder wherea depress ion
has approx imately 40% heritability. 14 M enta l
illne ses carry both a hi gh ocia l stig mati zation
and a low geneti c determinati on, two conditi ons
that Spri ggs el a / all eged require strin gent
j ustifi cati on for geneti c te ting. 14 However, the
low
geneti c
detem1in ati on
means
that
identifi cati on of a gene carri er need not be a
di agnos is, rather it may be an opportunity for
proph ylacti c intervention. 14 T hi s ha been termed
the 'geneti c w indow ' . 17
The fi na l c larifi cation is the di stincti on
between patho logy and vari ation. T here w ill
naturally be vari ati ons in genes, but these
di ffe rences need not be COITe lated w ith di sea e. 12
Therefore,
a
geneti c
di agnos is
may
inappropri ate ly labe l an indi v idual as "ill. " The
anti thes is of patho logizing the hea lth y 1s

legitimizing the plight of the ill. Mental health is
often viewed as a di sorder, something that is the
responsibility of the affected person or the
consequence of poor moral fibre. 14 Once there is a
genetic diagnosis, the disorder may qualify as a
legitimate di sease, one that is now the
responsibility of the health care system. 14 • 16 Thus,
genetic diagnoses must be approached with
caution:
they
have
equal
potential
to
inappropriate ly or appropriately cast individuals
in the sick role.

Nature Versus Nurture
The distinction between a clinical and
genetic diagnosis hinges on the multi-factorial
nature of di sease. Specifically, the express ion of
genes can be influenced by the indi vidua l's
environment. In a document classic in the rea lm
of health promotion, Hancock summarized these
multiple influences in the Mandala of Health
(F igure 1). The individual is viewed as the centre

,/
r

of a web of influence, with each spoke having the
15
potential to create or treat disease. Therefore,
wh il e genes themselves cannot be altered by
promoting healthy li vi ng, there is the potential to
mitigate disease through environmenta l and
12 14
lifestyle interventions. '

Reactions to a Genetic Diagnosis
Wi th the meaning of "genetic diagnosi s"
clarifi ed, the reaction to uch diagnoses can be
examined.
A genetic diagnosi s can decrease
12
blame and stigma as oc iated with disease. In an
of preventi ve
hea lth
and
personal
era
responsibility , Minkler summarized these va lue
judgements as "when ill is redefined as being
16
guilty". In the past, sufferers of mental illness
were the victims of soc ieta l sti gma large ly
because mental patho logy does not fit into the
class ic Western biophys ica l approach as there is
often not one eas ily delin eated causal mechanism .
If there is a causal gene identified, however, the
di sorder becomes a biophysica l di sease and the

~ li 'estj·l e

i

\
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THE MANDALA OF HEALTH
Figure 1. Hancock 's Mandala of Health . The individual is viewed as the centre of a series of spheres of
influence, each providing an opportunity for hea lth promotion interventsions. 15
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person now has legitimate claim to the sick role .
Notw ithstanding thi s pos itive reacti on to a genetic
diagnos is,
there
can
also
be
negati ve
13
ramifi cations. Whil e there was nothing yo u
could have done to prevent the di sease, there is
nothing yo u can do now. M inkl er wa rns that a
geneti c diagnos is may be the same as labellin g
someone as fa tall y fl awed. 14 However, thi s
fa talistic approach di sregards the multi -factorial
nature of most mental di seases. 13 The same
argument appli es to those who rece ive their
geneti c di agnos is before the onset of clini ca l
symptoms - th e optimi m of environmental
modifi cati on should temper the doom of one's
bi ologica l lot.
G iven thi s spectrum of poss ible reactions,
the impact of a genetic diagnosis must be
conside red at three leve ls: the pati ent, the hea lth
care sy tern, and soc iety. An indiv idual rece iving
a genetic di agnos is is now a candidate fo r earl y
interventi on and a legitimate actor in the sick ro le.
Converse ly, the geneti c di agnosis may tum a
hea lthy indi vidual into a ti cking time bomb ,
wa iting anxiously fo r the onset of symptoms that
14
now seems inev itabl e.
Thi s emphas izes the
importance of not viewing a geneti c di agnos is as
a label of defecti veness nor as an immutabl e
entity. These issues can now be considered in the
contex t of a spec ifi c illn ess- alcoholi sm.
Genetic Diagnoses in Practice: Alcoholism

A number of studi es demonstrate that
children of alcoholi cs suffe r fro m a vari ety of
behav ioural and psychopatho logica l prob lems,
such as substance abuse, anxiety, depress ion,
conduct di sorde rs and delinquency. 10 Thi s type of
behav iour, however, is not consistent across all
childre n of alcoho li cs. By deve loping a better
understanding of these vari ati ons, clini cians ca n
attempt to ensure that children of alcoho li cs will
not succumb to potenti all y avo idabl e hea lth
probl ems.
The mode of inheritance of an alcoho lic
"gene" is fa r from esta blished, yet there is
ev idence to sugge t that alcoholi sm is indeed a
di sease of both geneti c and enviro nmental
etio logy.' Past research ha demon trated an
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increased ri sk of alcohol abuse in the children of
al coholics. 2 ' 3 ' 4 It is poss ible that thi s is due to
5
"verti cal cultural transmi ss ion" . This theory
describes the transmi ssion of disorders, or traits
which lead to increased susceptibility to a disease,
through parental-offspring learned behaviour.
However, studi es have demonstrated that
behav ioural transmi ss ion IS not the only
contributing fac tor w hen the children of
alcoho lics develop drinking problems of their
own.
For exampl e, a twin-family study by
Ke ndl er et al examined the mode by which
alcoho lism was passed from parents to
daughters .6 The results indi cated that a solely
environmental etio logy was insufficient to explain
alcoho li sm. Furthermore, the researchers found
th at in the best-fitting model, usceptibility to
alcoholi sm was due in large part to a geneti c
predi spos iti on.
In a cohort study by Goodw in et al, the
preva lence of alcoholi sm was compared in two
group of adoptees: a group w hose biol ogical
parents were alcoho li cs, and a contro l group
whose bi o logica l parents were not alcoholi cs. 7
The researchers fo und that 18% of those adoptees
whose bi o logica l parents were alcoho li cs suffered
from the same di sease; nearly four times the
preva lence found in th e control group . These
fi ndings offer further evidence of a genetic
co mponent of alcoho li sm .
As th ere has not yet been a sing le c ulpable
gene identifi ed, one canno t be "diagnosed" with
the potenti al fo r deve loping a lcoho li sm.
Notwithstanding, fa mil y hi story may be utili zed
as a proxy by which to identi fy targets for hea lth
promoti on intervention . For exampl e, in a study
of co ll ege students in th e U.S., the children of
probl em drinker (COPDs) were identifi ed and
compared to a contro l group, and COPDs were
17% more likely to engage in heavy epi odi c
drinking tha.n non-COPDs.8 Additi onall y, they
were approx imately three times more likely than
non-COPDs w ith simil ar drinking habits to eek
help for their drinking probl ems. Thi s was
parti cularl y true of students who had prev iously
consumed a lcoho li c beverages but had abstained

from drinking in the past year. In light of these
results , it stands to reason that when possible,
COPDs, particularly those who have recently
attempted to curtail their own drinking, should be
targeted for counselling and treatment in order to
prevent future alcohol dependency.
Walker and Lee, however, caution that
clinicians should not pathologize the children of
alcoholics (COAs). 9 They indicate that COAs
who come from "famil[ies] with strong emotional
bonds and ... warm, supportive environment[s]",
are able to maintain caring and empathetic
interpersonal
relationships , and
will
not
necessarily develop psychiatric disorders , as has
been suggested to be typical of COAs. The
authors elaborate, explaining that alcoholic
families may have " reservoirs of strength", which
can come in a variety of forms , which clinicians
should seek out and draw on in order to provide
treatment.
For
example,
sibling-sibling
relationships within alcoholic families may be the
only instance in which a family member is
consistently emotionally available, and thus these
relationships should be encouraged in an effort to
promote healthy living and an avoidance of
alcohol dependency .
Walker and Lee emphasize the plasticity
of human development and the fact that it can
drastically influence the qualities exhibited by
COAs; specifically, the exhibition of resilient or
maladaptive behaviours. 9 The key to this process
is to determine which relationships (i .e. marital ,
parent-child, sibling-sibling) within the family are
resilient, and then encourage the fostering of these
relationships, the affirmation of belief systems,
and the improvement of communication. Resilient
relationships within families may be the
counterbalance to genetic predisposition.
Wemer 11 adds that COAs who do not
develop serious problems tend to have good
communication skills, are goal-oriented, have a
positive concept of self, and believe in self-help.
While these determinants may possess a
somewhat innate component, they are also
qualities which can be addressed in counselling.
By encouraging the development of the
aforementioned attributes, it is poss ible that
UWOMJ, Vol 78, Issue 3

susceptible
individuals
may
alter
their
envi ronments in such a way as to not fa ll victim
to a genetic predisposition to alcoholi sm.

Impact of a Genetic Diagnosis - Conclusions
Genetic diagnosis can be costly not only in
terms of the gene test itself, but in terms of
treating the pati ents we have created. Before the
advent of gene testing, these asymptomatic
indi viduals did not cons ume health care
resources. Ethical and politica l consideration s
arise of whether we have an obligation to treat
those that we have identified as be ing ill or at
risk, regardless of a lack of clinically recogn izab le
di sease. An additional societal consideration is
the creation of the "other" - a group of genetically
di stinct indi vi duals, almost a separate spec ies.
This us-versus-them attitude sterns from the view
of a genetic diagnosis as a fatal flaw and has the
potential to perpetuate rather than reduce
stigrna. 13 ' 14
On the other hand, early identification of
at-risk individuals opens the poss ibility of hea lth
promotion and disease prevention interventions.
Alcoholism is but one example of di seases which
are all too frequently attributed to a lack of "will
power" on the part of the ilL By acknowledging
the sc ientifically demonstrated genetic component
of thi s disease we can play a dec isive role in the
prevention of alcoholism in those who are most
susceptible to the disease.
Being cognizant of the issues discussed in
this article is an important step in improving our
understanding of the individual and soc ietal
implications of genetic testing. Furthermore,
recognition that phenotypic expression of
genotype is environmentally mediated prov ides
an opportunity for health promotion interventions.
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HISTORY OF MEDICINE
Vampire Projects or Long Ago Person Found? A History of Genetic
Research in First Nations Communities
Kate MacKeracher (Meds 2012) and Michael Livingston (Meds 2011)
Faculty Reviewer: Dr. Michelle Hamilton
Genetic research of Indigenous populations has been fruitful for scientists and the wider public, but has it
benefited Indigenous communities themselves? We explore past (ab)uses of genetic research in Canadian
First Nations communities through case studies. Although early projects were largely research er-driven,
the Human Genome Diversity Project of the 1990s catalysed a change towards participatory, communitycontrolled genetic research in Canadian Aboriginal communities.

Introduction
Indigenous* peoples have often been
subjects for biomedical research , and the benefits
to mainstream society include improved vaccines
and better understanding of type 2 diabetes
pathophysiology.' Genetic studies of Aboriginal
populations have yielded dissertations and
scholarly artic les on subjects ranging from
rheumatoid arthritis, 2 to breast cancer,3 to
evolution and migration of human populations.
But to what extent have Indigenous communities
themselves benefited from this research?
Through selected case studies, we exp lore the
history of genetic research in Canadian First
Nations communities, with a particular emphasis
on the degree of community control.

Why Community Control?
In the late 1960s, Vine Deloria (Standing
Rock Sioux) drew attention to research in
Aboriginal communities that was driven more by
researchers ' interests than by " the needs of the
people."4 Given that these communities are often
struggling for survival against the political ,
economic,
and
social
consequences
of
colonialism, Deloria condemns " pure research" of
Indigenous peoples that benefits only the

researcher: "We should not be objects of
4
observation for those who do nothing to help us."
Indeed, power disparities between a community
and outside researchers can make the research
process into a form of exploitation,5 undermining
Aboriginal knowledge and overeignty : "The
Indian explanation is always cast aside as a
superstition," Deloria observes, " Indians must
simp ly take whatever status they have been
granted by scientists." 6
Furthermore, research ethics in North
America have traditionally focussed on individual
rights , neglecting co llective rights of groups. 7•8 •9
Yet many Indigenous communities consider
infom1ation about the group to be communal
10
property.
Even something considered so
individualistic, at least in mainstream Canadian
society, a DNA may be seen as a common
resource, as Debra Han-y (Northern Paiute)
describes: " We ' re talking about something that
has existed co ll ective ly. It doesn't belong to the
present generation." 7 Outsider researchers may
lack the lmowl edge to negotiate these political,
cultural, and ethical complexities, and so the
long-term distribution of benefits and harms from
a project will be influenced by the degree of
community controiY· ''

• We use " Indigenous" and " Aborigina l" interchangeab ly.
In a Canadian context, " Aborigina l peoples" include First
Nations, Metis, and Inuit populations.
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" He Used Us like Guinea Pigs" : Two Cases of
Genetic Research
In 1989, the Havas upa i people of A ri zona
gave blood to researchers from Ari zona State
U ni versity, seeking to understand the hi gh
preva lence of di abetes in their communi ty. In the
earl y 2000s they rea li sed the bl ood had also been
used
fo r
unrelated
studi es
by
severa l
11
researchers.
Of parti cular concern to some
donors was the use of their DNA in popul ation
evo lution stud ies that contradicted the ir oral
hi story; Havasupai Cha irwoman Carletta T ilousi
expl ains, "They chall enged our identity and our
origins wi th our own bl ood without te lling us
what we were doi ng." 7 Ani shinaabeg scho lar
W inona LaDuke argues that such stud ies have
po liti ca l, as we ll as cultura l, signi fica nce.
Governments or others w ith interest in Abori g ina l
peop les' trad itional lands, she suggests, may use
the authori ty of "genetic evidence" to portray
Indi genous groups a mi gratory "settlers" w ith no
7
higher claim to land ri ghts.
T he Havasupai
T ribal Council and several co mmuni ty members
have fi led multi-milli on-do ll ar laws uits against
12
the researchers and the ir uni versity.
Members of N uu-chah-nulth First Nati ons
in Bri tish Co lumbi a gave their blood to Ryk
W ard, a genetic ist at the U ni versity of British
Co lumbi a (U BC), in the mid- 1980s, hoping to
uncover the rea on fo r th eir community's hi gh
13
rates of infl amm atory arthriti s.
They heard
nothing more until 2000, w hen the N uu-chahnulth learned that W ard fa il ed to find signifi cant
res ults in his arthriti s stud y and had taken the ir
blood w ith him to new a ppo intments at Utah State
Uni versity and Ox ford Uni ve rsity. He and
coll eagues rece ived fundin g fo r fu rther, unre lated
analyse of th e blood, inc luding popul ati on
13
evoluti on studi e . N uu-chah-nulth peopl e, led
by Larry Baird, one of the blood donors, have
successfully lobb ied for the return of the bl ood,
14
and it i now stored at UBC.
Baird ex plained
hi s efforts to retri eve th e bl ood fro m Ward in a
Nuu-chah-nult-run newspaper: " He profited at our
ex pense. He published over 200 papers and
became top guru in hi s fi e ld because he was
carryin g our bl ood around w ith him . He used us
14
like cheap guin ea pi gs. "
Page
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Note the di versity of communities'
responses. Baird obj ected to a researcher ~rofit~ng
from his community w ithout rectproctty;
Havasupai donors protest the use of their DNA in
populati on studi es that contradict their oral
hi story ; others, such as members of the
Amazo nian Yanomami peopl e, have cultural
15
be li efs aga inst the preservation of blood; and
di ffe rent groups w ithin communities may have
con fli cting responses to the secondary use of their
sa mples. 9
What these cases have in common are
researchers who stored, shared, and re-used
geneti c sa mples w ithout donors' knowledge.
Geneti c ists treated the samples much as biologists
treat bacteri al cultures: as scientific resources to
be tudi ed and bared. But indi vidua l donors did
not consent to these uses; and since genetici sts
were naming a specifi c Indigenous community in
their ana lyses, research was a lso being done on
the communi ty as a who le, without its consent.
Perhap fo r the e researcher , operating re lati ve ly
early in the genetic era, complex ethi cal reasoning
had not yet caught up w ith scientific technique
and curi osity. In an interv iew w ith Nature, W ard
implie hi s secondary use of N uu-chah-nulth
sampl es was simply the "way peopl e operated at
the time ... it didn ' t cross anyone's mind -- we
didn ' t mean to be ev il , and we are more careful
,., 13
now.

" The Vampire Project"
T he increas ing vig il ance of Indi genous
communiti es , and corTesponding tendency of
genetic ists to be " more careful now," deve loped
over the 1990s in th e context of the Human
Genome Di vers ity Proj ect (HGDP) controversy.
Conce ived as a supplement to the Human
Genome Proj ect, the not-for-profit HGDP a imed
to co ll ect samples fro m geneti ca lly iso lated
Indi genous communiti es around the world, create
immorta li zed cell lines, and make the DNA
avail abl e to not-for-profit scienti sts. T he initi a l
goa l was to facilitate study of popul ati on
16
evo luti on and mi gration ,
although later
representati ons of the proj ect empha ised
potenti a l hea lth research. 17

An Indigenous resistance movement to the
project developed very quickly . By 1993, the
World Council of Indigenous Peoples had
christened it "The Vampire Project" for the
emphasis on retrieving blood, and the tenn stuck
in North American Aboriginal newspapers . 18-20
HGDP organizers attempted to mitigate criticism
by forming a North American Regional
Committee with two Aboriginal members, and by
drafting a Model Ethical Protocol for collecting
21
samples.
Nevertheless, Canadian and American
government agencies ultimately declined to fund
the project, and it has stalled in North America. 22
Why did a project considered innocuous
22
by its originators
generate such resistance?
Representatives of Indigenous organizations from
the Americas outlined common problems with the
HGDP in 1995 , including spiritual objections to
immortalized cell lines, potential military or
commercial abuses, and objectification of
Indigenous
peoples
" to
satisfy
scientific
curiosity" without benefit to the peoples
themselves ? 3 Was true informed consent from
individuals and communities possible, given
24
linguistic and cultural barriers? Would genetic
research support population migration theories
that dismissed community origin stories and
undermined struggles for land and sovereignty
25
rights?
One of the most frequent objections
stemmed from the language of the HGDP's draft
project
proposal;
genetically
distinctive
Indigenous populations are refen-ed to as "isolates
of historical interest" whose genetic resources
need to be collected immediately, before the
.
d.1e out or d.1sappear. 1s'25-27 .L a D u ke
popu 1at10ns
explains many Aboriginal individuals' outrage at
the idea of salvaging genes instead of saving
people: " Why would so many resources be
involved in collecting the genetic materials from
'vanishing populations ' rather than working to
7
preserve those peoples and their cultures?"
As evidenced by the presence of lawyer
Catherine Twinn (Sawridge First Nation) and
anthropologist Russell Thornton (Cherokee) on
the
HGDP's
North
American
Regional
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Committee, Indigenous opposition to the proj ect
has not been universal. Defences from A bori g inal
persons in scholarly literature or the popular
press, however, are difficult to find. Th e most
prolific Indigenous writer on the HGDP in
academia
has
been
Frank
Dukepoo,
a
Hopi/Lacuna genetici st. Citing the moral naivete
of the project 's ori g inators, th e real ri sks and
uncertain benefits to Indigenous peoples, and the
lack of community control inherent in open-ended
gifts of genetic resources, he has generally argued
28
against the project. Yet he asserts that not all
Indigenous individuals and communities rej ct
genetic research per se; the HGDP 's mistake, he
suggests, is its " paternalistic" approach to
conducting " research on rather than with
.m d.1genous peop Ie.,29

Participatory Research
Early in the 1990s, the people of Oji-Cree
Sandy Lake First Nation (Ontario/Manitoba
border) decided to address their community's
high prevalence of type 2 diabetes. They formed a
partnership with two physician-researchers that
"incorporates the principles of participatory
research," according to the project website.30
Community leaders and researchers established
goals
determining
community-specific
prevalence and risk factors , implementing
primary and secondary prevention programmes and continue to discuss all aspects of the project,
from protocol designs to dissemination of
30
results . Protocols must be approved by the Band
Council, and research is conducted by trained
30
community members.
Preyalence of type 2
diabetes was found to be five times the Canadian
average, and a range of environmental and
lifestyle risk factors were isolated; based on these
findings , the project partners began to develop
community-run, culturally-specific intervention
programmes in 1995 .31
The following year, the project organizers
invited researchers from Robarts Research
Institute at UWO to seek possible genetic
components to diabetes in Sandy Lake First
32
Nation.
Analysis of DNA from 728 community
members showed that a mutation unique to this
community in gene HNF JA increased the risk of
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deve loping type 2 di abetes by up to 15 times in
homozygous
indi viduals,
compared
with
communi ty members hom ozygous for the normal
32
a ll ele. The clini ca l appli cability of testing for
thi s mutati on was examined as a means for
directing enhanced prevention support to
genetica lly susceptibl e indi vidua ls.33 The re lati ve
importance of geneti c and env ironmental ri sk
factors for earl y onset type 2 di abetes in
communi ty members was quantitati ve ly assessed,
w ith the conclusion that "changes in environment,
at the leve l of li fes ty le, could overturn geneti c
susceptibility, probably rapidly, and in a ' lowtech ' manner. " 32
The e genet ic studi e have not occurred in
reductioni st iso lati on, as a ll too often happens in
bas ic science research, but rather are embedded in
a communi ty-contro lled research proj ect that
inc ludes probl em , causes, and communityspec ific so luti ons in its scope of inqui ry, and that
requires results to be relevant and meaningful for
a ll parti es. Canadi an Mohawk scholar Marl ene
Brant Caste llano observes that thi s sort of
coll aborati on makes fo r more effecti ve research,
and cites th e Sand y Lake First Nation di abetes
proj ect as ev idence that " Ho li stic awa reness and
hi ghl y foc ussed analysis are compl ementary, not
.
, JO
contra d 1ctory.
Long Ago Person Found
In 1999, th e body of a youn g man who
di ed hund reds of yea rs ago was fo und pre erved
in a g lac ier on traditi ona l Champagne Aishihi k
34
First Nati ons (CAFN) land (BC/Yukon border).
T he F irst Nati ons assumed respons ibility fo r the
rema ins, in keeping w ith a 1995 treaty affim1in g
the ir contro l over cultura l resources on the ir
land.34 CAFN E lders named th e rema ins Kwad'!Y
Dan Ts' inchj (Long Ago Person Found ), 35 and
togeth er w ith the Band Counc il and oth er
community members, dec ided to in vestigate hi s
34
on g ms.
After consulting w ith ne ighbouring First
Nati ons, th e CAFN Ba nd Counc il signed a
manage ment agreement with th e BC government
34
to a llow fo r research on the rema in .
Researchers wo uld not be abl e to own geneti c or
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other materials gathered at the discovery site and
34
would return all samples after analys is.
T~e
research included a compari son of mitochondnal
DNA (mtDNA) in the remains to nearly 250
35
Th.
Abori ginal volunteers from the area.
IS
geneti c test suggested Long Ago Per~on Fo~nd
has li ving re lati ves in CAFN and ne1 ghbou~mg
35
Abori g inal communities.
Since the relat1 ves
identifi ed by materna lly-inherited mtDNA are all
members of the W olf/Eagle clan, Elders
concluded the ir ancestor like ly was as well, given
35
the matrilineal c lan structure of their nations .
Th is identifi cation a llowed for a memorial
potl atch to be planned by E lders of the correct
c lan. 35
Sympos ia at the Royal BC Museum and
th e CAFN reserve in 2008 and 2009 made
info rmati on gathered about the remains accessible
to loca l Indigenous people and the genera l publi c.
Thi s inc luded sc ientifi c and cultural talks,
traditi onal accounts of lost travellers and trade
routes to complement forensic ana lyses of
cl othing materi al and stomach conte nts, and local
genea logies to fill m the gaps of hi gh
35
spec ifi c ity/low sens1t1v1ty mtDN A testing.
Requested by the communi ty and contextualized
with oral hi story and other studi es, thi s DNA
ana lysis demonstrates th at community-controlled
geneti c
research
can
sometimes
support
Abori g ina l peopl es' psycho oc ia l, as well as
bi omedi ca l, we ll-being.
Jn thi s case, the community ' desire to
know more about the ir ancestor coinc ided w ith
outside researchers' curios ity , and DNA testing
was deemed acceptabl e by Band Counc il, E lders,
and bl ood donors. Not a ll Abori gina l peoples w ill
make s imil ar decision about rema ins found in
the ir land, however, and interested genetic ists
must not suppose that DNA ana lys i w ill a lways
be we lcomed or acceptable in these situations. 36
Conclusions
In response to the increasing power and
voi ce Indi genous peopl es have negoti ated for
themse lves about re earch in the ir communities
Canadi an government funding age ncies hav~
begun requiring spec ial ethi ca l conside ration , in

addition to usual practices, from those seeking
grants for research with Aboriginal peoples. 8•9 For
examp le, the 2007 CIHR Guidelines for Health
Research Involving Aboriginal People emphasises
community/group con ent, participatory research ,
ownership of biological pecimens and data by
the community, and new informed consent before
any secondary use of amples and data, among
other requirements.9
Although these regulations apply only to
CIHR-funded resea rchers, Canadian First Nations
communities are beginning to establish their own
codes of conduct and research ethics boards. 10
These efforts flow from Canadian Aboriginal
peoples ' constitutional right to se lf-government,
according to a report by the National Aboriginal
Health Organization (NAHO), and reflect the
principles of "OCAP": community ownership,
control, access, and possess ion of research and
37
biological samp les.
When they learned how Ward had used
their samp le , the Nuu-chah-nulth Tribal Council
formed a Research Ethics Committee chaired by
Larry Baird, the community member most active
in repatriating the blood. " We ' re not c losing the
door on research ," Baird exp lains, noting that
some Nuu-chah-nulth people are interested in
renewing inquiry into the arthritis that still
14
plagues their communities. But the "way people
operated" when Ward took their blood in the
1980s will not be tolerated , Baird warns: " From
now on our eyes are w1'de open. '14
'
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INTERDISCIPLINARY COLLABORATION
Multidisciplinary Management at Key Stages in the Huntington's
Disease Neurodegenerative Process
Abhijat Kitchlu (Meds 2011) and Allanah Li (Meds 2012)
Faculty Reviewers: Dr. Shannon Vena nee and Dr. Christopher Hyson

Introduction
Huntington's Disease (HD) is an adultonset neurodegenerative disorder with significant
motor, cognitive, and psychiatric manifestations.
Symptoms are progressive, with no effective
treatments currently available and death occurring
15-20 years after onset. 1 HD is inh erited in an
autosomal dominant manner. Affected individuals
display an expanded CAG trinucleotide repeat in
1
the HD gene on chromosome 4 . Given the
devastating natural history of the disease and its
hereditary basis, HD can present many challenges
for patients, their families, and healthcare
providers. In this article, we describe some of the
complex issues that arise during key stages of the
HD neurodegenerative process and emphasize the
importance of comprehensive, interdisciplinary
team management at each stage.

Predictive Testing for HD
Predictive testing for HD based on
trinucleotide repeats has been available since
1993, with a less definitive linkage ana lysis test
avai lable in the mid-1980s. While some argue that
the test can relieve uncertainty and enable
planning for the future, only 4-24% of those at
2
risk for HD go through with testing. Decisions
regarding testing have many ethical, legal, and
psychosocial implications and at-risk patients
must find a way to navigate through these
concerns. Patients must consider the psychosocial
effects of declining or postponing testing, as well
as the effects of undergoing testing and receiving
either a positive or negative result. Moreover, the
results of testing can have a significant effect on
the patient's family, who may become future
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caregivers or future patients due to their at-risk
status. 3 Patients also face the possibility of
discrimination based on genetic information,
particularly regarding eligibility for disability or
life insurance and obtaining employment. While
there are only anecdota l reports of genetic
discrimination
in
Canada,
the
fear
of
discrimination remains a very powerful influence
4
on patients and physicians. • 5
The healthcare team at this stage takes a
primarily counselling and supportive role. Genetic
counse lling, often done by genetic counsellors or
medical geneticists, is particularly important
during this time. Counse lling provides patients
with disease information, takes them through the
impli cations of testing, and offers psychosocial
support. 6 Counse lling must provide the patient
with all necessary and relevant information,
because the far-reaching consequences of testing
neces itate truly infom1ed consent for the
procedure. Genetic counsellors must present
information regarding HD and predictive testing
in a balanced and non-directive manner,
ultimately respecting the patient's autonomy. 5
Patients must be assured of privacy and
confidentiality. In order to support the patient
through their decision of whether or not to
undergo testing, other services that may become
involved at this stage include social work, family
support and counselling, psychology, psychiatry,
neurology, and family medicine. Management
should be specific to the individual patient, while
taking the family and cultural contexts into
account.
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After Undergoing Testing for HD - Living
with the Results
The results of predictive testing for HD
can have a profound impact on patients and their
families. A Canadian study examining the
p ychological consequences of predictive testing
found that although psychological well-being was
ignificantly improved for the majority of
participants,
6.9%
experi enced
clinically
s ignificant
adverse
psychological
events,
including di agnosed clinical depre s ion and
7
suic ide attempts. The e adverse events occurred
in individual g ive n po iti ve and negative te t
re ults. The paradoxical reaction of some pati ents
with a nega ti ve test res ult (noncarriers of the HD
gene) has been ca ll ed "survi vo r's guilt" and
involve psychological distress from be ing spared
1
from HD. Patients receiving a po iti ve te t result
(carriers of the HD gene) must come to tern1s
with the meaning for their own health , as well as
implication for their family, career, and life
plans. Although fear, anxiety, and depression may
be understandable responses to a positive test
result, these are also poss ible psychiatric
manifestation of HD and pati ents must be
followed for earl y onset of symptom s. 3 A pos itive
result can a lso ha ve a tremendous impact on
family dynamics, with studies showing hi gher
di vo rce rate among carri ers than noncarri ers in
the 6 month following test results, and parents
poss ibly experi encing guilt for ha ving tran ferred
2
ri sk tatus to their offspring. Thu for HD and
other geneti c disease , the unit of care is often the
family rath er than the patient. 3
Following predictive testing for HD ,
patients are faced with new chall enges that may
require multidi sciplinary in vo lvement. It is c lear
that psychologica l counse lling and follow-up
mu t be available to all patients undergoing
predictive testing rega rdl ess of test result, and
psychiatric care may also be required at thi s stage.
Support and education hould be offered to th e
patient's family and may require the he lp of soc ial
workers, nurses, psyc hologists, and therapi st .
Early collaboration between the family doctor and
a spec iali t in HD can monitor for onset of
di sease symptoms.
Physician s
must also
formulate a plan with the pati ent for future
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management. 3 In addition to the formal healthcare
team, patients and their families may benefi~ from
joining a support network like the Huntmgton
Society of Canada.

Reproductive Decisions
HD presents complex dilemmas for
patients and their families with respect to
reproductive decision-making. Although HD
follows autosomal dominant inheritance, the
penetrance of the disease varies with the extent of
the CAG triplet expansion. Triplet repeats of 40
or more are fully penetrant, those 36 - 39 are
thought to be variably penetrant and those less
than 35 repeats do not typically manifest as
disease. The expansion (and, in some cases,
contraction) of the repeats during gametogene is
further complicates reproductive choices and can
pre ent a challenge for health care professionals
when communicating risk .
Qualitative research has identified several
difficult deci sion s facing patient and their
healthcare team : whether to have children at all,
whether to undergo prenatal testing or preimplantation genetic diagno is, and whether to
abort gene-po itive fetuses. Many patients who
wish to have children expre s opposition to giving
birth without attempting to prevent pa ing on the
di ease; how ver, thi concern is often superseded
by patient ' fears of their illness preventing them
from providing for and rai s ing children. 8 For this
rea on, pati ents must be coun elled with
con ideration and potenti al involvement of their
partn ers, families, and wider social support
networks. Thi in tum can be a concern for
pati ent , as many report the influence of others a
a major factor in deci ion-making .9 Thi includes
the influence (whether or not intentional) of the
healthcare team , which is an important
con ideration in light of a recent tudy which
indicated that 38% of Mexican neurolo a ists
0
'
psychologi sts and psychiatri sts felt that those with
the HD mutation should not have off: pring. 10
Prenatal testing for HD currently exists via
amniocentesis . or chorionic villu
sampling.
However, testmg rates for those at risk for HD
remain low; within the United Kingdom and

Australia only 5 - 25% of at ri sk populations
undergo prenatal testi ng.8 Within Canada, a
survey exa mining 15 of the 22 centres offering
testing found that onl y 15 prenatal tests were
completed between 198 7 and 2000. T he 12
fa mili es w ho underwent these tests were
estimated to represent approximately 0. L% of the
11
at-ri sk popul ati on. W o men were shown to be
more like ly to request prenatal testing as we ll as
predicti ve testing for themse lves. 11 More recently,
pre-implantati on geneti c di agnos is has become
ava ilable to ensure only mutati on-negati ve
embryos are implanted. Thi s process, however,
can be di ffi cult fo r many couples and may not be
an option for many due to personal beli efs and
12
preferences. Pre-implantation genetic di agnos is
is now also offered without infom1ing the parents
of their own HD gene status, whi ch is preferabl e
to some pati ents who des ire certainty th at they are
not pass ing on the di sease to their children, but do
not want to detem1ine their own gene status.
Despite these difficulti es, many HD
pati ents and carri ers do opt to have children. A
European study demonstrated that L4% of HD
carriers had subsequent pregnancies following
predi cti ve testing, compared to 28% of noncarriers. 12 Furthermore, many pati ents consider
adoption as a potential a lternati ve depending on
their expectati ons of di sease onset. 8

Interdisciplinary Care of the Symptomatic HD
Patient
The management of symptomati c HD
patients is a broad topi c, and in its entirety is
beyond the scope of this overv iew; instead, a brief
outline of the interdi sc iplinary nature of HD care
is presented here.
The nature of HD requires a team-based
approach to symptom management. An optimal
healthcare team includes leadership not onl y from
a neurologist or psychi atrist spec ia lizing in HD,
but also a family physician to monitor
3
compli cations in the late stages of the di sease.
Allied health care profess ionals, including nurses,
dentists, di eticians, physica l, occ upational and
speech therapists, psychologists, and social
workers also play maJor rol es. Advance care
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plann ing is also extremely important in
establishing quality of life goa ls and end-of- life
care di rec ti ves.
The stages of symptomatic HD d ictate the
need fo r each of these team-members. The
Shoul son-Fahn sca le, origina lly designed for
research, has become usefu l in eva luating the
severi ty of HD . The fi ve stage scale is based on a
Tota l Functiona l Capac ity (TFC) score fro m 0 to
13 that assesses the pa ti ent's fu ncti onal skill s and
ability to carry o ut activities of da ily li vi ng. In
stages I through 3, the focus of care inc lude
treatment
of
chorea,
sleep
d isturbance,
depress ion, anxiety, impulsivity, irri ta bili ty a nd
o ther psychiatric symptoms. 3' 13 In these tages the
phys ician members of the team are fo remost.
However, the ro le of psycho logists and social
workers may be crucial in the transiti on fro m
working li fe to di sability status for some patients
and their fa mili es. It has been suggested that one
of the most preva lent deficiencies in HD
treatment i di sproporti onate foc us on mi nor
findings of chorea, without proper management of
depress ion
and
deteri orati on
of
fa mil y
re lati onships. 13 Medica l therapy including anti depressants and mood stabili zers may be of va lue
and neuro lepti cs may be warranted in cases of
. b e l1avwur.
.
13
more aggress1ve
Mid- to late-ph ase HD requires fo llow-up
v1s1ts to phys icians to assess fo r compli cati ons,
but also increased invo lvement of other hea lthcare
profes ionals. Occupati onal therapi sts may be
invo lved in assess ing driving ability and
determining necessary restricti ons. Pati ents often
have large appetites, and may have di ffi c ul ty
meeting nutriti ona l requirements g iven increas ing
dysph agia and lack of coordinati on (aspirati on
and subsequent pneumonia are often the terminal
events for HD pa ti ents). For thi s reason,
d ieticians' expertise and nursing or persona l
support worker ass istance w ith feeding can be of
great benefit. Phys icia n fo ll ow-up may invo lve
the reduction of medi cation for chorea, w hi ch
paradox ica lly decreases in the late stages and is
suppl anted by rigidity and dystonia. These
symptoms are often worsened by excess
pharmacotherapy for chorea, whi ch must become
13
more judicious.
Ph ys ic ians must a lso he lp
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patients and familie
deal with increasing
cognitive impairment and mood a lterations, and
a
such, behavioural coun e lling is often
3
required. In the end stage of the disease, hospice
nursing and palliative care specialists ensure
patients are as comfortab le as possible and assist
familie with the patients ' death .

6.

7.

Conclusion
Huntington 's di sease pre ents significant
challenges for the hea lthcare tea m. Despite the
paucity of treatment ava ilable to delay di sease
progre ion , a well-coordinated, multidi sc iplinary
team can as ist pati ents and the ir famili es with
manag ing the evolving nature of their illness and
he lp them make informed dec isions. Through
appropriate co llaboration, care can be optimized
and th e burden of thi multi-faceted di sease can
be reduced.

8.

9.

I 0.
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MEDICINE AND THE LAW
Who's in Your Genes: A Physician's "Duty to Warn" Patients' Relatives
about Genetic Risk
Colin Meyer- MacAulay [Meds 2012)
Faculty Reviewer: Dr. Victoria Siu
The genetic information of a patient as it relates to disease risk may prove invaluabl e to blood relati ves who
may wish to use it to make informed decisions about health care or reproduction. On the other hand,
diagnosis of a genetic disorder may carry with it a certain social stigma , as well as concerns about
discrimination with regards to employment and life insurance. Furthermore, genetic risk cannot be altered
nor is it caused by the actions of the patient. A physician 's "d uty to warn" individuals who may be put at
risk by the actions of a patient has been recognized in the context of both infectious disease and psychiatric
illness. However, it is unclear whether these same precedents may apply in the context of genetic
information. Nonetheless, a number of lawsuits in the United States have been brought against physicians
for their alleged failure to warn relatives of genetic risk. Canadian Policy deci sions on thi s issue must be
made based on an understanding the benefits and limitations of genetic medicine, as well as a clear
appreciation of the physician's dual duties to maintain confidentiality and prevent harm . In light of this, this
article reviews the available literature to address legal and ethical issues as well as potential policy
directions surrounding a physician 's "duty to warn" patients ' relatives about genetic risk.

Introduction
Recently, well-known Harvard professor
and bestselling author of The Stuff of Thought,
Steven Pinker, allowed his entire genome not
only to be sequenced, but also to be posted on the
1
Internet for the world to see. In so doing he has
given celebrity status to key questions in the era
of personalized genomics. These include whether
one has a responsibility to disclose the results of
genetic tests to family members who might
likewise be affected, 2 and who should protect the
consumers of the health care system from what
3
has become known as "genetic discrimination".
To date, instances of so-called genetic
discrimination have been scarce in the United
States 3 and nearly unheard of in Canada, aside
from the odd account of discrimination with
respect to life insurance. Furthermore, this topic
has been well covered by this publication in a
previous article and will not be expanded upon
further. 4 However, an issue that does warrant
further investigation is whether physicians have
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an ethical and legal obligation to warn the
relatives of patients with a positive genetic test if
that information may benefit them . A thorough
understanding of the theoretical benefits and
limitations of genetic testing, as well as how these
translate to our patients in practice, will ultimately
have to guide policy in this matter.

Genetic Testing
According to Knoppers et a!. (2004),
genetic tests can be defined in a legal sense as
either those tests that are based on "the presence
or absence of pecific genetic abnormalities" or
more broadly, those that include " tests based on
the end products of most genes." Knoppers et a!.
argues that in the latter case, genetic risk factors
amount to nothing more than probabilities, and
thus are difficult to distinguish from other routine
predictive tests performed by a family physician. 5
Some diseases can be conferred by a single gene
mutation, or the inheritance of two mutated genes
at the same genetic locus. In contrast, many
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common diseases such as diabetes, cancer, and
heart di sease have a multifactorial etiology,
invo lving the interacti on between genes and the
environment. U p to now, most genetic tests have
been a imed at detecting s ingle gene di sorders, and
often prov ided definiti ve di agnoses when the
clini ca l pi cture was suggesti ve of genetic di sease .
With the advent of whole genome sequencin g,
tests that enabl e clini cians to assess geneti c ri sk in
much the same way as a fa mil y history are
increa ing ly ava il abl e. 6

Genetic Medicine
Med ica l uses of geneti c in fo rmati on are
nearly as di verse as th e defi niti on of genetic
testing is broad. Phys ician ca n use geneti c
in fo m1ation to make diagnoses in newborn s (e.g.
pheny lketonuria, PKU), to ide nti fy future hea lth
ri sks (e.g. BRCA l and 2 mutati on ), and to
pred ict drug respon es or even to predict hea lth
ri k to children not ye t bom .6 Most pertinent to
the current di scuss ion are th ose geneti c di agnoses
or predi cti ve genetic te ts that may indi cate a
fa mili a l ri k of di sease. Often so me of thi s ri sk
can be mi tigated through ea rl y recogniti on of a
geneti c risk fac tor. Converse ly however, there are
geneti c di eases w here pre-symptomatic di agnos is
confe r no progno ti c advantage, but whi ch may
carry a ignifi cant assoc iated burden of di sease,
such
a
Huntington
di ease
(HD).6
Centra l to the ethi ca l dilemm a of
predi cti ve geneti c tes ing i w hat the infonnati on
w ill actua ll y mean to th e pati ent in terms of hea lth
care o pti ons. ln fac t, acco rd ing to Wyli e Burke
onl y about 20% of th o e at ri sk fo r deve lopment
of HD in the UK had o pted for predi cti ve testing
as of 2002. 6 T hi s reluctance to pur ue predi cti ve
tes tin g fo r an incurable di ease may li e in the
p yc hosoc ia l consequence of an unfavo rabl e
result. O ne study by Gi argiul o et a/. found th at of
I 19 pati ents who underwe nt predi cti ve testing for
HD, a s ignifi cantly greater number of presymptomati c carri e rs ex perienced depres ive
7
epi ode than those fo und to be non-carri ers.
Those peopl e w ho do choose to pursue predicti ve
te ting often do so in order to make informed
dec isions about reprodu cti on, rather than for th e
78
ho pe of treatment. • ln thi s se nse, predi cti ve
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genetic testing can be used to make deci s!ons t~at
limit the poss ibility of birthing a chtld wtth
significant ri sk of di sease deve lopment. On the
other hand, many geneti c di sorders show
incomplete penetrance, w ith some indi_v iduals
having an a ltered genotype but showmg no
6
ev idence of di sease.

Confidentiality and the Duty to Warn
Phys icians have a duty to protect the genetic
info rmati on of a pati ent from unauthorized
disc losure to any third party. However, under
certa in circumstances confidenti ality may be
justifi abl y breac hed, as is the case when
legis lati on mandates it, or w hen it is breached
9
w ith th e aim of preventing harm to a third party.
N umerous lega l precedents, including Tarasoflv.
Regents of the University of California 10 and
Pitman Estate vs. Bain 11 recognize a phy ician 's
" du ty to warn " under circumstances where
" di sclosure is essenti al to ave rt danger to others". 9
Furthermore, the Per onal Health lnfom1ation
Protecti on Act provide that physicians or other
hea lth care wo rker " may di close persona l hea lth
info rmati on if th ere are reasonable grounds to
be lieve that the di c losure i necessary to
e liminate or reduce a ignifi cant ri k of serio us
bodil y harm to a pe rson or a group of persons." 12
It is important to understand thi di tinction
when con id ring w hether or not a family
member may be entitl ed to know about a pati ent' s
geneti c infom1a ti on. An excu abl e breach of
confidenti a li ty i techni ca ll y ill ega l, though the
court may c hoo e not to mandate compensation
or puni shment ba ed on well-intentioned
9
moti ves. Thu , a pati ent ' ri ght to confidenti a lity
is lega ll y protected in genera l, though th e courts
recogni ze that under ce rta in c ircum tance it may
be ethi ca ll y nece sary for a physician to breach
thi s confidenti ality. By contrast, a phys ic ia n '
"duty to wam " refer to a lega l obli gation to
inform a third party of imminent ri sk to the ir
we ll -be ing, regardl e s of a patient' s ri ght to
. 1' 'l 9 13
con fid
1 entr a rty. ~ · ·
Wh ether or not uch a breach
of confidenti ality mi ght be ju tified in the case
where di sc losure of geneti c informati on to famil y
members may enabl e them to decrease the ir ri sk
of di sease deve lopment remains to be determined

29

by the courts. ' On the other hand where genetics
is concerned, physicians become pri vy to
information that has implications to both the
patient and their relatives. In thi s sense, the
calculation of genetic risk in one person may
violate another's right to personal autonomy
where health care decisions are concerned .9 Thus
Dickens et a/. argue that health care profess ionals
may take on a new and very real set of duti es as it
pertains to sensitive information that may be very
beneficial to individuals who may in fact not be
their actual pati ents. 9
While a "duty to warn" has been
recognized in the context of both psychiatric
10
illness and infectious disease, 11 Canadian courts
have yet to set similar legal precedents where
genetic information is concerned. 2 Wh ether or not
the aforementioned precedents mi ght apply to
cases where di sclosure of genetic information
may benefit a third party is questionable. Disease
ri sk conferred by your genotype is not
preventable, nor can relati ves be viewed as
potential victims of the patient (i.e. the patient
2
does not directly cause the risk). ' 9 Finally, less
than 1% of physicians surveyed in the US
believed a " duty to warn" was reasonable in
instance where no valid medical therapy exists. 13
Notwithstanding, as of 2004 failure to
warn a relati ve of genetic risk had already
resulted in 3 lawsuits against physicians in the
13
United States. In all three of these cases, State
Appellate courts ruled in fa vor of the plaintiffs,
asserting that physicians must ensure that
immediate family members are warned of
impending genetic ri sk (though in one case the
actual jury eventually decided in favor of the
physician). 13 Currently in Canada there is no
obligation to warn family members of genetic
ri sk, and disclosure could even potentiall y be
punishable by courts or profess ional regulatory
bodies.2 Some strategies aimed at reso lving this
issue include: strict confidentiality, a universal
duty to warn, and informed consent or as Offit et
. M.Iran d a warnmg.
· , 2' t3
a!. would say a " genetic
This third strategy involves physicians informing
their patients of the circumstances under which
they would be obliged to disclose information
prior to genetic testing. While the first strategy
UWOMJ, Vol 78, Issue 3

does not adequately protect the interests of the
family members, the latter two strategies are
coercive and do not respect the patient 's ri ght to
make a utonomous deci ions about health care. In
addition, it is like ly that they wo uld adverse ly
affect patient utilization of predictive testing
2 13
beca use of perce ived genetic discrimination . '
Thus, the cun·entl y accepted strategy is to adopt
an
" intermediate
position"
whereby
confidentiality is respected as a rul e, but it is
recogni zed that circumstances exist in wh ic h
di sc losure of genetic informati on may be
justifiable?· 9
Conclusion
While no formal lega l duty to warn
currently exists in Canada, there is a general
consensus that phys ici ans should make a va li ant
effort to inforn1 their patients that genetic
information may prove inva luable or even life
sav mg to th eir relatives. In cases where
penetrance is hi gh, ri sk of imminent and severe
harm is great, and viab le treatme nt option s do
ex ist, th e benefits of di sclosure to a third party
may so far outweigh the potential harm to the
patient as to make it justifiable in a court of
2 13
Iaw . •9• Thus the phys ician 's dual duti es to
maintain confidentiality while simultaneously
acting in a spirit of beneficence continue to be at
odds in thi s matter. Unfortunately it is likel y that
they will remain so until more is known about the
circumstances under which knowledge of their
relative's genetic risk mi ght actually prove
beneficial to an indi vidua l.
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MEDICINE AND TECHNOLOGY
Personalized Cancer Management
j enny Shu (Meds 2 01 2) a nd Pencil/a Lang (Meds 2 011)
Fa culty Reviewer: Dr. Robert Hegele
The aggression of cancer is characteri zed by its multi geni c and heterogeneous nature. With the com plet ion
of the Human Genome Projec t in 2003, there has been growin g interest in the fie ld of persona lized
medic ine fo r cancer management, using an indi vi dual's geneti c compos iti on to d irect prevention, detection,
prognosti c, and therapeutic efforts. Thi s rev iew w ill prov ide an overview of so me of th e mo lecul ar profi ling
techniques that are cutTentl y in use, in clud ing transcrip to mi cs, proteomi cs, and genom ics usin g asse ment
of sing le nucleotide po lymorphi sms (SNPs), copy number vari ati on (CNV) and hi gh- throughout gene
sequencing. Some recent exa mpl es of persona li zed medi c in e appli cat ions in the screening, d iagnos is, tumor
class ificati on, and targeted therapy of vari ous ty pes of ca ncer wi ll a lso be discussed. A lthough mo re
va lidati on and con o lidati on of these research studi es is req uired before personalized med icine is w ide ly
used for cancer management, its potenti a l benefits ho ld impli cati ons fo r ph armace utica l companies,
di agnosti c agencies, hea lthcare providers, and most importantl y, pati ents .

Introduction
A di agnos is of 'cancer' is a life-chang in g
event for pati ents. An es timate of over I 0 milli on
peopl e g loball y w ill di e annua ll y as a result of
1
cancer in the year 2020. It is not surpri sing that
there is a dri ve to furth er our understanding of the
disease mechani sms, pathophys iol ogy, and
treatment of cancer. The multi geni c and
heterogenous nature of cancer has long been
recogni zed, and thi s hete rogeneity can determine
the aggress iveness of cancer in an indi vidua l
patient. 2•3 The compl etion of the Huma n Genome
4
Proj ect in 2003 ' 5 has brought forth the hope of
advancing medi ca l practi ce into a "genomi c era"
that w ill identi fy key therapeutic targets and
disease biomarkers for cancer. Despite these
advancements, much of the systemi c therapy fo r
6
cancer pati ents is still empiri cal and two pati ents
who may be at apparentl y 'identica l' stages of
cancer and harbor the 'same' tumor type w ill
exhibit significantly di ffe rent clini ca l outcomes as
7
measured by survi va l and therapy response.
Instead of continuing to progress down th e
traditional ' trial and error' method of testing for
new therapeutic agents, the personali zed medi cine
model has been proposed because of its
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theo retica l appea l: in thi s mode l, an indi vidua l's
geneti c compos iti on he lps foc us and d irect
prevention, de tecti on, prognosti c, and therapeutic
efforts .7 Thi s article w ill provide an overv iew of
th e current status of mo lecula r profiling
techno logies and their current appli cati ons in
persona li zed medi cine, fro m the initi al stages of
identi fy ing signifi cant ca usati ve and modul a ting
genes to the integrati on of multiple genes w ithin a
personalized profil e that w ill direct th erapy in the
sub-population of cancer pati ents.

Molecular Profiling Techniques
Th e main mo lec ul ar pl atfo m1s cun·e ntl y
w ide ly used in persona li zed medi cin e are
tran criptomi cs, proteomi cs and genomi cs, w hi ch
ing le nucleotide
in cludes th e ana lys is of
po lymorphi sms (SNPs), copy number vari ati ons
(CNV s) and hi gh-throughput gene sequencing.7
O f course, these are often not mutua lly exc lusive
and one of the current goa ls in persona lized
medi cine is to deve lop an approac h to utili ze a nd
the
info m1a ti on
fro m
d iffere nt
integrate
techniques.
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Transcriptomics, the study of altered
express ion of the leve ls of messenger RNA
(mRN A) w ithin cancer ti ssue samples or biopsies,
has led to the deve lopment of Internet-based
resources such as Oncomine Research Pl atform 8
that ma intains a cata logue of published
transcriptome profi les so th at clini cians and
sc ienti sts can eas ily access the informati on.
A lthough mi croarray techno logy, the main means
of transcriptome profilin g, is cost-effecti ve and
accurate, it is
till inhibited by sampl e
heterogene ity and the absence of a hi gh-quality
multi-institu tional tumor ti ssue library that would
be necessary to cater to a large po pulati on.
Proteom ics
also
expl ores
genetic
express ion, but at th e leve l of tra nslated pro tein
quantity, structure and fun cti on w ithin cancer
tissue sampl es . While techni ca ll y more d iffi cul t
th an transcription profi ling, p roteo mi c ana lys is
has th e adva ntage of more di rec tly examining
mo lecul ar mac hinery of ce ll physio logy, posttranslati ona l modifi cati ons, and pro tein-protein
compl exe .9 Mass spectro metry and protein
mi croarrays have also been used to target spec ific
bi omarker in s igna ling cascades, a lthough there
are some limitations with respect to di ffi culti es in
large-sca le ta rget identi fica ti on as the exact
number of polypeptides produced 1s still
uncertain . 10
F inally, there is a w ide range of genomi c
DNA vari ati ons that predi spose or propagate the
development of ca ncer. Exa mpl es inc lude ing le
nuc leoti de polymorphi sms (SNPs), whi ch are
geneti c va ri ati ons in th e DNA sequence due to the
di ffe rence of one nucl eotide a mong indi vidua ls.
Copy number vari ati on (CNV ) refer to largersca le changes, in c luding gene dupli cati on,
de leti on, in vers ion or trans locati on events. Both
SNPs and CNVs have been linked to a w ide range
of di fferent ph ysio logica l ph enotypes and
di seases. However, thi s is onl y an initi a l step; the
examin ati on of genomi c DNA in a pati ent 's
germlin e or in somati c ce lls taken from ca ncerous
ti ssue can strati fy ri sk and identi fy new ca usati ve
gene and path ways, but thi s infom1ati on a lone is
not suffi c ient to defin e mec hani sms of di sease or
therape uti c approaches.
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The ultimate genomic assessment is
whole-genome sequence analysis, in which all 3
billion nucleotides of genomic DNA from an
indi vidual pati ent or the cancer tissue sample are
analyzed using automated nuc leotide sequencers
to determine potenti al fun cti ona l changes from a
norma l reference sequence. T here ha ve been
many initi atives such as the Human Cancer
Genome Proj ect and Cancer Genome Anatomy
Proj ect to use hi gh throughput gene sequencing to
identi fy nove l di sease-associated mutations at a
.
has
genome-w ide leve l. I I Much of the attentiOn
shifted
from
mastering
the
technologies
th emselves to extracting biologically relevant
in fo m1ati on - a fi e ld call ed " bioinfom1atics" such as pairing screen results with fun ctional
7
assess ments of a specifi c neoplastic process.
Despi te the more comprehensive sequence
in fo rmati on at the expense of a hi gher cost, there
have been some appli cati ons of genomic and
12
bioin fo rmati c ana ly i in tumor c lass ifi cati on.

Screening and Diagnostics
Preventi ve measures taken aga inst cancer
can u e per ona lized medi cine to screen for one's
predi spos ition to cancer, which is important in
prov id ing a w ider range of therapeuti c options for
the pati ent and guiding in clini cal deci ion
ma king. Geneti c screening is parti cularl y useful
for indi vidua ls w ith a fa mil y hi story of can cer,
where the presence of oncogenic mutations such
as APC (adenomatous po lypos is co li ), BRCA J
(breast ca ncer l , early onset), and BRCA2 (breast
cancer 2, earl y onse t) can be used as ri sk fa ctors
before any ymptoms or even ce llul ar dyspl a ia
13
occur . Ce lecox ib, the current chemopreventi ve
agent of cho ice for co lorecta l can cer, is only
recommended for hi gh-ri sk pati ents w ith famlial
adenomatous po lypo is linked to the APC
13
oncogene mutati on. There is a lso a dri ve to
utili ze
persona li zed
medicin e
m
c linical
di agnosti cs. Although the
pro tate-spec ifi c
anti gen (PSA) is th e go ld-standard for detecting
prostate cancer, greater diagnosti c acc uracy m
unscreened popul ati ons can be achi eved if
biologicall y-based prediction mode ls are used to
link biom a r~e r leve ls to other indi v idua l fac tor
such as age.

Prognosis and Tumor Classification
Another important goal in personalized
medicine is to consolidate infonnation from
traditional prognostic factors and genetic profiles
in order to optimize treatment for patients. An
important prognostic biomarker for breast cancer
is the human epidermal growth factor receptor 2
(Her2), which encodes a transmembrane receptor
protein that is overexpressed in breast cancer
15
cells. Specifically, these levels can be used to
predict clinical outcomes; serial changes in the
circulating Her2 extracellular domain (ECD)
levels have paralleled the clinical course of
disease regardless of the treatment. Specifically,
higher ECD levels have been corre lated with
earlier recurrence of breast cancer. 15 There is also
a 186-gene "invasiveness" gene signature (IGS)
generated from differentially expressed genes that
has been found to be strongly associated with
metastasis-free survival and overall survival of
medulloblastoma, lung cancer, prostate cancer,
16
and
especially
breast
cancer.
Hence,
bioinformatics-centric prediction models have
been gaining ground in predicting the therapeutic
response of common tumors based on their gene
expression profiles.

Targeted Therapy
Current research has been progressmg
towards a consolidation of our current knowledge
on diseases, genetic alterations, and drug
responses, allowing both the creation of new
chemotherapeutic drugs and expanding existing
ones on the market. For instance, imatinib
meyslate (Gleevec) is a drug that was initially
approved by the Food and Drug Administration in
2001 to treat chronic myelogenous leukemia
17
(CML) by targeting the BCR-ABL protein.
Later, G leevec became the first specific effective
treatment against advanced gastrointestinal
stromal tumors (GISTs) after researchers found
that the link between the mutant KIT protein,
which shows similarities to the BCR-ABL
1
protein, and GIST aggression.
However,
researchers are still looking into ways to probe
into individual resistance mechanisms to combat
.
.
.
19
the issue of Gleevec res1stance m patients.
Gefitnib (Iressa) is another anticancer drug that
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targets the epidermal growth factor receptor
(EGFR), an important component leading to lung
cancer aggression. The concept of personalized
medicine may explain why there were largely
negative results of clinical trials as only 10-15%
of the test patient population carried the EGFR
20
gene mutation or gene amplification.
Hence,
clinicians are looking into the possibility of
conducting more targeted trials that restrict
e li gibility of subjects to those whose molecular
profile predicts a better re ponse to a particular
chemotherapeutic agent.

Challenges and the Future of Personalized
Medicine
Although there is much hope regarding the
potential of personalized medicine, there are still
many barriers preventing its widespread usage.
Duffy et a/. 6 illustrate some of the key challenges
in the field, including underpowered studies,
invalidated results from independent patient
populations or prospective trials , multiple end
points and subsets of patients used, and poor
quality of design and unreliable data. These
problems can be addressed in part by better
coordinated multi-centered prospective studies
using much larger patient cohorts than have been
studied to this point. Nonetheless, the potential
benefits of personalized medicine - with respect
to improving positive outcomes and minimizing
side effects and costs of treatment - are worth
taking the time and effort to pursue. This holds
implications for pharmaceutical companies,
diagnostic agencies, members of the healthcare
profession, and most importantly, patients.
Indeed, there is a movement towards focus on the
individual and not just the disease- what has
been a barrier to treatment in the past may very
well be the key to unlocking mechanism of
di ease to combat cancer in the future.
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THINKING ON YOUR FEET
Marfan Syndrome
Kalpa Shah (Meds 2012) and Aiman Alak (Meds 2011)
Faculty Reviewer: Dr. Victoria Siu
Marfan syndrome was first described in 1896 by Antonine-Bernard Marfan, Professor of Pediatrics in Pari s.
It is a relatively common inherited connective tissue disorder with an incidence of 1 in 10,000 individuals.
The condition is inherited in an autosomal dominant pattern , with an equal di tribution in males and
females.

Case
The following case is meant to serve as a prompt
to guide the discussion on the clinical aspect of
Marfan Syndrome.
An 18 year old man develops sudden chest
pain while playing basketball. He is noted to be
quite tall at 6'5" and has long fingers and
toes. Does he have Marfan syndrome? What are
the diagno tic criteria? If he has Marfan
syndrome, what are 3 possible causes of his chest
pain? It wou ld be relevant to note whether the
patient wears contact lenses as individuals w ith
Marfan syndrome are often near- or far-sighted
and/or have other eye abnorma liti es.

Clinical Presentation
Most patients who have Marfan syndrome
are usua ll y diagnosed incidenta lly. Typically,
patients with Marfan syndrome present with tall
stature, lens dislocation (ectopia len ti s), aortic
root dilatation and a positive family history . Less
common presentations include:
• Dominant ectopia lentis with variab le
ske letal
and
negligible
cardiac
involvement
• Mitral valve prolapse without ske letal
features
• Dominant
aortic
aneurysm
without
ske leta l and ocular features

UWOMJ, Vol 78, Issue 3

• Presentation at
birth, rapid aortic
dilatation, deformities (such as pectus
deformities,
where
the
breastbone
protrudes inward or outward), and death
1
• Sudden death

Pathogenesis
The genetic basis for Marfan syndrome is
a mutation in the gene encoding fibrillin-1 (FBN1) found on chromosome 15 . Fibrillin is a
g lycoprotein that is an integral part of microfibril s
found in the connective ti ssue of the body.
Microfibrils function as the main component of
elastic fibres, anchoring fibres between the dermis
and epidermis, as we ll as in the lens of the eye.
C lassically, it was thought that the ubiquitous
features of Marfan syndrome could be attributed
.
.
.,
to weak or deformed connective tissue.- However,
recent re earch sugge t that a defect in the
fibrillin-1 structure reduces its abi lity to bind to
the cytokine TGF-8 , which results in increased
ex pres ion of TGF-8. 1n mouse model s, increased
TGF-B
signaling
was
associated
with
myxomatous mitral va lve leaflets and aortic
dilatation, both feature of Marfan syndrome.
Furthermore, by admini tering an antibody that
binds TGF-8, it was shown that these common
features cou ld be prevented. 3 Thus, it IS now
thought that it is the over-expres ion of the
cytokine TGF-B , due to the inability of the
defective fibrillin-1 that would m norn1al
circumstances bind TGF-8 , that results in the
features of Marfan syndrome.
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Marfa n
syndrome
has
di verse
m anifesta ti ons that can affect many organ systems
such as the skeleta l, ocular, cardiovascular
systems and can a lso invo lve the skin, lungs and
musc le ti ssue - an exampl e of pl e io tropy.

Clinical Diagnosis
The d iagnosis of Marfa n syndro me (MFS)
is usua ll y ba ed on cl ini ca l fea tures and fa mil y
4
hi story. The fea tu res of M arfa n syndrome may
overlap w ith other connecti ve ti ssue di sorders and
the presentati on of Marfan synd rome vari es
w idely,
even
among
fa mil y
member .
Nonethe less, the deve lopment of a set of
guide lin es, known as the Ghent cri teri a, has
4
bro ught c larity to the issue.
•

If an ind ividua l has a fi rst-degree relative
affected by Marfan syndrome, a diagnos is
of Marfa n syndrome req uires maJor
invo lvement in one organ system
(ske leta l, cardi ovasc ul ar, o r oc ul ar) and
minor invo lve ment of a second organ
system.
• In the ab ence of a fa mil y hi story fo r
Marfa n syndro me (or ambi g uous famil y
hi story), a di agnosi of Ma rfa n syndrome
require maj or criteri a in two di ffe rent
organ systems and min or in vo lvement of a
third .
Pl ease refer to Tab le I attached at th e end
of the arti cle for more deta il s on the c lini ca l
fea tures that wo uld constitute majo r o r mm or
in vo lvements in di ffe rent organ systems.
As a s implifi ed g uide lin e, fo r a pati ent
suspected of hav ing Ma rfa n sy nd ro me orne
in vestigati ons that are he lpful in making a c lini ca l
di ag nos is inc lude:
•

Examin ati on by an an ophtha lmolog ist to
look fo r lens di slocati o n o r sublu xati on;
often pati ents with Marfa n ynd ro me are
near-sig hted (myopi a) and at increased
ri sk fo r deve lopin g catarac ts and
g laucoma
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• Referral to a cardiologist for an
echocardiogram to assess if there are any
cardiovascular abnormaliti es su ch as
mitra l valve prolapse, aortic root dila tation
or a011ic dissection
• Phys ica l exam to assess ske leta l fea~re~ :
rati o of arm span-to-he ight ratio w hich IS
cons idered sig nifi cant if it is greater than
1.05, or wrist and thumb sig ns.
(A
pos iti ve w ri st sign is present if the thumb
and fifth fin ger overlap w hen encircling
the opposite w ri st. A pos itive thumb sign
is present if the entire thumbnail protrudes
beyond ulnar border of hand w hen the
thumb is adducted across the pa lm .)

Differential Diagnosis
The di fferenti al di agnosis for MFS
incl udes ho mocystinuria, congenita l contractura l
arac hnodacty ly, mild ao rti c root dilatati o nske leta l-skin (MASS) syndrome, E hlers-Danlos
syndro me, Sti ckler synd ro me, congenita l bic uspid
aorti c va lve di sease, ao rti c coarctation, LoeysDi etz yndro me, and fa mili al th oracic aortic
aneury m wi th aortopath y. T he most s imilar
di ffe renti a l i homocystinuri a as the two di seases
share a imil ar phenotype. Fea tures that overlap
between Marfa n syndro me and homocystinuria
inc lude ecto pi c lenti s, severe myopi a, mitra l va lve
pro lapse, and ke leta l abno m1a liti es, such as body
habitus, c hest defo rmiti e , and spine defom1iti es.
Pati ents w ith homocys ti nuri a are at an increased
risk for th ro mboembo lic events, but many
pati ents w ith thi s co nditi on are respo n ive to
pyridox in e. T hus, it is impo rtant to screen for
homocystinuri a w ith meas urement of urinary
amin o ac ids, as th ere are impli cati ons for
rna nage men t. 5

Management
O verall, the prognos is for M arfan
syndro me is re lati ve ly favo rabl e. Acti v ity
restri cti o ns, medi cati ons, monitoring, and e lecti ve
surgica l interventi on we re associated w ith an
improved life span for M FS patients fro m 4 1
years in 1993 to 6 1 years in 1996 .6•7

Aortic disease is the most significant
source of morbidity and mortality for patients
with MFS. Untreated MFS can be associated with
an aortic dissection spanning the entire length of
the aorta. Aortic dissection occurs earlier among
patients with MFS compared to the other cases of
aortic dissection. Assessment for aortic root

dilatation and regurgitation can be performed by
thorac ic echocardiography; however, if that yie lds
incompl ete
or
insufficient
information,
transesophagea l echocardi ography can be used.
Routine measurements ca n be performed annua lly
as long as th e aortic root diameter increases
proportional to increases in body surface area. If

Table l. Ghent Criteria for Diagnos is ofMarfan Syndrome*
System
Majo r
Family/genetic
history

•
•

Skeletal

•
•
•
•
•
•
•
•

Ocular

•
•

Cardiovascular

•

Minor

Hav ing a first-degree relati ve who meets
these diagnostic criteria
Presence of a mutation in FBN I known to
cause Marfan syndrome

•

None

Presence of at least 4 of the following
manifestations:
Pectus carinatum
Pectus excavatum requiring surgery
Reduced upper-to-lower segment ratio or
arm span-to-height ratio > 1.05
Wrist and thumb sign
Scoliosis > 20 degrees or spondylolisthe is
Reduced extension at elbows (< 170
de grees)
M edial di splacement of medial malleolus
causing pes planus
Protrusio acetubu lare of any degree
Ectopia lenti (dislocated lens)

•
•
•

Pectus excavatum of moderate severity
Joint hyperrnobility
Highly arched palate with crowdin g of
teeth
Facial appea rance (do lichocephaly, malar
hypoplasia, enophthalmos, retrognathia,
down-slanting pa lpebral fi ss ures)

Dilatation of ascending aorta with or
without aortic regurgitation and in volving
at least the sinuses of Valsalva or
di ssection of ascending a011a

•

•
•

Abnormally flat corn ea
Increased axial length of globe

•

Mitral va lve prolapse with or without
mitral va lve regurgi tati on
Dilatation ofthe main pulmonary a11ery, in
the absence of valvular or peripheral
pulmonic tenosis or any other obvious
cause in patients < 40 year
Calcification of mitral annulus in patients
<40 yea r
Dilatation or di ssection of the descending
thoracic or abdominal a01ta in pati ents < 50
years
Spontaneous pneumothorax
Apical blebs

•

•
•

Pulmonary

•

None

•
•

Skin and
integument

•

None

•

Dura

•

Lumbosacral dural ectasia (by CT or MRI)

•

Stretch marks not assoc iated with weight
changes , repetitive stress
Rec unent incisio na l herni as

•

None

*Adapted from Rangasetty UC, Karnath BM. (2006) 1
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the increase is di sproportiona l, or if the aorti c root
diameter is greater than 4 5 mm, bi annual
measurements should be performed.
The European Soc iety of Cardi ology has
publi shed recommendations for the treatment of
8
pati ents with M F S. The standard of care in vo lves
beta bl ockers whi ch can de lay the progress ion to
aorti c di ssection . Beta blockers decrease
myocardia l contractili ty and pul se pressure and
may a lso improve the e lasti c properti es of the
aorta, parti cul arly in pati ents w ith an aortic roo t
10
diameter <40 mm .9·
In a randomi zed tri a l,
treatment w ith pro pranolo l was as oc iated with
de layed prog ress ion of aortic dil atati on, and
hi gher surv iva l at approx imate ly fi ve years.
Longer term surv ival di ffe rences between
proprano lo l and pl acebo were Ies c lear. 11 No
randomi zed tria ls have been done to establish the
12
efficacy of beta blockers in children. However,
many c li nic ians wo uld give beta bl ockers to a ll
childre n with MFS . In the fu tu re, therapy di rec ted
at the renin-ang ioten in -a ldosterone system may
prove benefi cia l, but th e ro le of these drugs in
MFS ha not ye t been e tabli h ed . 13 ' 1 ~
Pati ent w ith MFS may parti cipate in low
to moderate in te nsity, non-competiti ve exercise
uch a bow lin g, go lf, tati onary bike, or modest
hikin g. Strong ly di couraged acti vities inc lude:
weight li ft ing, ice hockey, rock c limbing and
surfing. 15 The cho ice of permi ss ibl e acti viti e
requi res indi vidua l assess ment. For chil dren to
comply w ith th ese actj vity re tri cti ons, there mu st
be coordinati on between parents, schoo l offic ials,
and ph ysical ed ucators.
Electi ve surgica l repair fo r an aorti c
dil atati on is assoc iated w ith reduced mortality
compa red to urgent or emergent repa irs. For
adults and children, surgica l repair should be
cons idered at an ao rti c root di ameter of 2': 50
mm. 16 Uncertainti es ex ist regarding the root
di ameter fo r perfo rming e lecti ve surgery. The
2006 A meri ca n Co ll ege of Cardi o logy/A meri can
Heart
Assoc iati on
(ACC/ AHA)
guide lines
recommend e lecti ve surgery for an ao rti c root
di ameter 2':50 mm , w hil e European Soc iety of
Ca rdi o logy (ESC) recommends surgery fo r an
17
. .on to
aorti c root di ameter of 2':4 5 mm . I n a dd 1t1
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the absolute size of the aortic root di ameter, other
considerations are a famil y history of aortic
di ssection or a rapid increase in aortic size (i.~ .,
.
2': 5 mm per year). 18 Some suggest usmg
ao rt tc
root dimensions re lati ve to body surface area.
This factor is parti cularl y important for children.
For children, the o nl y clear indi cations for
surgica l intervention are: an aortic root diameter
of 2':4 5 mm ("giant aneurysm"), rapid enlargement
of > l 0 mm/year, or progress ive
aortic
in suffi c iency. Other cut-offs for aortic root
di ameter are less clear.
A few opti ons exist regarding the surg ical
technique and the cho ice depends on patient
factors. O ne approach in vo lves tota l replacement
of the ao rtic roo t. 19 A lternati vely, for patients
with structura ll y norma l va lves th e nati ve aortic
va lve may be reta ined using remodeling and
20 2 1 I
. Iantat10n
.
.
re1mp
tee hmques.
·
n th.IS Iatter
opti on, li fe -long anti-coagulati on is not required;
however, repeat operati ons may be necessary .
An tibi otic prophy lax is hould be indi vidua lized.
As other sites throughout the aorta maybe
in vo lved, fo llow- up radiography using MRI or
CT angiography is requi red inde finite ly.~ 2
Ocular and mu ke loske le ta l problems also
require attenti on. Eyeg lasses can correct myopi a,
whil e arti fic ia l lens inserti on should onl y be
undertaken w hen growth of th e eye is compl ete .
Furth er, ph otocoagulati on can correct retina l tears
and detac hment. If interventi on w ith phys ical
th erapy and brac ing fa il s, sco li os is may require
urgica l tabili zation of the spine. Orth o ics can
correc t fl at foot, whi ch i as oc iated w ith musc le
cramps and leg fa ti gue.

Answers to Case
Di agno is wo uld be made based on Ghent
criteri a. Poss ibl e causes of che t pa in are :
musc le/li gament tra in , aorti c root di section , and
pn eumothorax .

Glossary
pectus carinatum : deformity of the chest
characterized by protrusion of ribs and temum

pectus excavatum: deformity in which several ribs
and the ste rnum g row abnormally, producing a
concave appea rance in a nte rior ches t wall
protusio acetabulare:
protrus ion
of
the
acetabulum (socket that r eceives fe moral head to
make the hip joint)
pes planus: flat foot
dolichocephaly: elong ated s kull
enophthalmos: rece ss ion of eye ba ll within the
orbit
sinuses of Valsalva: al so known as a orti c s inus;
the space be tween each se milunar v a lve a nd th e
w a ll of th e aorta
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ZEBRA FILES
Human Statues: Challenges in Management of Patients with
Fibrodysplasia Ossificans Progressiva
Anna Burianova (Meds 2 01 2J Ashley Brown (Meds 2011J andjenna Ashkanase (Meds 2011)
Fa culty Reviewer: Dr. Kathleen Hill
Fibrodys pl as ia oss ifi cans progress iva (FO P) is a rare geneti c di sorder in whi ch soft tissues transform into
bone, caus ing pati ents to gradua lly become entombed in th eir own bodi es. Earl y symptoms ty pically
invo lve infl ammatory les ions that are often confused with a va ri ety of tumours and other conditions,
leading to delays in d iagnos is and medi ca l procedures that may ca use significant detriment. The recent
di scovery of th e FOP gene may he lp to all ev iate thi s issue, as DNA testing can allow for earlier
identi fica ti on of the condition. A case study is presented to exempli fy the challenges faced when treating a
pati ent w ith FOP, and po sibl e compli cati ons are detail ed to emphasize the consequences if precautions are
not taken. W ith a spec ifi c gene target in sight, it is hoped th at treatments can extend beyond supportive care
and be abl e to prevent or ha lt thi debilitating conditi on.

Introduction
Metamorphos is
IS
defin ed
as
the
transformati on of one norma l ti ssue or orga n
system in to anoth er through a patho logica l
1
process.
W ithin
its
rea lm ,
heterotopi c
oss ifi cati on (HO) describes the abn orma l
formati on of true bone within ex traske leta l soft
tissues. Fibrodys pl as ia oss ifi cans prog ress iva
(FOP) is an exceeding ly rare geneti c di sorder
whi ch has , until rece ntl y, been one of medi c in e'
most e lusive mysteri es and the most di sabling
conditi on of extras keleta l os ifi cati on kn own in
humans.2 ·3

Genetics
FOP is an ex treme ly rare conditi on,
occulTing at a popul ati on frequency of about I per
2 milli on w ith no ethni c, rac ial, gender or
12
geographi c predi spos iti on. ' Th e severe di sability
of FOP results in low reproducti ve fitn ess and
fewer th an ten multi generati onal fa mili es are
1
known wo rldw ide. Most cases of FOP are
sporadi c w ith onl y one affected indi vidua l in a
famil y,
though
when
ob erved,
geneti c
1 2
transmi ss ion is autosoma l dominant. •
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A rece nt breakthrough in the study of FOP
was attained with th e identification of a recurrent
s ing le nuc leotide mi ssense mutation in activin
receptor
INacti v in-like
kinase
2
1
(ACV R l/ A LK2).
Thi
bone
morphogenic
protein (BMP) type I receptor ca uses ske letal
morph ogene is, and is therefore the fir t
identifi ed
human
metamo rphogene. u
The
mutati on ha been reported in a ll sporadic and
fa mili a l case of cl ass ic FOP wo rld w ide, making
it one of the mo t hi ghl y spec ifi c di sease-ca using
mutati ons in the human genome .3

Clinical Features
The c lass ic presentati on of FOP is defin ed
by two clini ca l features: conge nital ma lformation
of the great toes and progress ive H0.3 Congenital
ma lfonnati on of the great toe i the earli est
phenotypi c fea ture present in a ll class ically
affected individua ls, w ho appea r otherwi se
1 2
unremarkable at birth . • Other ke leta l anomali es
often associated with FOP inc lude deve lopmental
anoma li es of the cervica l spine, short ma lfonned
thumbs, clinodacty ly, hort broad femora l necks
and proximal medi a l tibi a l osteochondromas. 1

During the first decade of life, children
with
FOP
deve lop
painful
and
highl y
inflammatory soft ti ssue swellin gs (or flare-ups)
that progress ive ly and permanently transform
13
connective ti ssues into heterotopic bone. ' The
ossification in FOP progresses in characteri sti c
patterns that mimic normal embryonic skeleta l
development, with the first episodes typi ca lly
12
occurring along the upper back and neck. •
However, several
musc les
including
the
diaphragm, tongue, extraocular and cardi ac as
well as smooth muscle are eni gmatically spared
1
from the FOP process.
Interestingly, the clinical features of earl y
involvement in the ax ia l regions differ from those
seen in the appendicular regions. 1' 3 Even though
swelling appears more rapidly than typically seen
with neoplasms, the bulbous les ions which appear
on the neck and back are often mistaken for
tumours. 1,3 In the limbs, on the other hand , the
swelling is often diffuse and may be mi staken for
13
acute thrombophlebitis. •
The natural progress ion of the di sease can
al so be altered by environmental factors, as any
trauma leading to ti ssue injury has the potenti al to
induce HO. Thi s leads to epi sodes of explosive
and painful new bone growth, with cumulati ve
immobility. 1'2

Case Report
An 18-month-old boy from Brita in
presented w ith a brainstem les io n in need of
neurosurgery. He had recently been diagnosed
with FOP, and physical exam prior to surgery
revealed heterotopic ossifi cation of the dorsal a nd
lumbar
paravertebral
muscles,
the
left
sternocl eidomastoid, and fu sion of the C4-C6
vertebrae. Although the brainste m lesion was in
this case unrelated to hi s FOP, hi s condition
nonetheless complicated the procedure to remove
it. His montelukast was switched to predni sone to
prevent inflammation 24 hours before surgery and
Direct
continued until four days post-op .
laryngoscopy was not possible due to the fu sion
of his cervical vertebrae, therefore fiberoptic
broncoscopy via the nostril was necessary to
intubate him . Traumatic injury was avoided by
UWOMJ, Vol 78, Issue 3

using sili con carpets and a headrest, as we ll as by
padding every po int of contact w ith cotton woo l.
Because hi s FOP was recogni zed and attended to
properl y, the procedure produced a favo urable
outcome and the c hild had no signs of progress ion
of the di sease at two months post-op.-1

Complications of FOP
The case repo rt above illustrates some of
the diffi culti es in managing pati ents with FOP.
Since it is cruci al to prevent exacerbati ons, one of
the mainstays of proper care is to avo id the
associated
w ith
certain
medi ca l
trauma
procedures . Surgeri es
in
parti cula r pose
di ffi culti es for pati ents if, as in the case report,
fu sion of the cervi cal vertebrae has occurred and
impedes intubation . Anesthes ia in an FOP pati ent
can also be extremely di ffi cult if anky los is of the
jaw is present, w hi ch could be tri ggered by
something
as
simpl e
as
minor
dental
45
procedures. • Biopsies are also contraindi cated,
but since they are the investigation of cho ice for
most tumours, they are often performed before a
diagnosis is made.
One of the most severe compli cati ons of
FOP is cardiopulmonary compromi se. FOP can
lead to ankylosis of the costovertebra l j oints,
oss ifi cati on of the intercostal and paravertebral
musc les, and progress ive spina l deformity such as
kyphosco liosis or thorac ic lordos is.
Chest
expansion is drasti ca ll y limited, resulting in
reduced vital capacity and restri cti ve lung di sease.
Ri ght ventricular hypertro phy can also occur due
to th e thoraci c insuffi c iency.5•7
Pati ents w ith FOP are also more prone
th an th e general population to kidney stones as
well as conducti ve hearing loss due to fusion of
th e bones of the middl e ear. They are also prone
to fracture of heterotopi c bone, whi ch requires
closed reduction and splinting, as we ll as
analges ia, as in fracture of normotopi c bone in
5
any patient. Thus, pati ents should be educated
about ri sk factors for fa ll s to avoid precipitati on
of a cyc le in w hi ch a fa ll leads to furth er
ossification and joint anky losis, whi ch in tum
increases the ri sk of future falls. 5 ·6
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Discussion
FOP is an extremely debilitating di sease.
Most affected peopl e are wheel chair-bound by
the ir 20s and life expectancy is less than 40, as
thoracic insuffi ciency usua lly occurs by thi s
.
4
.
pomt.
Pat1 ents must li ve w ith th e constant
know ledge that they have a progress ive di sease.
As more and more j oints and musc les become
permanentl y oss ifi ed over time, pati ents with FOP
are essenti all y trapped in ide the ir own bodi es
until they can no longer move or even brea the.
T he recent breakthro ugh di scovery of the
FOP gene has ide nti fie d a spec ifi c target fo r
pharmaco logic therapy and a ll owed for th e
deve lopment of a DNA di agnosti c test w hi ch
expedites
di agno is . and
limits
ham1ful
2
interventi ons. However, the opportuniti es fo r
in sight prov ided by stud ying the FOP gene extend
fa r beyond thi s rare di sorder a lone. That is,
characteri zati on of the underl yin g mec hani sm

causing HO in FOP has much broader
impli cati ons fo r pati ents with more common
forms of HO and fo r deve loping tissue
engineering strategies for ske leta l bone and
cartil age repair. 2.3
Conclusions
Due to th e rarity, variabl e severity and
epi sodi c c lini ca l course of FO P, clini cians often
fail to assoc iate the rapidl y deve loping ax ia l soft
ti ss ue swe llings witb the di stincti ve ma lformed
g reat toes. 3 When such assoc iati ons are not made,
FOP is comm onl y mi staken for other conditi ons,
1
de lay ing pro per trea tment. ' 3 Not surpri sing ly,
mi sdi agnosed indi vidua ls often undergo a battery
of unnecessary bi opsies and tests th at exacerbate
progress ion of th e conditi on. Earl y di agnos is and
cauti ous manage ment of pati ents w ith suspected
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FOP are therefore very important. Finally,
although the current medi cal management of FOP
is largel y supportive, the goal of research
continues to be the deve lopment of treatments
that will prevent, halt or even reverse progressiOn
3
of the di sease.
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FEATURE
Quality of Life Consequences of Long QT Syndrome
lshvinder Chattha (Meds 2011) and Caleb Zeleniel::: (Meds 201 1)
Faculty Reviewers: Dr. Raymond Sy and Dr. Andrew Krahn
Long QT syndrome (LQTS) is a genetic condition characterized by abnormal repolarization of cardiac
ventricular myocytes predisposing the individual to ventricular tachyarrhythmias. The first manifestation of
LQTS is typically syncope and less frequently cardiac arrest or sudden cardiac death. This article examines
the effect of LQTS on patients' quality of life. This includes the psychosocial and physical consequences
that may result from both the diagnosis of a potentially lethal genetic disease and its subsequent
management. Current guidelines are based on expert consensus and recommend moderate and at times
strict exercise restriction, even in asymptomatic patients. Broad exercise restriction affects the social
development of children and also removes the protective effect that exercise has against developing both
psychological and physical health problems related to inactivity. Due to the potential decline in a patient's
quality of life resulting from strict exercise restriction, future research should focus on determining the
effectiveness of exercise restriction in the prevention of ventricular arrhythmias.

Introduction

Long QT Syndrome

Genetic disorders are unique in their
impact on patients. Often incurable, patients not
only need to deal with the wide array of feelings
surrounding the initial diagnosis, but there is
often guilt related to the possibility of passing the
disorder onto their children. 1 Given the
implications for family members, genetic testing
and resultant therapy is offered to relatives. The
diagnosis can also influence family planning.
These consequences are in addition to the effects
of the disease itself.

The
QT
interval,
seen
on
the
electrocardiogram, is a measure of ventricular
depolarization and subsequent repolarization.
LQTS is characterized by abnormally delayed
repolarization of ventricular myocytes. Lt is
caused by abnormalities of cardiac ion channels
which result in abnormal amounts of sodium or
potassium moving across the cell membrane,
interfering with the normal action potential. At
least 12 ubtypes of congenital type long QT
syndrome have been described resulting from
mutations in any one of nearly a dozen genes
controlling the expre sion, regulation , or
assembly of cell membrane ion channels.3
Subtypes are classified based on the gene
affected, with LQTL (KVLQTI mutation)
accounting for approximately 50% of cases,
LQT2 (HERG mutation) nearly 40% , and LQT3
(SCNSA) about 5% .3

This is the reality for patients diagnosed
with congenital long QT syndrome (LQTS). In
addition to the difficulties related to the
acceptance of a lifelong and incurable disorder,
LQTS management imposes a potentially
significant decline in quality of life. Severe
exercise restriction is currently recommended in
patients with LQTS to prevent symptoms from
arising. 2 This sudden change in lifestyle can be
especially devastating for children, as it can leave
them feeling like outcasts (Figure 1). This article
examines the impact of LQTS on the quality of
life of patients and their families.
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Although
most
patients
remam
asymptomatic, the first manifestation of LQTS
may be syncope, cardiac arrest or sudden cardiac
death. Specific actlvtttes or triggers can
precipitate cardiac events in LQTS patients these include startling auditory stimuli such as an
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'

'-----

-

Figure l . Pi cture drawn by a young ma le di agnosed w ith LQTS . The patient experi enced yncope during
an ice hockey game w hi ch led to the subsequent di agnos is of LQT S. A a result of the di agnos is and
res ultant exercise restri cti o n, th e pati ent quit hi s ice hockey team and abandoned hi s dream of play ing
profess ional hockey. Pati ent identifi ers have bee n removed fro m th e drawin g.
a lann c lock o r lo ud door be ll , emoti o na ll y
charged events, o r even ph ys ical exerti o n as bri ef
4
as running to catch th e bus. Commonl y
presc ribed
med icati ons
in c ludin g
certa in
antibi otics,
bro nchod il ato rs,
hypertens io n
medi cations, and antidepressa nts can ca use
furth er pro longati on of the QT interva l and
increase the ri sk of cardi ac atThythmi a in
susceptibl e pati ent . Whil e 50% of pati ents
rema in asy mpto mati c th ro ug ho ut their lifetime,
th e severi ty of th e sympto ms has crea ted a foc u
o n preventati ve med icine as an important as pect
of manage ment.

Quality of Life lssues- Impact on Patients and
Families
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The di agnos i of LQT S can be quite
devastating to indi vidua ls. Th e impli cati o ns that it
has o n longev ity, menta l state, and day to day life
are immense. Fam sworth et a /. (2 006) conducted
a eri es of interview w ith parents w ith LQT S,
and o ne pati ent 's descripti o n was: "your w ho le
li fe is shattered . Yo u fee l w hammi ed off thi
4
earth ." Another parent described the chanoes
in
0
her son after being di agnosed : " He is spo rt o ri ented, oc ia l, and wa nts to fl y for the A ir
Force. He can ' t pl ay hockey now .. .. H e can ' t fl y.
He is on ho ld, hoping thi w ill a ll go away." 4
Sudden cardi ac death ts th e first
manife tin g symptom in a lmost 12% of cases.
Because of thi s, pati ents constantl y li ve w ith the
uncerta inty of the ir own future a we ll a the

future of their loved ones in the context of a
genetic disorder. 4 Two thirds of parents
interviewed by Farnsworth et a!. (2006) expressed
fear of their children dying. For example, one
interviewee said, "When I walk into their rooms
in the morning to wake them I am always aware
4
in the back of my mind ... will they be cold?"
The management of unrelated medical
conditions such as infections may also create
anxiety because certain prescribed medications
may prolong cardiac repolarisation as a sideeffect. There are over 130 recognized drugs,
ranging from anti-hypertensives, to antibiotics,
heartburn aids, and antidepressants, that should be
avoided by LQT patients as they have been shown
to further prolong the QT interval, thus increasing
the risk of a cardiac arrhythmia. Furthermore,
cardiac events may be precipitated by dehydration
and inadequate nutrition, which are commonly
seen in many disease states. The fear of
precipitating a cardiac event is always present:
"Anytime she gets sick it is a big deal. It is a
totally different ballgame. Medications are a big
deal.. ..We do flu shots every year. I am more
4
worried, it is always in the back of your mind."

Quality of Life Issues -Impact of Treatment
Once diagnosed, a management strategy
focusing on prevention of LQTS related cardiac
events
is
implemented.
Management
is
multimodal, combining lifestyle modification,
medication or even surgical options. Lifelong beta
blocker therapy is the mainstay of medical
2
treatment for LQT1 and LQT2 subtypes. Trigger
avoidance is also important for successful
prevention. The most common trigger is physical
exertion. As a result, the American Heart
Association
guidelines
recommend
severe
exercise restriction for LQT patients (Table 1).
These restrictions may range from withdrawal
from all competitive sports to students potentially
sitting out of physical education class. Such broad
exercise restriction may impair physical as well as
psychological wellbeing.
Individuals that are physically active are
less likely to suffer from mental health problems.
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Physical activity improves se lf-esteem, can foster
identification with peers, red uces stress, and is
5
inverse ly rel ated to adolescent depress ion.
Exercise deprivation has been shown to lead to
increased symptoms of pain , fatigue , cognitive
6
problems, and negative mood. With children
there is added danger beca use proper soc ial
development requires common identification with
peers, and thus this targeted exclusion from team
activities can have a significant negati ve
7
psychological impact (Figure 1). The elderly are
also at particular risk from exercise restriction as
exercise has been shown to reduce CNS
dysfunctions such as cognitive decline. 8
With the rising prevalence of obesity, the
physical health benefits of exercise have been
given increased attention. Physical activity is
unanimously recognized as an essential element
in combating the obesity epidemic.9 Resea rch has
repeatedly shown regular exercise decreases lipid
profiles, obesity, hypertension , and development
of some cancers and cardiova cular diseases, and
it increases bone mineral density. Physical
activity is also used in the management of
10
numerous chronic diseases.
Physical activity rates are decreasing in
Western populations. Numerous community
interventions are being implemented to promote
regular exercise to achieve the recognized
benefits . The diagnosis of LQTS presents another
road block in achieving a healthy lifestyle.
Participation in competitive sports as a child, an
activity shown to be predictive of physical
activity levels in adulthood, is not permitted in
patients with LQTS. 5
Participation in sports is an enjoyable
method of physical activity. Participants repot1
enjoyment stemming from affiliation with peers,
competitive excitement, gaining competency, and
11 12
a source of psychosocial support. ' On the field
people can learn sportsmanship, fair play,
personal responsibility, and moral reasoning. 13
Because LQTS patients are not permitted to
participate in popular sports such as basketball ,
hockey, soccer and football, these key elements of
personal development are potentially missed.
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Table l . Permissibility of common physical activities for LQTS patients
Guidelines

Activity
HIGH INTENSITY

Basketball
Body building
Ice hockey
Racquetball/squash
Rock Climbing
Running
Skiing
Soccer
Tennis (singles)
Touch football
Windsurfing
MODERATE INTENSITY

Baseball/softball
Biking
Motorcycling
Jogging
Sailing
Surfing
Swimming
Treadmill
Weightlifting
Hiking
LOW INTENSITY

Bowling
Golf
Horse back riding
Scu ba diving
Skating
Snorke lling
Brisk Walking
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Not Permitted

Maybe
Permitted

Permitted

2

Conclusions
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Long QT syndrome has a large impact on
patients and their families on multipl e leve ls.
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stress of parents facing the poss ibility of cardiac
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familie on the genotype-specific triggers and
encourage them to take an active part in managing
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certain prescribed medications prolong the QT
interval putting them at increased risk for cardiac
events, and they should be instructed to screen all
their future medications against a list of known
QT-prolonging drugs (www.qtdmgs.org).
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The American Heart Association (AHA)
has
published
recommendations
for
the
management of LQTS. They call for severe
exercise restriction as a preventative measure.
The premise is based on athletes not using proper
judgement in extracting themselves immediately
from the physical activity, even upon realization
that medical attention may be needed. Due to the
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palpitations, fatigue, and dizziness can incorrectly
be attributed to the sensations which accompany
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The AHA recommendations are based on
the experience and insights of a panel of experts
and by their own admission, are not specifically
from scientific evidence. With the negative
psychological and physical health effects that
exercise restriction can have on patients, it is
important for future research to focus on this area,
which might serve as a basis for validating or
amending
the
current
recommendations.
Important areas of research include determining
the effectiveness of exercise restriction on the
prevention of cardiac events in each LQTS
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FEATURE
Genetic Susceptibility in Rheumatoid Arthritis
Kimberley Colangelo (Meds 2011) a nd Caleb Zelenietz (Meds 2011)
Faculty Reviewer: Dr. j anet Pope
Rheumatoid arthritis is a cond ition that causes chroni c infl ammatory arthritis. It has been linked to multiple
etio logies; the cause is thought to be a combinati on of the environment, infec ti o n, ho rmones and a genetic
component. T he prec ise contri buti on of geneti cs to the deve lopment and course of rheumatoid arthriti s is
curren tl y under investigati on , and numerous gene candidates have been identified . The HLA-DR gene has
been wide ly studied and numerous a lle les have been identifi ed that correlate to the development of
rheum ato id arthritis . The role of geneti cs in rhe umato id arthriti s is expl ored in thi s article.

Background
Rheumatoi d arthriti s (RA) is a chro ni c
auto immune d isorder w hi ch causes infl ammatory
arthritis and occurs in approx imate ly l % of the
1
popul ati on. It freq uentl y presents as periphera l
polyarti cul ar arthri ti s, is symmetri ca l, and often
progresses wi th j oint damage and loss of fun cti on.
T here may be periods of remi ss ion, altho ug h
vari ations on this pattern occur. In addition, the
extra-arti cular mani festat ion s vary greatly among
pati ents . W itho ut treatm ent, it leads to signifi cant
defo rmiti es as cartil age and bone are destroyed,
so ca ll ed erosive d isease.
T he prec ise cause is unknow n, but geneti c
pred ispos iti on, the enviro nment, infec ti ons, and
ho rmones (potential prec ipitators) are th oug ht to
a ll pl ay a ro le. The geneti c component has been
the subj ect of much research in recent decades, as
RA has been fo und to c luster in fa mili es and
occurs more frequentl y in fa mili es with o ther
auto immune di so rders. The heritability of RA is
estimated to be approx imately 60%, w ith a 122
15% concordance rate amo ng tw ins.
Severa l key genes have been targeted as
th ey are impli cated in the deve lopment of RA and
the course of the di sease. The group of human
leukocyte antigen (HLA) genes o n chromosome 6
has been at the fo refront of geneti c research in
RA. Certa in a ll e les have been associated w ith an
in creased ri k of deve lopin g the di sease and
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predicting its severi ty, and others are invo lved in
protecti on fro m RA. The HLA gene products are
invo lved in immune fu ncti on, particul arl y coding
fo r anti gens expressed on the surface of w hite
bl ood ce lls. Many genes as ide fro m the HLA
group have been li nked to RA.

Current Research
T he HLA regio n in the human genome is
one of the most heterogeneou and is frequently
in vo lv ing
di sease
targeted
fo r
tudies
susceptibili ty . For RA , th e HLA-DR fa mily has
bee n studied extensive ly. Severa l theori es exist
fo r how the HLA mo lecul e could influence the
immune ys tem. HLA m o lecul e bind peptides
and present th em to receptors on the C D4+ T
lymphocyte , so the epito pe assoc iated w ith RA
could determine w hi ch peptides bind uccessfull y,
th e affinity w ith w hi ch they bind, th e epitope
itse lf could be anti geni c, or the epito pe could
influence w hi ch T lymphocytes surv ive in the
th ymus (i.e. g iving a pro pensity fo r autoreacti ve
lymphocytes to surv ive). 1 In the maj o rity of
genetica lly -linked cases of RA , a shared epitope
at amino ac id pos iti ons 67-74 of HLA-DRB 1 (the
beta l subunit of the HLA-DR mo lecul e) has been
fo und. H LA-DR4 , one of th e most we ll studi ed
s~ems to be assoc iated w ith bo th hi g her ri sk of
d1 sease and wo rse prognos i , parti cularl y certain
hapl o type w ithin HLA-DR4 such as 0401 .3

Interestingly, some HLA-DR alleles are
associated with protection from RA, even
counteracting the increased susceptibility when
the sister allele was associated with an increased
4
RA risk.
These protective HLA-DR all eles have a
different conserved seq uence than the so-called
shared epitope associated with an increased risk.
A well known example is HLA-DRB 1 with the
conserved epitope DERAA at positions 70-74 of
the amino acid sequence. This allele was not only
correlated with a lesser risk of developing RA,
but was also linked to a less severe form in people
with RA.5
The presence of the HLA alleles with the
shared epitope has also been shown to have a high
concurrence with the presence of anti-cyclic
citrullinated peptide
antibodies (anti-CCP),
which are used in diagnosing RA. One theory is
that the citrullinated peptide binds the HLA
shared epitope resulting in activation of T
lymphocytes. This may in tum lead to increased
autoantibody production that results in the
formation of anti-CCP antibodies.6 Anti-CCP is a
stronger predictor of radiographic damage in early
inflammatory arthritis than Rheumatoid Factor
(RF) and is especially useful as a marker in those
with negative RF who have RA. However, anti CCP is not sufficiently sensitive to identify all
those who will have radiological damage in early
inflammatory arthritis.
Some important discoveries related to the
7
HLA susceptibi lity region include :

•
•
•

•
•

Having two copies of a susceptibility
allele makes a person even more like ly to
deve lop RA compared to hav ing on ly one
copy
Havin g one or two copies of a
susceptibility allele makes a person more
likely to have severe di sease
The combination of alleles present alters
th e relative ri sk (i.e DR4/ DR I vs. DR4/X)
Presence of the allele may also influence
if a person will have extra-articular
manifestations
The timeline of progress ion of RA is
influenced by the alleles present

The HLA-DR genes cannot be the only
genetic contribution though, as not all RA
patients have the implicated alleles and there is
still a wide clinical heterogeneity amongst those
that do . It has been estimated through sibship
studies that HLA linked genes contribute about
8
30-40% of the genetic component in RA.
Numerous other genes have been identified, and
the more popular ones are summarized in Table 1.
The products of these genes are proteins or
molecules that are invo lved in the immune
response; as an intracellular signalling molecule,
in the fom1ation of antibodies, or in carrier
molecules. A physiologic mechani sm through
which they contribute to the deve lopment of RA
has been postulated for each one. Currently,
screening of who le genomes of families where
RA is preva lent is being undertaken to poss ibly
di scover other genes and better characterize the
genes that have been discovered .

Table 1. Summary of genes that confer susceptibility to rheumatoid arthriti
Gene
Product
9
HLA-DR
Encodes cell surface antigens that present protein to the T ly mphocytes
STAT4 10
PAD14

Encodes a transcription factor for signals from ce11ain cytokines

11

Encodes an enzyme that catalyzes peptidyl arg inine to peptidyl ci trulline

N22/PTPN22 II
SLC22A4
FCRL3

Encodes intracellul ar tyrosine phosphata e in T and B cells

12

Encodes for an organic cation transporter

13

CTLA4/CD 152

Encodes a B-lymphocyte specific membrane molecule
1
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Encodes a protein produced by activated T ce ll s
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The presence and implications of these
genes vary widely by ethnic population with
respect to rheumatoid arthritis. The prevalence of
RA itself differs by ethnic group, for example
Native Americans have been reported to have a
prevalence as high as 2% whereas Asian
14
populations as low as 0.3 %. In addition, the
polymorph isms of the human genome sequence in
the alleles that are related to RA vary by ethnic
populations, wi th hi gher concordance amongst
15
more close ly rel ated popul ations.

Relevance
The key question regarding thi s research is
whether it is limited to being an expensive
research too l or if it will become relevant to
patients and physic ians. Given that many of these
alleles are common in the general population,
gene screening will not be useful as a screening
tool to di scover asymptomatic patients that will
develop RA . However, since HLA alleles remain
constant over a lifetime, typing may be useful as a
predictor of the course of di sease in patients
already diagnosed with RA, it can be used to
decide which patients will have more severe
di sease and who will progress quickly so that
aggressive therapy can be initiated. Whether thi s
will change outcomes needs to be studied . For
now, its value seems limited to research where
family members at ri sk for RA are being
prospecti ve ly studi ed, particularly those who have
already developed anti-CCP or RF .

Conclusions
It cannot yet be said what interaction and
combination of alleles is neces ary for th e
development of RA and for the specifi c
phenotypes that are expressed. RF testin g is done
to determine who with early inflammatory
arthritis will deve lop erosions, but combining RF
and HLA may increase the sensitivity and
specificity so that early aggressive treatment can
be implemented. Since anti-CCP antibodies may
have hi gher specificity for the development of
RA, the combination of these two components
could poss ibly increase the ability to predict the
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development and course of progression of the
disease.
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FEATURE
Nuchal Translucency and Prenatal Diagnosis of Congenital Heart
Disease: Progress and Future Directions
Xiangning Fan (Meds 2010)
Fa culty Reviewer: Dr. Eva Welisch
N ucha l tran lucency thi cknes is an important compo nent of prenata l screening prog rams, w hi ch ex ist to
he lp quanti fy the ri sk of certa in chromosomal and anato mi ca l abnorma liti e in a fetus in utero . Abnormally
increased nucha l trans lucency thi ckness has been used as a oft marke r fo r Down's Syndrome and other
aneupl oidi es fo r more than a decade. Recentl y, an as oc iati o n has been identifi ed between increased nucha l
translucency thi cknes and congenita l heart di sease, rais in g the possi bili ty that nuchal trans lucency
thi ckne s may he lp identi fy affec ted fe tuses as earl y as 11-1 4 wee ks gestati on. However, the
pathophys iologica l mechani sm whi ch produces an abnorma l nu cha l tran lucency thi ckness in the fetus is
no t we ll understood and an abnorma l measurement is not spec ifi ca ll y a oc iated w ith any one type of
le ion. Therefore, nucha l trans lucency thi ckness cannot be used for di agno i of congenital heart di ea e in
utero, but may be very he lpfu l in identi fy ing fe tuses at ri sk, w hi ch may he lp improve diagnosti c accuracy
and direct resource-effi c ient u e of diagnosti c meth od such as fetal echocardi ography.

Introduction
A lthough it has lo ng been the ho ly grail of
prenata l care to be abl e to ass ure every woman a
hea lthy in fa nt at term, 2-3% of infa nts are born
w ith at lea t o ne anatom ica l deformi ty. The
congenital heart di sease are co ll ecti ve ly the most
comm on congenita l defects, with a combin ed
inc idence estimated at app rox imate ly l/ 100 at
term, and hi g her in th e prenatal popul ati on. 1
Ca rdi ac les ions may occur in iso latio n, or
altern ate ly a part of a ge neti c yndro me. Even in
iso lated cases, th ere appea r to be a genetic, likely
multi fac tori a l, compo nent to the ir eti o logy. They
range from inc identa l findin gs of no g rea t
fun ctional signifi cance (e.g. small atri a l septal
defect ) to les io ns w hi c h, if left untreated, are
immedi ate ly life-threatening to the neonate (e.g.
transpos iti o n of the great arteri es). Stru ctural
hea rt defects a re tho ught to contribute to up to
20% of a ll neonata l death s and up to 50% of all
2
in fa nt dea th .
Recentl y, attenti o n has foc used on th e
utili ty of ultraso und mea urement of the free fluid
behind th e neck of the fe tus- te rmed the " nucha l
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trans lucency" (NT)- in predi cting congenital
heart di ea e in th e fe tu . It has been suggested
that the ub et of fe tuse w ith abno rmal N T
measurement i at increased ri sk for congenital
hea rt defect ; therefore the N T thi ckness may be
of u e in prenata l di agno is of congenita l heart
di ea e.

What is Nuchal Translucency?
The NT mea urement is a measure ment of
the thi cknes of th e free fluid layer behind the
feta l neck. Thi is meas ured by ultrasonography
between I I and 14 weeks gestati o n. There are
stri ct cri te ri a to establi h an ultra ound imaae
a
0
adequate fo r the assess ment of
nuc ha l
tran lu cency and the no rma l limit to the
measurement is dependent upon gestationa l age.
The NT measurement was first suggested as a soft
marker for feta l aneupl o idy by Ni co la ides and
co ll eagues in 1994, and thi s assoc iati o n wa la ter
confim1ed by o ther researchers. 3-6 It is now
known that the nucha l trans lucency mea urement
i 77% ensiti ve and 95% specifi c for D ow n '
Syndrome/Tri o my 2 1, the most common of the

13

three autosom al aneuplo idies that are compatible
with li fe. 4
However, the NT measurement is also
assoc iated w ith a host of other abnormaliti es in
the fe tus.
Even in chromo omall y normal
fetuses, increas ing NT is associated with adverse
fe tal outcome .7•8 Bila rdo and co ll eagues report
that up to 20% of chromosomall y normal fe tuses
with increased NT experi enced an adverse
outcome, defin ed as mi carri age, intrauter1ne
death , parental cho ice to terminate the pregnancy,
or one or mo re structura l or geneti c di sorders in
the fe tus. Of the 86 adverse outcomes, 14 (1 6% )
were pregnancy termina ti ons. The likelihood of
adverse outcome appeared to correlate w ith
increasing degrees of NT abnormality.8

Nuchal Translucency and Congenital Heart
Disease
Recently,
in
both
euploid 9 - 12 and
aneupl oid 13- 16 fe tuses, an abnonna ll y elevated NT
measurement has been described in assoc iati on
with congenita l heart di sea e in th e fetus. There is
increas ing ri sk of cardi ac les ions as the NT
12
become progress ive ly more abn ormal. Ghi and
co lleague report the overa ll incidence of major
cardiac defects to be 4.5% in fe tuses with NT
above 2.5 mm , w ith 7% incidence in fetuses w ith
nuchal translucency thi c kness equal to or greater
than 3.5 mm. 12 They s uggest that abnorma l NT
may be more of a ri sk fac tor for maj or congenita l
cardi ac le ions than maternal di abetes, pos iti ve
fa mil y hi story of congenital hea rt di sease o r
exposure to teratogeni c agents, and that therefore
fe tal echocardi ography is indi ca ted fo r all fe tuses
At a NT
with elevated NT mea urements.
111
thi ckne s at or above 3.5 mm (roughly th e 99
percentile), maj or cardiac anomali es appea r to be
present in 5-10% of screen-pos iti ve fe tuses. 12• 17- 19
11
Hyett and colleagues
propose a cutoff of
111
111
between the 95 -99 percentil e as the optimum
point
to
1mt1ate
referra l
fo r
fe ta l
echocardiography.
Hyett suggests the nucha l
translucency measurement could contribute to the
detection of approximately 30% of all cases of
19
congenital heart defects.
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Prev io usly, Hyett and co ll eagu es have
suggested
that
th e
nuchal
tran lucency
measuremen t may be related to fai lure of the feta l
heart ra ther than to the d irect effects of
ane uploidy. As card iac lesions are seen in many
of the genetic syndro mes, this is certainly a
pl a usibl e expl anatio n for the close assoc iati o n
seen between in creased nuchal translucency,
a neuplo id conditi ons and congenital heart d isease .
However, thi s interpre tation is by no means
20 2 1
unanimou ly accepted, and mu ltipl e authors •
report that the degree of NT abnorma lity is not
spec ifica ll y assoc iated w ith any parti cul ar heart
21
report that
les ion. Makrydima a nd co lleague
there is consid erabl e overl ap between th e average
NT measure ment fo r di ffe rent ca rdi ac le ions and
the identity of the les ion; thus, the NT
measurement is not helpfu l fo r the specific
di agnos is of fe tal congenital heart di sease except
to indi cate th at a cardi ac lesion may be present.
T he unde rl ying path ophys iology remain unclear,
and alternate expl anati ons for th e elevated NT in
ca es of congenital heart di sease include venous
congesti on in th e head and neck of th e fe tu s,
abn orn1ali ties of lymphatic drainage , altered
of
subcutaneo us
ti ssue,
d istr1buti on
g lycosaminoglyca n
and
proteoglycan
accumul ati on, fe ta l anemi a and/or decrea ed fe ta l
..,.., 23
c
.
movement.--·
T heretore, the NT may mdeed
identi fy fe tuse w ho are at increased r1 sk of
congenital heart defects so that these can be
referred on fo r more spec ia li zed di agnostic testing
However, in
(e.g. fe ta l echocardi ography) .
iso lati on, it doe not appear to be sen itive or
pec ific eno ugh to be a d iagnosti c te t fo r
. I heart d.1sease. 17
congemta
24

Mo f has uggested that relying on nuchal
translucency to identi fy fe tuses w ith Down' s
Syndrome may in fact preferentially identi fy
fe tuses in w hom there is an as oc iated cardiac
defect. G iven the re lati ve incidence of congenital
heart d isease ( l/ 100) and Down's syndrome
( l/800-l 000 overa ll ) 25.26 , the NT measurement
may in fact pi ck up more babi es w ith congenital
heart d isease w ho incidenta ll y have Down's
syndro me th an bab ies wi th Down' s syndrome
w ho have an assoc iated cardi ac defect.
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The clinical implications of this finding
are less clear. It could be argued that, even if
increased NT is a marker for congenital heart
disease in the fetus, it is not useful clinically as it
is a standa rd of care to offer all pregnant women
(regardl ess of NT meas urement) a morphological
ultrasound scan at L8-20 weeks during which
structu ral cardiac les ions can be identified. The
current recommendation is a four-chamber view
of the heart and imaging of the ve ntri cular
outflow tracts in an attempt to identify major
27
anomalies.
However, it has been previous ly
noted in population studi es of prenata l patients
that
morphological
echocardiograph y
JS
dependent
upon
the
ex perti se
of
th e
ultraso nographer
and
consequentl y
an
inexperienced one may mi ss a signifi cant
proportion of major cardiac defects .28 ·29 In their
tudy, Hyett and co lleagues'' report abnormal NT
mea urement in 55 % of fetuses w ith major
congenital heart disease, compared to an
ab no rma l four chamber view on prenata l
ultrasound in 26% of those same babies. The
26% detection rate in that study was consistent
2
w ith pri or estimates.
Wald and colleagues have
suggested, based on a meta-ana ly is of studies of
the utility of nuchal trans lucency measurements
and congen ita l heart disea e, a detection rate of
52% and a fa lse- po itive rate of 5% us ing a
screenin g cutoff of L. 7 multipl es of the median .30
This is greater than that ac hi eved using a four
chamber view alone, and, therefore, the nucha l
trans lucency shows great pro mi se as a potenti al
screen in g tool for congenita l heart di sease which
can he lp direct ap propri ate and resource-effi c ient
use of fetal echocardi ograp hy.

normal chromosomes. Routine measurement of
the nuchal translucency shows great promise in
helping to identify fetuses at increased risk of
congenital heart disease, and therefore may help
direct
resource-efficient
use
of
fetal
echocardiography. However, by itself, i~crease_d
nuchal translucency does not predict the d~agnos1s
of a specific type of cardiac defect in the fetus .
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The Legacy of a Life Lived: Trans-Generational Epigenetics and Cancer
Development
Mark Kirchhof(Meds 2 00 9)
Fa culty Reviewer: Departm ent of Pathology, UWO
Your grandfa ther smoked everyday, your mother was stressed w hil e pregna nt, your fa ther w orked in the
petroc hemi ca l industry, sho ul d any of thi s matter to yo u? Ev ide nce is emerg ing that the li ves we li ve affect
us fa r beyond the boundaries of our own body and can reach we ll into the li ves of fu ture gene rations.
T hese lingeri ng traces of li ves li ved mani fes t themse lves in changes to the D NA of o ur cells, commonly
referred to as epi geneti cs. E pi geneti cs is defi ned as inheritabl e changes in gene express ion that don ' t a lter
the ac tual DNA equence itse lf, most commonl y mediated by DNA meth ylation and/o r hi stone m ethy lation
o r acetylati on. In thi s paper, we w ill di scuss some of the epi geneti c changes that have been associated with
the deve lopment of di sease w ith spec ifi c foc us on the deve lo pment of cancer. Moreover, we w ill look at
environmental ex posures in current generati ons that may affect ca ncer developme nt in future generati o ns.
We may mere ly be guardi ans of our DNA fo r future generati ons, and perhaps the impact of the way we
treat our bodies should now be examined in thi s new li ght.
M y parents are childre n of World War ll.
Th ey grew up a mongst the bo mbings, death and
destructi on. T heir li ves were foreve r changed by
these experi ences at a leve l far deeper than one
would expect. Beyond the psycho logica l,
emoti onal or physica l impact of th ose
ex peri ences, those mo me nts wo uld fo rever
c hange th eir DNA . Such are the findin gs of Dr.
Yehuda, who fo und that traumati c events ca n
permane ntl y alter the ex press ion of th e tres
1
ho rmone, corti so l. Yehuda fo und that childre n of
mothers who suffe red psycho log ica l trauma from
th e events of WWll had children who had lower
leve ls of corti sol producti o n.:! T hi s change in the
offspring re lated to mate rn a l be hav iour or
ex pe ri ences has been linked to changes w ithin the
D NA of th e child ren. T hese changes are refen·ed
to as e pigene ti cs, w hi c h is defin ed as inheritabl e
c hanges in gene express io n th at do n ' t alte r the
ac tua l DN A seque nce itse lr_3 ln thi s arti cle, we
w ill expl ore th e re lati o n hip between the
environment, epi geneti cs a nd cancer.
Th ere are two maj o r moda liti es by whi c h
DNA can be altered to change the expres ion of a
pa rti cul ar gene: th e meth y lati on of DNA a nd
Page I 66

modifi cation of hi stones . T he me thy lation of
DNA invo lve the additi on of methy l groups to
the cytos ine bases in the C pG do ma ins.4 ·5 The
modifi cati on of hi stones is the o ther major
epige neti c regulatory mechani sm .
T he more
tightly the DNA is wrapped around the hi stone
compl ex, th e lower th e ex press io n of th e genes
coded on that p1 ece of DNA . Hi stone
modi fica ti on invo lves th e meth y lati o n o r
acety lati on of amin o ac id suc h as lys ine, a rg inine
and serin e. Hi tone ace ty la ti o n gene rally results
in the loosening of the a soc iati on be twee n the
DN A a nd th e hi tone, a ll ow ing fo r increased gene
67
expre sion. ; T he effects of hi sto ne me th y lati on
are mo re va ri abl e and can res ults in the increase
or decrease in gene ex pre sio n de pe nding on
whi c h res idues are modi fie d a nd w here w ithin the
hi sto ne protein the modifi cati on ta kes place .6 •7
Epi geneti c changes have lon o been
assoc iated w ith cancer. T he fi rst maj o rb findin g
was that the DNA of cancerous ce lls wa g loba lly
8
hypo me th ylated . In additi on, the degree of
hypo meth y lati on of the DN A seem ed to corre la te
with th e aggress ivene s a nd prognos i of a
49
parti c ul ar cancer. ' There is some debate a to the

effects of DNA hypomethylation, but several
theories have garnered attention. These include
the idea that hypomethylated DNA is more
unstable and thus leads to deletion s and
translocations, potentially creating truncated
genes or genes that have different promoter
10
elements.
Other theories are based on the
observation that imprinted DNA, that is selective
DNA methylation to inactivate the expression of
either a maternal or paternal allele, is di srupted in
3 11
cancer cells. ' Therefore, hypomethylated DNA
may correspond to the disruption of genomic
imprinting. As an example, it is known that the
loss of imprinting of the insulin-like growth factor
. a ns
. k 1actor
c.
c.
gene IS
10r
co Iorecta I cancer. 1 2- 1 c~
The other major epigenetic mechanism
that has been found to be prevalent in cancer cells
is the inactivation of tumour-suppressor genes. 6
Tumour-suppressor genes prevent the progression
of cancerous cells and some of their functions
have been related to the inhibition of cell di vision,
the initiation of apoptosis and the mediation of
cell adhesion. 4 -6 Hypermethylation in the
promoter regions of tumour-suppressor genes is
one of the major steps required for the
transformation from benign to malignant Two
well known genes, the retionoblastoma tumoursuppressor gene (Rb) and the breast cancer
susceptibility gene 1 (BRCAl) are examples of
genes that have hypermethylated promoter
15 16
regions in cancerous cells. • The inactivation of
tumour-suppressor genes by hypoacetylation and
hypermethylation
of hi stones
have
been
associated with colon cancer, prostate cancer,
12 17
liver and breast cancer. 6 ' '
The question now concerns why these
changes arise and how they result in cancer. W e
are all familiar with the concepts of nature and
nuture intersecting to result in the genetic changes
required to initiate the transformation into
For example, lung cancer
cancerous cells.
requires a genetic predisposition on top of an
environmental
factor, commonly smoking.
Research has shown that exposure to cigarette
smoke can induce the hypermethylation of
BRCA l/BRCA2 and XRCC, all tumoursuppressor genes, as well as the hypomethylation
. oncogene, SNC G . 18, 19 Other
of the pro-metastatic
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exampl es of environme ntal agents that induce
cha nges to the ep igenome res ulting in increased
inc idence of cancer include aniline dyes and
bladder cancer, so lar UV radiation and skin
cancer, and a lfatox ins found in the soi l and on
plants and li ver ca ncer. :!0-22 We are a ll aware of
thi s direct link between an env ironmenta l factor
and the deve lopment of cancer. But what of the
offspring of a person exposed to these
environmental agents, are they ultimately at risk
as well?
Exposure to environmenta l toxins has
been shown to increase the transgenerational risk
of di seases, in cluding cancer. One of the most
widely studied toxins is vinc lozo lin, which is an
anti- androgenic compound used as a fungicide in
the fruit industry.23 Transient exposure of
gestating rats to vinclozolin leads to a variety of
diseases in offspring up to four generations later,
including tumour deve lopment, pros tate disease,
kidney di sease, immune abnormalities and defects
24
in sperm formation ? 3• Bi spheno l A is perhaps
the most well known endocrine di srupte r believed
to change the epigenome. Bisphe nol A is an
organic compound that, until recently, could be
found in many baby bottles, baby and children's
toys, and in the epoxy resins that coat a lmost
1? 14
every c.tOO d an d beverage can .-?Q ·--·Neonata l
exposure to bisphenol A has bee n show n to a lter
the methylation status of a variety of genes and
result in cellular tran sformations th at promote the
development of pro tate cancer. 25 Prenatal
exposure to bispheno l A has been linked w ith a n
ri k
of
breast
cancer
via
increased
26
hypomethylation. Whil e the temporal effects of
bisphenol A have been shown in the first
generation, furth e r studi es are required to
determine if changes are transmitted to
sub equent generations. Other links have emerged
betwee n environmental tox ins and cancer
including the transgenerational effects of alcoho l
leadin g to colon cancer and benzene leading to
.
Ieu k em1.a.27,28 A s th e researc h mto
ep1.genetics
grows, we will undoubted ly continue to see an
ex pansion of the environmental agent that can
alter the epigenome.
The
relation ship
between
nutrition,
epigenetics and the di sease processes warrants
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further considerati on.
One of first multigenerati ona l epi geneti c studies was done in
Sweden, where pari sh registri es and harvest
records were u ed to link di sease in generations
after feasts or fa mines. 29 ,3 ° These studies found
that if a paterna l grandfather experienced a
surplus of foo d before th e onset of puberty, the
grandc hild had a fo ur-fo ld increased chance of
dying from compli cati ons of di abetes. 29 •30
Interesti ngly, the chil dren of moth ers who
experienced ab unda nce of foo d before the onset
of puberty had ch il dren who were pro tected from
d i ea e re lated to d iabetes.29 · 0
In terms of
cancer research, ev idence is emerging that links
nutrition,
epigenome
status
and
cancer
deve lopment.
xcessive materna l weight ga in
d uring pregnancy leads to increased ri sks of
31
breast cancer in th e chil d.
In additi on, the
nutritiona l con tent of th e di et has been shown to
be important in deve loping and maintaining the
epi genome.
pec ifi ca ll y, the ava il abili ty of
meth yl donors, including fo late, cho lin e and
methi onin e seem to be important in preventin g
di ea e.32 •33 In rat mode ls, decreased ava ilability
of meth yl do nor has been shown to induce the
deve lopment of li ver cance r, even in th e absence
of any known carcin ogens.33 In th e ago uti mouse
model , di etary suppl ementa ti on in utero with
fo li c ac id, vitam in B 12, cho line, beta ine and zinc
was assoc iated with a lowe r ri sk of cancer,
diabetes and obes ity and an increased life
ex pectancy. H 35 Low prote in di ets in utero a l o
seem to affect DNA meth y lati on and di sease m
offspring, leadi ng to increased susceptibili ty to
d1.a betes, hyperten .ton and ca ncer. 3 1·36

epi genetics is the histone deacetylase (HDAC)
inhibitors.
These drugs have been fou~d ~o
induce cell-cycle arrest and apopt~s1s ~n
vitro."·37,4l,.n Suberoylanilide hydroxam1c ac1d
(Vorinostat) is th e first HDAC inhibitor approved
for the treatment of cancer, specifically cutaneous
T-cell lymphoma. 4 1•42 While these drugs have
been approved, they lack specificity for _cell ~pe
which may lead to unintended effects, mcludmg
th e express ion of previously silenced oncogenes.
As w ith any cancer therapeutic, the eventual goal
w ill be to deve lop agents that target only
cancerous ce lls, sparing normal ti ssue and cells.
If the las t century be longed to DNA and
the genome, thi s century w ill surely belong to
epigenetics and the epi genome. We are slowly
di scovering that the epi genome is an important
pl ayer in th e deve lopm ent of di sease. What has
co me as a urpri e is the degree to which the
epi genome i influenced by the environment, by
everything from drugs, tox ins to vitamins and
calori c intake. Even more astonishing is the
emerg ing data indi cating that what we experience
in our li ves w ill ultimately influence the lives of
our children and perhap even their children. In
effect, we are th e guardi ans of our genes and need
to wa tch over th em o th at we may pass them on
in the be t conditi on we ca n.
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Amish, Mennonite and Hutterite Genetic Disorder Database
Michael Payne (Meds 201 OJ
Faculty Reviewers: Dr. C. Anthony Rupar and Dr. Victoria Mok Siu
Clinical Example
A newborn baby girl presented with bowel
obstruction. The possibility of cystic fibrosis was
raised, particularly since there was a positive
family history of cystic fibrosis in a deceased
relative. CFTR mutation ana lysis was ordered
using a panel that included .6.F508 and 28 other
common mutations which account for 85% of al l
CF mutations. The results were negative for all
mutations in the screening panel.
Since the parents were members of the
Old Order Am ish community, the Amish,
Mennonite and Hutterite Genetic Disorder
Database was accessed via the Internet and it was
determined that a specific mutation (3905 ins T)
had been described in the Old Order Amish.
Further DNA testing confirmed that the baby was
homozygous for the 3905 ins T mutation.
Although the sweat ch loride test is the go ld
standard for cystic fibrosis testing, it can be
difficult to obtain suffic ient sweat vo lume
1
collection in the newborn period.
Correct diagnosis of newborns with CF
through mutation ana lysis is important as this will
help direct therapies and improve overall
outcomes. 2 This case illustrates the usefulness of
the Amish, Mennonite and Hutterite Genetic
Disorder Database as it a ll ows medical
professionals to identify genetic disorders and
specific mutations which otherwise may be rare in
the North American general population.

Introduction
The Amish, Mennonite, and Hutterite
Genetic Disorder Database was created in
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response to a paucity of resources for Canadian
medical practitioners who treat ''Plain People."
The database focuses on genetic diseases which
are found with higher prevalence in these groups
due to their unique cultural history. The database
can be viewed at:
http ://www.biochemgenetics.ca/plainpeople/

Common Backgro und
The Amish, Mennonite and Hutterite
populations share some similarities. They all
arose in Europe during the Protestant Reformation
1
in the 16 h century. 3 In contrast to other
Protestants and Catholics, they are Anabaptists,
believing that chi ldren shou ld not be baptized at
birth, but instead at an age when they can make a
consciou decision to join the church. They also
believe in the separation of church and state.
These views were seen as heretical and led to
their persecution in Europe by the Protestant and
Catholic majority.
The Anabaptists are a lso
pacifists who do not engage in war and believe in
segregating themselves
from
the general
3
population . "P lain People" is a term which refers
to their plain dress and restricted use of
4
technology .

History and Migrations
In order to understand present day genetic
issues surrounding the Plain People it is important
to understand where they originated and how they
came to Canada and the USA. They can broadly
be divided into 4 groups: the Hutterites, Old
Colony Mennonites, Old Order Mennonites and
Amish.
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The Hutterites were follo wers of Jakob
Hutter in Austria, and their co lony was founded in
5
1528. They were persecuted for most of their
history and were fo rced to migrate between
settlements in Morav ia, Romani a, Hungary and,
U kraine. From 1874 to 1879, 443 indi viduals
immi grated to the United States. 5 They settled o n
the prairi es and prospered until WW 1 when they
refu sed to accept conscripti on. Canada offered
them land and exempti on from military serv ice.
Many Hu tterites imm igrated to Canada during
thi peri od and settl ed in Alberta, Saskatchewan
and Mani toba. T here are a lso a few co loni es in
Briti sh Co lumbia. Their curre nt population in the
5
US and Canada numbers over 40,000. The
Hutteri tes beli eve in communal ow nership, w ith
minima l personal posses ion .
They li ve in
communa l co loni es, use modem fa rming and
manu fac tu rin g techni q ue , and utili ze modem
hea lth care.6
Mennonites are named fo r the ir foundin g
leader, Menno Simons. The Menno nites can be
di vided into two groups: Dutch-North German
and Swiss-South German.
The Dutch-North
G erman (O ld Co lony) Menno nites o ri ginated in
the low countri es of Europe in th e 16th centu ry .3
A a res ult of persecuti on th ey were forced to
move to Pruss ia and li ved there in re lati ve peace
until the 18th centu ry. With continued growth ,
land shortages fo rced emi grati o n from Pruss ia to
Russ ia. In 1870, 7000 Menn o nites immi grated to
Manitoba, w hil e another I 0,000 immi grated to th e
3
Ameri can Midwest. Anothe r wave of Russian
M enno nite came to Canada in 1920 fo llow ing
th e Ru sian revo luti on.3
In the 1920s, 7000 of th e Canadi an O ld
o lony Mennonites emi grated to Mex ico, Beli ze
and South Ameri ca. Recentl y, many O ld Co lony
Menn onites have return ed to Canada fro m
M ex ico and South Ameri ca, ettling mostly in
3
So uth western Ontari o, Alberta and M anitoba.
Today, O ld Co lo ny Menn onites in Canada
number ove r 27,000. T hey speak Low German at
ho me, and Hi g h German for more fo n11a l
3
occas io ns, uch as church.
T he Sw iss-South German Mennonites
were fo unded in the 16th centu ry in Sw itzerl and .
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In 1693 follow ers of Jakob Amman split from the
Swiss-S,outh M ennonites to form the Ami sh sect,
7
a more conservati ve group . Both the Swiss-South
German M ennonites and the Ami sh suffered
persecution in Europe . Between 1683 and 18_80,
approximately 8000 Sw iss-German M ennomtes
7
immigrated to the United States. With the onset
of the revo lutionary wa r in the USA, members of
the M ennonite and A mi h communities trave lled
to Canada, settling in the Kitchener- Waterloo and
Ay lmer- St. Tho mas area .
In
1824,
A mi sh
families
began
immi grating directl y to the W aterloo and Perth
8
County areas of Ontari o fro m Europe. In the late
19 111 century, Old Order M ennonites (OOM) split
from the oth er Sw iss-Mennonite groups in the
USA and Canada due di ffe ring opinions over
7
Sunday schoo l and hig her education. OOM and
the Ami sh are both quite con ervati ve and can be
een dri ving buggies and wearing conservati ve
7
c lothes.

Suitability for Genetic Study
T he unique hi tory of Pla in People g roups
make
them espec ia ll y
uitabl e fo r genetic
re earch. They are oc ia ll y isolated w ith little
geneti c inflow . They k ep exten ive genea logica l
records, mainta ined by loca l mini sters. The ir
initi a l founder popul ati on are we ll know n. Th ey
have ex peri enced many geneti c bottlenec k events
cau ed by succe s ive mi grations over their
hi story. Large fa mili es are commo n, w ith low
rate of non-paterni ty . T hey have a re lati ve ly hi g h
ta ndard of medi cal ca r .9
T he fo under effect i quite prono unced in
Pla in Peopl e popul ati on . For exampl e, most of
the over 40,000 Hutterite in North Ameri ca can
trace th eir ance try bac k to a group of 89
5
founding members. T he Ami sh and M ermonite
popul ation s of North Ameri ca are similar with
. ma ll fo ~ndin g po pul ~ ti o n s a n~ iso lation re ulting
m genetic homogene ity. T his can hi g hl y skew
the preva lence of certain di eases in the i ol ated
popul ati ons, particul arl y auto o ma l reces ive
~o nditi ons. For exa mpl e, nephropa thi c cy tino is
1 . a rare a uto~o m a l rece s ive lysosomal storage
d1 o rder affectmg abo ut l in 100,000 children in

7

the general population with a carrier frequency of
about 1 in 150. 10 In the Old Order Amish
population of Ontario, the cystinosis carrier
frequency is 1 in 4.5 , predicting an extraordinarily
high incidence of 1 in 78. 11 The increased
incidence of these otherwise rare conditions allow
for linkage analysis and identification of causative
12
genes.
These genetic studies are not only useful
for Plain People, but also for the general
population. Since 10-20% of each generation of
Old Order Amish and Mennonite children have
chosen to leave their communities, many alleles
have entered the general population. 13 Also, many
of the mutations causing disease in the Plain
People can be found in Europe, where the
13
founding populations originated.
Genetic
linkage studies in the Mennonites has led to the
discovery of the genes for many conditions, such
as hypophosphatasia and X-linked congenital
stationary night blindness. 3 The Clinic For Special
Children in Pennsylvania specializes in care for
Plain People and have been successful in isolating
over 50 different mutations causing disease in the
Mennonite and Amish communities over the past
5 years. 14

The Database
The Amish, Mennonite, and Hutterite
Genetic Disorder Database is intended to be used
as a resource to assist in research and diagnosis of
genetic conditions for patients of Plain People
ancestry. It has been compiled by researching
published genetic conditions for Plain People.
Literature searches were performed on PubMed.
Some disorders and mutations were entered based
on personal communication with other genetic
researchers.
For each disorder, the group affected is
recorded along with the geographic location (e.g.
Amish, Ontario). This is important because
disease prevalence can vary between locations,
even within a specific group (e.g. Hutterite), as a
result
of differences
in
the
founding
12
populations. The specific gene and mutation(s)
are also listed, if known. The journal articles
detailing the illness with specific mutation(s)
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found in Plain People are listed along with the
OMIM reference number. Finally, the clinical
symptoms of each condition are listed, assisting
healthcare providers in recognition and diagnosi s.
In order to navigate the database, users
search by disorder, mutation or clinical signs and
symptoms. When searching by disorder, the user
is able to input either the OMIM number or the
name and is directed to the corresponding page.
Alternatively, the user can input a specific gene
and identify any disorders which are caused by
mutations in that gene. Finally, the user can
search the database by clinical manifestations of
the genetic conditions. This is done using a dropdown menu divided by different body systems.
The clinical search may be limited to one specific
Plain People group and a geographic location.
Finally, users are provided a link in order to
communicate with the site administrator if they
have questions or new information to add to the
database.

Conclusion
Plain People have unique healthcare needs
as a result of small founding populations and
cultural isolation. It is our hope that The Amish,
Mennonite, and Hutterite Genetic Disorder
Database will improve the healthcare delivery to
Plain People in Canada. We view it as an ongoing
project, with continuing updates to the database
with future discoveries.
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FEATURE
Hemochromatosis - Screening for a Common Condition
Nick Sunderland (Meds 2010)
Faculty Reviewer: Dr. Kami/ia Rizkalla
Hemochromatosis is a common genetic disorder in the Caucasian population. It can go unrecogni zed in
many patients for years before manifesting itself as multisystem end-organ damage. There is debate as to
whether this condition should be screened for on a routine basis; as such this article serves to explore the
basics of the disease and to review current guide lines for screening at the primary care level.

Case
A 26 year old female fashion student
getting lab work for allergy testing was
incidentally found to have significantly increased
serum transferrin and ferritin levels. Subsequent
genetic testing revealed homozygous mutation for
gene
encoding
the
HFE
protein .
the
Retrospectively , the mother reports a history of
improvement in chronic fatigue and joint pains
following elective phlebotomies at the local blood
bank. Her testing revealed a compound (double)
heterozygous mutation in the HFE gene, but no
abnormality in her liver function tests or iron
levels . The father and 24 year old brother have
normal ferritin and liver enzymes; the 28 year o ld
brother, however, has markedly increased iron
stores.

Introduction
Hereditary hemachromatosis (HH) is an
autosomal recessive inl1erited disorder in which
mutations in specific genes related to iron
transport proteins lead to increa ed iron
absorption from the diet. This eventua ll y leads to
deposition of iron in the parenchyma of the liver,
heart, pancreas and pituitary g lands if left
untreated, and can cause significant long tenn
1
morbidity.
This disorder was originally described as
"bronze diabetes" by Armand Trouseau in 1865,
when he observed an association of skin
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pigmentation with diabetic patients. 2 The first
report of deposition of iron in tissue leading to
dysfunction was by Yon Reckinghausen in 1890.
The sequencing of the human genome has
all owed identification of the specific mutations
associated with the HFE protein, the commonly
affected protein in HH. Mutations in this protein
are the focus of this article. Note that there are
other, less common hereditable defects in iron
metabolism.

Genetics
The most common genetic defect is in the
HFE protein, which interacts with the transferrin
receptor and other iron regulating proteins to
regulate absorption of iron from the GI tract.
There are two common mutations in HFE,
C282Y and H63D. The mutation is most
prevalent in Caucasians of European decent, with
a homozygote prevalence (C282Y) of about l in
200. The prevalence is about l in 250 in the
general population.
In this same population, 12% are carriers
of the C282Y and 25 % the H63D mutation. Most
HH patients are homozygous for the C282Y
mutation. The penetrance of the H63D mutation is
considerably lower, thus compound heterozygotes
(C282Y/H63D)
and
H63D
homozygotes
35
constitute l 0% of HH patients . -
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Pathogenesis
The HFE prote in as mentioned is
important in regu lating the up take of iron from
the diet in the G I tract. Iron can only be lost
through sweat, skin and the GI tract, menses in
fema les, and during times of growth such as
pregnancy
and
ado lescence.
Ma les
lose
approximate ly
l mg/day
and
fe ma les
proportiona ll y more ( l .5-2 mg/day). In HH, th e
abi lity of the body to sense overa ll iron stores is
lost, leadi ng to an extra absorpti on of l -4mg of
iro n dail y, w hich ave rages over a year
approx imate ly I gram . T he s low acc umul ati on of
iro n i genera ll y asy mptomati c until the tota l
body iron stores are greater tha n 20 grams.

the ensuing fibrotic reaction from chronic
damage. Cirrhosis, pancreatic . insufficien~y
secondary to islet cell destructw.n and skm
pi gmentation are all fairly late findmgs , b.ut a~e
considered the class ic " triad" . Hypogonadism IS
related to alteration of the hypothalamic-pituitary
. I
ax is.
The differenti a l for HH includes other
causes for elevated iron stores. Most alternative
di agnoses are secondary causes of iron overload,
most commonl y chroni c transfu sions, either alone
or in associati on w ith ineffective erythropoiesis.
T he latter conditi on results from RBC being
destroyed before they can leave the bone
marrow. 6

Screening
Excess ive iron is tox ic to ti ss ues by free
radi ca l reacti ons,
timul ati on of co ll age n
fo rmati on, and interacti on w ith DNA. Most of
th ese changes are revers ible if the iron is
removed. Depos iti on of hemos iderin , an
intrace llul ar iron storage compl ex, in the ce lls of
th e li ver, pancreas, myoca rdium , pituitary ,
adrena l, th yro id and parath yro id g lands, j o ints and
skin lead to di sco lourati on, fibro sis, and
dysfunction. Interacti on w ith DNA has lead to
increased ri sk fo r hepatoce llul ar carcinoma
(HCC) in advanced cases. 1' 7 HCC and cirrhos is
are the leadin g causes of morta li ty due to HH.

Presentation and Differential
Most cases of HH are di scovered through
screening, as either an inc idental findin g when
bl oodwo rk is done for another reason or becau e
of a re lati ve w ith a di agnos is. T he manifestati on
of HH usua ll y occur after age 40 in ma les (50 in
fe ma les), after iron stores are grea ter th an 20
grams. The most frequent symptoms in c lude
hepatomega ly, abdomina l pain , skin pi gmentati on
(especia ll y on sun ex posed areas), altered g lucose
metabo li sm or di abetes, cardi ac arrythmias, and
an atypi cal arthriti s. Hypogonadi sm resulting m
amenorrh ea in fema les and a drop in libido m
ma les is also a common initi a l presentati on.
Eac h of the symptoms is due to
hemos iderin depos iti on in orga n parenchyma and
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The understanding of the underl y ing
pathophysiology of thi s di sorder has come a long
way. At a popul ati on leve l, it has been debated
w hether ro utine screening (via a fa sting serum
transferrin saturati on ) should be implemented,
due to the hi gh preva lan ce of the mutation, ability
for early di agn os i and treatment, and ease of
geneti c testing. However, a t thi s time widespread
screening has not been recommended, due to lack
of predictabili ty about the express ion of the
mutati ons and lack of information on ri kstrati fy in g pati ents. 3 · 6- Labe lling of indi vidual s
who test pos iti ve through geneti c testing but are
a ympto matic is a l o anoth er concern and could
lead to diffi culti es w ith obta ining in urance, for
exa mpl e.7
T he va ri abl e ex press iOn m thi s condition
has been a focus of some re latively large
cree ning studi es, inc luding a study by Beutl er el
a/. (2002) whi ch invo lved 4 1,000 US indi v iduals
tested for the C282 Y and H63 D mutations. They
found no difference in th e age di stribution or
frequency of signs and symptoms of HH between
the cases and contro ls. However, a more recent
study of 3 1,000 Austra li an pati ents of northern
~ u ropean decent (fo ll owed for 12 year ), bowed
Iron-overl oad re lated di sease in 28% of mal e and
1.2%
of
fema le
homozygotes. 5
Other
observational studi es have identifi ed a substantial
percentage
of first degree
re la ti ve
of

homozygotes with subclinical conditions related
to HH. 10
Following from this, a reasonabl e strategy
for screening would include targeting hi gh ri sk
individua ls, such as adult men > 25 years o ld of
northern European decent and first degree
relatives of pati ents w ith known hered itary
hemochromatosis. The screening test of choice
would be a fasting serum transferrin saturation
(men > 52% and women > 50%) or a fasting serum
unsaturated iron binding capacity. Follow-up to
4
thi would be genetic testing. 3• • • 10

Diagnosis
The di agnos is of HH rests on a
combination of the clinical features mentioned
above, and an e levated serum ferritin and fasting
transferrin saturation. In the past, a li ver biopsy
was used in confirmation of the di sease; however,
genetic testing has largely replaced thi s invas ive
test except in the case of documented li ver
impairment and need to determine extent of
cirrhosis. The serum ferritin value needs to be
analyzed with caution as it is an ac ute phase
reactant. Excluding the secondary causes of iron
overload is important (Table 1).

Treatment
The definiti ve treatment of HH and the
associated iron-overload is phlebotomy, 500ccs
weekly. Thi s is continued until iron-deficien cy
erythropoiesis is induced as ev idenced by a
reduced MCV and decreased Hb value, and/or

se rum ferritin leve ls and transferrin saturation
markers are within the target range , w hi ch are
below 50% and 50ng/ mL , respectively . Patients
w ill usually require a phlebotomy every 2-3
m o nths as maintenance therapy, which in many
cases can be accomp lished by regular donations
to the loca l bl ood bank. Patients testing pos iti ve
for HF E mutati on but witho ut labo rato ry ev idence
of iron ove rload can be followed annua lly for
evidence of disease, but do no t require active
treatment.
There is no need for patients to avo id red
m eats and other di etary sources rich in iron ; a
well ba lanced di et is acce ptabl e. Pati ents can be at
hi gher ri sk for certa in infections such as Vibrio
vulnificus, and as such eating raw seafood is
discouraged .

Case Discussion
The case represents a common scenario, in
thi s case a Caucas ian fam il y with a compo und
heterozygote mother (C282Y/H63D) and the
da ughter homozygous for the C282Y mutat io n.
This ca e illustrates the need for aware ness on the
part of family doctors of at-ri sk popul ation to
determine the need for geneti c testing. Had the
fashion tudent (homozygote) not bad her blood
tested she may have gone years w ithout any
knowl edge of her conditi o n, until pre entation
w ith signs of end organ da mage. While a number
of incidental cases of iron-overload are in ev itabl e
until better ev idence is ava ilabl e for specifi ca ll y
ide ntifying those at ri sk, targeting the at-ri sk subg roups should minimize thi occurrence.

Table 1: Cause of iron overload 6 (*focus of arti cle)
Hereditary hemochromatosis

Related to HFE gene*
African (Bantu) hemochromatos is
Ju venile hemochromatos is
Neonatal hemochromatosi

Exogenous iron overload

Chroni c iron supplementation
(in ab ence of blood loss)
Transfusion
Iron dextran inj ection

Chronic anemias

Chronic liver diseases

Thalassemia major
Sideroblastic anemia
Congenital dyserythropoietic anemia
Conoenital
atransferrinemia
b

Viral hepat iti s
Alcoholic li ver di sease
Nonalcoholic steatohepatitis
P01phyria cutanea tarda
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FEATURE
Amniocentesis: Safety, Reliability and Alternatives
Caleb Zelenietz (Meds 2011), Kimberley Colangelo (Meds 2011), and lshvinder Chattha (Meds 2011)
Faculty Reviewer: Dr. Robert Gratton
Amniocentesis is the most commonly used technique for prenatal genetic diagnosi s. It is an effective
procedure with a high diagnostic success rate, but carries the risk of severe complications including
miscarriage. Despite the risks , amniocentesis performed in the second trimester remains the safest means of
prenatal genetic diagnosis. With the introduction of biochemical and first trimester ultrasound screening for
fetal aneuploidy, amniocentesis usage rates have declined.

Background of Prenatal Genetic Screening
Pregnancy can be a time of worry, when
concerns over fetal health and well-being are at
the forefront of many women's minds. Modem
clinicians have a wide array of tools at their
disposal to allay parents ' fears. Prenatal screening
for genetic anomalies has become a cornerstone
of care for expectant mothers.
In Ontario, Integrated Prenatal Screening
(IPS) , Serum Integrated Prenatal Screening
(SIPS), and First Trimeter Screen (FTS) are
offered to all women presenting before 14 weeks
gestation . 1 The testing uses serum markers and
nuchal translucency (in the case of IPS and FTS)
to assess the risk of trisomies 18 and 21 along
with open neural tube defects. Testing is
undertaken in both the first and second trimester,
with results becoming available after the second
set of testing. Many screening options are
possible but IPS and SIPS (if nuchal translucency
23
is not available) prove most accurate and safe. '
These tests give the mother the risk of her fetus
having one of these conditions, but are not
diagnostic.
The costs to the health care system of
screening have been estimated to be around
4
$15 ,000 US per quality adjusted life year gained.
The screening tests are non-invasive and do not
pose a risk to the fetus in and of themselves , but
are associated with an increased risk of pregnancy
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loss due to follow-up diagnostic tests. After a
woman has screened positive as having increased
risk of one of the fetal anomalies , she must be
offered further testing; screening should therefore
only be performed when follow-up diagnostic
testing is available. When used in the absence of
screening, based on matemal age , amniocentesis
and chorionic villus sampling cost about
$100,000 US per abnormal birth averted, giving
substantial weight to the use of screening
programs as a first step in assessing the risk of
genetic abnormalities in a fetus. 5 From a safety
perspective, however, the use of amniocentesis
with the sole risk factor of advanced maternal age
is justified as the risk of aneuploidy is comparable
to the risk of miscarriage .6

Positive Screen: What Comes Next?
Several options are available after a woman
has screened positive: she can choose to continue
the pregnancy without further testing, she can
have chorionic villus sampling (CVS) in the case
of FTS , or she can have amniocentesis. Both CYS
and amniocentesis are invasive procedures that
pose ri sks to the fetus, but are also highly
effective diagnostic tools with close to l 00%
78
.
.
d mgnosttc success rates . '
Amniocentesis involves the withdrawal of
amniotic fluid from the uterine cavity. Typically,
a 20 or 22 gauge needle is inserted into the
amniotic sac transabdominally under ultrasound
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guidance. It can be done both fo r obtaining cells
to culture for geneti c testing, fe tal blood typing,
and diagnosi ng fe ta l infec ti on. 9 When used for
geneti c diagnosis, amni ocentes is is typi call y
perfo rmed in the second trimester. It is most
effecti ve at obtaining a usefu l sampl e after 15
weeks gestation and before 24 weeks. 1 Cell
cultures typica lly take 7 days to grow before they
can be tested. For more ra pid results, interphase
flu orescence in situ hybridi zati on (FISH) can
de tect aneupl oidy of chro mosomes 13, 18, 2 1, X,
Y in one to two days . An a lternate procedure fo r
obtai ni ng genetic mate ria l fro m the fe tus is
chori on ic v illus sampling (CVS). CYS invo lves
samp ling the place nta either transabdomina ll y or
transcervically. It is usua ll y performed in the firs t
trimester, after 10 weeks gestati on. T he rate of
both amniocentes is and CVS use has decreased
w ith the introducti on of IP S, FTS , and SIPS. 11 • 12

°

Safety of Early Versus Late Amniocentesis and

cvs
The safety of earl y versus late (first rather
than second trimes ter) amni ocentes is and CVS
has been studi ed ex tensive ly in the literature.
Earli er tes ting prov ides a definiti ve di agnos is
mu ch qui cker after a pos iti ve test, but is not
w ithout added ri sk of complicati on. A Coc hrane
rev iew of 16 randomi zed contro ll ed tri a ls fo und
second trimester amniocentes is to be the safest
method
of
pre natal
geneti c
di agnos is.8
A mni ocentes is performed before th e second
trimes ter is assoc iated w ith a hi gher rate of
pregnancy loss (7.6% versus 5.9% relati ve risk of
1.29 95 % cr 1.09 to 1.8 1) than second trimes ter
testing , thu s it is not as safe an a ltern ati ve as later
amni oce ntes is. CVS is th e safest method of first
trimester sampl ing, but has a hi gher loss rate th an
second trimester a mni ocentesis w ith a hi gher tota l
pregnancy loss (re lative ri sk of 1.40; 95 % Cl 1.09
to 1.8 1) and spontaneous mi scarri age (9.4%; RR
1. 50; 95 % CT 1.07 to 2.11 ).8
Risks of Amniocentesis
T he materna l ri sks of amni ocentes is are
low; of much greater conce rn are potenti a l feta l
compli cati ons. Th e onl y randomi zed controlled
tri a l comparing second trimester amni ocentes is to
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pl acebo, a study of 4606 low risk women aged
25-34 years, found the rate of spontaneous
abortion to be 1.7% in the second trimester
amniocentes is group versus 0.7% in the control
13
ultrasound group (relative ri sk of 2.3). Current
consensus from various trials estimates the loss
rate from second trimester amniocentesis to be
14
between 0.6% to 1.0%. Fluid leakage is more
common after amniocentes is than in controls, but
is not associated with negati ve pregnancy
13
outcomes.
With ultrasound guidance, direct fetal injury
is extremely rare 13 , although it has been
reported. 15 • 16 Indirect feta l 111Jury is more
common, w ith respiratory di stress syndrome and
pneumoni a be ing more common in newborns
,.,
·
.
. 13' 11 A large
a .tter
secon d tnmester
amniOcentesis.
cohort study of women 35-49 years old (with
7 1,586 parti cipants) found an increased incidence
of muscul oskeletal deformiti es and respiratory
di stress in newborns w hose mothers underwent
2n d trimester
amni ocentes is. There was no
increase in limb reducti on defects, infant and fetal
morta lity, prematu rity, low birth we ight, or fetal
18
di stress w ith amni ocentes is. There is no long
tern1 increased ri sk fo r di sabiliti es in children
19
after amni ocentesis.
Verti ca l transmi ss ion of infections such as
cy tomega lov irus, hepatiti s C Virus, and human
immuno defi c iency v irus has been linked to
amni ocentesis perfonned in infected women. 20•21
L ike a ll invas ive procedures in chroni ca lly
infec ted wo men, amni ocentes is should be used
onl y w hen abso lute ly necessary.
Advantages of Early Versus Late Diagnosis
A lthough second trimester amniocentes is
has been conc lu sive ly shown to be the safest
meth od of prenata l geneti c di agnos is, it is not
w ith out d isadvantages . Because it is performed in
the second trimester, there is a long lag time
between a screen pos iti ve test from IPS or SIPS
and definiti ve di agnos is. C VS is ava il able in the
first trimester, thus c utting the lag time
considerabl y. Several studi es of women's
subj ecti ve we ll being have shown shorter time to
materna l feta l bonding, earli er anx iety reduction ,

and improved health related quality of life in
women having a positive screening test followed
by a negative CVS as compared to a negative
24
amniocentesis? 2The
second
trimester
magnitude of the reduction of anxiety post test is
the same for the CVS and amniocentesis groups,
but occurs sooner because the CVS is done
earlier. 23 This benefit in anxiety reduction exists
despite the increased risk for miscarriage with
CVS. 23 The same is true for the maternal-fetal
bonding improvements, the bonding improves
markedly after a negative test result, equally for
CVS and amniocentesis, but the CVS is
performed earlier. 22 Whether these subjective
improvements outweigh the very real increased
risk of miscarriage should be discussed with each
patient.

amniocentesis remains the late availability of
results , which gives parents little time to make
deci ions based on the results of the testing. As
detection rates of genetic disorders by
anmiocentesis have increased, termination rates
have decreased. Amniocentesis remains a
valuable tool for prenatal genetic diagnosis.
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CASE REPORT

Ductal Carcinoma in situ in a 25-Year-Oid Male with Unilateral
Gynecomastia
Christoph er}. Coron eos (Meds 2010)
Fa culty Reviewer: Dr. Carolin e Hamm
DC IS in a yo ung ma le is rarely reported. O ur pati ent is a 25 year o ld male w ho presented w ith symptomatic
unilateral gynecomas tia. He presented w ith a trong fa mil y hi story of cancer on both matem al and paternal
sides of hi s fa mily including breast, lung (maternal) and melanoma, co lon and pancreatic (paterna l). Hi s
mother te ted negati ve fo r BRCA 1 and BRCA2. Th ere is no info rmation on the patem al geneti c testing . He
was treated w ith left subcutaneous mas tectomy. Upon hi stologic rev iew of th e sampl e, concurrent
gyecomas ti a and ducta l carcinoma in situ was di scovered. To date, only fo ur ca es of gynecomasti a and
DC IS have been described in yo un ger ma le pa ti ents. Since onl y 30 - 50% of pati ents w ith DCIS eventua lly
deve lop invas ive cancer in the subsequent 10 - 20 years, thi s fi gure in the general popul ati on may be
hi gher. Thi s case underscores the importance of fa mil y history in any pati ent presen ting with a breas t mass.
Patients must be made aware of the risk, however sma ll it may be, and phys icians must rema in ca utious of
malignancy in yo ung ma les w ith gynecomasti a.

Introduction
By definiti on, gynecomas ti a is a beni gn
conditi on affecting ma les characteri zed on
1
histology by g landular ti ss ue proliferati on. It
must
be
di stingui shed
first
from
pseudogynecomas tia, the depos iti on of fat w ith
absence of g landular ti ssue pro liferati on seen in
obese ma les and second, from breast carcinoma.
The increas ing size of th e breast is due to
parenchyma a nd/or fatty ti ssue. Gyneco mas ti a is
common and most preva lent in th e neonata l,
pubertal and e lderl y peri ods. 2 However, it is a lso
2
present in 33-4 1% of adult ma les aged 25 -45 .
Long-standing cases that are res istant to medi ca l
management or aesthe ti ca lly displ eas ing are
treated w ith surg ica l exc ision w ith or w itho ut
3
liposucti on .
In contrast, cases of ma le breast cancer
are
uncommon,
occurring
in
(MB C)
4
approximate ly 1 in 100 000 men and leading to
5
under 0.5% of ma le cancer deaths annua ll y. Th e
69
age of incidence is typically 65 -67 years. - Ri sk
factors
inc lude
testicular
abnorma lity,
imba lance,
Klin efe lter
estrogeni c/androgenic
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syndrome, BRCA mutati on, pos iti ve fa mily
hi story, obes ity , radi ati on exposure and li ver
8
Whil e
gyneco masti a
ha
been
di sease.
hypothes ized to be associated w ith MBC ,
research indi cates its in cidence is not hi gher
among MBC pati ents w hen compared to the
. 4 · 10' II Th e rare coex i. tence o f
genera I popu Iat10n.
the two conditi ons has been identifi ed in the
12 13
literature. • Still more rare are cases of ductal
carcinoma in situ (DC IS) w ith gynecomasti a,
espec ia lly in the yo un g ad ult popul ati on. To date,
onl y fo ur cases of DC IS in the settin g of
gyneco masti a have been described in pati ents that
14 17
are 25 yea r o ld or less - and only one of th ese
describes unilateral gynecomastia as our pati ent
16
does.

Case Report
A 25 year o ld ma le presented in 2007 for
cosmeti c mas tectomy. H e reported a hi story of
new onset locali zed d iscom fo rt in the peri areo lar
region of the left breast and a growth in the left
breast for one year, increas ing in size.
On
presentati on, both the size of the mass and th e
associated pain had decreased in magnitude .
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Phys ica l exam noted slight swelling deep to the
left nipple areo lar compl ex w ith no ax illary
lymph adenopath y.
T he right breast had no
di scernable changes.
Family hi story was
significant fo r ma li gnancy including the materna l
grandmother (metas tati c lung cancer to bone and
b ilatera l breast cancer at ages 4 5 and 46
respecti vely, death at 49), maternal great-aunt
(breast cancer, death at 65), second materna l aunt
(breast carc inoma at age 60, relapse and bone
metas tases, currentl y undergo ing treatment),
materna l grandfa ther (pancreatic cancer), paternal
grandfa ther (co lon cancer), paternal great-unc le
and two paterna l uncles (me lanoma) . He reported
no other hea lth concerns, and hi story was notabl e
only for surgica l herni a repa ir at age three. The
rema inder
of
the
phys ica l
exam
was
unremarkab le.
U ltrasound reported a sma ll amount
( 1.5cm ) of mi xed ec hogeni c tissue in the
retroa reolar region, consistent with beni gn
changes and gynecomas ti a. Left subcutaneous
mastectomy was performed.
Th e suspected
gynecomasti a was compl etely exc ised, measuring
approx imately 6.5x6 .0x2 .5cm, we ighing 48
grams. O n mi croscopi c examin ation, patho logy
reported gynecoma tia hav ing abundant fib ro us
stro ma separating ducts hav ing co lumnar ce lls
w ith inbudding. ln additi on, a cribiform pattern
of cellul ar change was prese nt. Pathology was
consistent with nuc lea r grade I/ lii DCIS, largest
focus 7mm . T he patho logy report menti oned the
re lative rarity of intraducta l ca rc inoma in the
demographi c group of our patient.
-F urth er
investigati on
included
MR
ma mm ogram at three month s post-operati ve,
reporting increased signal intensity in the left
retroareolar reg ion cons istent with post-surgica l
changes and no abnorm a l enh ancement. CA 19-9
was norma l at 13 kU/L.
Ultrasound of the
abdomen and bone scan de monstrated no
abnorma li ties.
Ultraso und of the right
(un affected) breast was unremarkable.
The
pati ent's mother has te ted BRCA I /2 negati ve.
The patient underwent fo llow- up w ith medi ca l
and radi ati on onco logi sts and received genetic
coun selling. G iven th e nega ti ve surg ical marg ins
described on path ology, low grade mali gnancy,
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absence of ax illary findings and potential
tox iciti es of adjuvant treatment in this young age
group, no furth er intervention was recommended.

Discussion
Breast cancer in males is far less common
than in females . On average, the typical age of
6
onset is up to ten years older th an in females.
Simil ar to fe male cases, incidence of MB C has
increased fro m 0.86 per 100 000 in 1973 to 1.08
in 1998 . 18 HER2 overexpression, a negati ve
prognosti c fac tor in women, is found less often in
ma les. 19 Ma le cases are more frequently ER and
PR pos itive ,8 perhaps indi cating increased
20
pro li fe rative acti vity .
21

DCIS acco unts fo r approx imately 7% of
M BC and is fa r less common than invasive ductal
(90% of case ), though lobular malignancy is still
18
more rare w ith only 1.5% of cases.
M edian age
2
of inc idence is 65 years >~
On hi stology, the
papillary form is most common though all
sub types present in fe ma les can potenti a ll y occur
22
in males. Pure DC IS occurs only in 5% of cases
as the path ology i often present in assoc iation
w ith infi ltra ting ma li gnancy e lsewhere.22 DCIS is
more common in fe ma les , representing 20% of
JI
case - . O nl y 30 - 50% of a ll ma le and fema le
patient wi th DCIS eventua ll y deve lop invasive
ca ncer in the ubseq uent 10 - 20 years, so actual
preva lence in the genera l populati on may be
23 25
hi gher. - Co mpared to males, fewe r intraducta l
papill ary ca e w ith hi gher grade and yo unger age
22 26
are een in fe ma les . ·
The eti o logy of DC IS is
unknow n fo r ma le s ince they lac k the termina l
duct lobul ar unit (TD LU) where th e ma li gnancy
has freq uently been fo und to ori ginate in
13
fe ma le . However, not all cases are assoc iated
with the T DLU and it is hypothes ized cases in
ma les ori ginate from epithe lium of ducts. 22 Only
a limited number of large studi es perta ining to
ma le DC lS are avail abl e.22 • 27 • 28
Breast ca ncer of any fo rm in young men is
excepti ona lly rare. At the time of our pati ent's
presentati on, onl y six cases had been described in
14, I 5, 29-32
rna Ies un der age 25 ,
and only four cases
of males of any age w ith breast cancer revea led
on path o log ica l exa minati on fo ll ow ing urg ica l

. t

.

.

14 15 29 33

m erventJOn for gynecomastia. ' ' '
To our
knowledge, among males 25 years of age or
younger, a case of unilateral gynecomastia and
DCIS has only been described once in the
literature with Chang's account of a 16 year old
16
male.
Our patient originally presented with
unilateral gynecomastia, though bilateral cases are
34
more common. There is no evidence that either
unilateral or bilateral gynecomastia increase risk
35
for MBC. Obesity is an independent risk factor,
and may confound the associatiOn with
15
gynecomastia.
Gynecomastia in adults is most
often due to persistence from puberty, drugs,
cirrhosis,
hypogonadism , testicular
tumor,
36
hyperthyroidism and idiopathic.
Beyond his
breast, our patient had an otherwise normal
physical exam and investigations.
Of note
however, is the comment in the surgical
pathology report of putative anabolic steroid use.
Use of anabolic steroids is not mentioned
anywhere else in the patient ' s medical record.
Some state that cases of gynecomastia should be
biopsied
if
presentation
includes
query
Klinefelter' s syndrome, bloody discharge, firm,
irregular or unilateral mass.37 ' 38 Others endorse
mammography to recognize mass since it
39 0
distinguishes between glandular tissue and fat, A
though it is not universally supported since male
breasts are small and dense. 41 '..n Mammography
for MBC has been reported as successful as 92%
43
sensitive, 91% specific. Our patient received an
ultrasound
which
demonstrated
findings
consistent with gynecomastia but made no
mention of possible malignancy. (t did not report
17
The
microcalcifications typical of DCIS .
patient was seen again in follow-up with no
improvement and surgical intervention of
gynecomastia for comesis was planned. The
possible increased risk of squamous cell
44
carcinoma and testicular cancer later in life is
considered prior to surgery in a younger patient
and annual screening is suggested for cases of
. 16
gynecomastia.
DCIS will most often present with bloody
21
nipple discharge and a mass , though mild
symptoms, concurrent gynecomastia and the
scarcity of its incidence result in frequent misUWOMJ, Vol 78, Issue 3

diagnoses. 14
Our pati ent had ma li gnancy
diagnosed on routine post-operati ve path ologica l
investi gation . Thus he did not benefit from preoperati ve diagnosti c evaluati on and tagin g. Fine
needle aspirati on cytology is acc urate in men
when suffici ent ti ssue is obtained, th ough up to a
quarter of cases have insufficient samples.45 ER,
PR and HER2 profiles are obtain ed.
The
remainder of diagnostic routine mirrors cancer in
women and investigation includes lab work, bone
scan, CT pelvi s/abdomen and plain films as
clinically relevant. 46
Research pertaining to the prognosi s of
DCIS is conflicting. Studies in the past concluded
a poorer prognosis in MBC when compared to
females , though the older age and delay in
diagnosis are thought to have been factors . 1 (t is
currently believed that prognosis MBC is equal to
that in females, 6 though specific outcomes for
DCIS unavailable. Breast cancer specific survival
for treated DCIS is as high as 99% in females and
85% in cases of invasive recurrence. 47 Cutuli el
a/. observed four recurrences among their 27
DCIS
patients
in
follow-up
following
lumpectomy who were then treated with radical
savage
surgery.I
~7

Treatment for DCIS in males does not
have an established benchmark and no definitive
trial has been published. Current treatment has
been guided by experiences reported in the
literature. 14 For any MBC, surgeons have the
option of mastectomy, local exciSion or
lumpectomy and adding adjuvant therapy as well
as axillary dissection.
Total mastectomy is
21
suggested
and a recurrence following this
42 49
procedure has yet to be described. '
Research
pertaining to lumpectomy and adjuvant radiation
21
therapy are sparse and it is not endorsed.
Though it bears the potential to improve
cosmesis,50 the potential long-tem1 toxicites of
radiation treatment in our patient's young age
group outweighs benefit. Nipple excision is often
necessitated42 since the male breast most often
14
leads malignancy to a subarelor presentation.
There is no evidence for axillary lymph node
dissection, tamoxifen and adjuvant radiation or
21
chemotherapy.
Since our patient received
treatment for what was thought to be
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gynecomastia, subcutaneous mastectomy was
performed.
The patient was well and no
recurrence was detected on follow-up at three
months .
There is no indication in the literature that
samples from gynecomastia procedures should be
routinely sent for pathological examination.
Given the unilateral nature in our patient, samples
were sent for examination to rule out the rare
occurrence of malignancy . Liao et a/. recognize
the routine hi stologica l examination of samples in
15
female cases of reduction mammaplasty.
It is
further suggested that the same procedure be
following for gynecomastia samples when
poss ible, noting suction lipectomy may make it
difficult because of large volume and destruction
15
of cells. Perhaps surgical mastectomy should be
applied to more cases, allowing for better review
of not only the sample itself, but also the surgical
margms .
Our patient had a
ignificant family
history of breast cancer, though his mother had
tested negati ve for BRCA 1 and 2. Fifteen to
twenty percent of all MBC patients have a family
hi story of breast cancer. Just as our patient was,
all MBC cases are routinely offered genetic
counselling.
Beyond BRCA, MBC has been
associated with PTEN mutation in Cowden's
51
syndrome as well as MLH l , a mi smatch repair
gene re lated to hereditary nonpolyposis colorectal
52
cancer syndrome.
Our patient did not undergo
genetic testing s ince hi s moth er had tested
negative .
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